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ABSTRACT 
Human T-cells play a major role in controlling and clearing Mycobacterial infections. The 
adaptive immune system deploys a complex network of specialised T-cell subsets in order 
to tailor an optimum immune response. Two categories of T-cells have been described that 
are characterised by the ligands they recognise: “conventional” T-cells (polymorphic, HLA-
restricted, peptide-specific) and “unconventional” T-cells (non-polymorphic, restricted by 
HLA-like molecules, non-peptide-specific). Both T-cell categories were shown to be 
important for the elimination of cells infected with Mycobacterium tuberculosis (M. 
tuberculosis) and their role, specificities and functionalities are under active investigation in 
order to develop optimum vaccination strategies. A large interest in unconventional T-cells, 
such as MR1-restricted MAITs or CD1-specific T-cells, and their role in mycobacterial 
infections has recently arisen. I initiated my studies by dissecting T-cell responses generated 
during direct ex vivo boosting of PBMCs with antigen presenting cells that had 
phagocytosed Mycobacterium smegmatis (M. smegmatis). M. smegmatis is a non-
pathogenic bacterium and is mainly eliminated by the innate immune system. However, T-
cells might respond to M. smegmatis antigens and therefore play a role in clearing the 
pathogen. Using polychromatic flow cytometry, I successfully identified major CD3+ 
conventional and unconventional M. smegmatis-specific T-cell populations and evaluated 
their respective frequencies and distribution. The identification of a significant frequency of 
M. smegmatis-specific unconventional MAITs pushed me to further analyse the specificity 
of this interesting T-cell subset. At the time of my studies, the ligand(s) presented by MR1 
to MAITs were still undiscovered. However, structural models of MR1 groove moiety 
provided evidences that MR1 could potentially present peptides to MAITs. Therefore, I 
attempted to identify the molecular and cellular mechanisms by which an M. tuberculosis-
specific MAIT clone recognises peptide loaded on MR1 and to refold this MHC-like 
protein. Vaccination strategies have been mainly focusing on targeting CD8 T-cells, known 
to be essential for the host defence against mycobacterial infections. Therefore a huge effort 
is made to discover new immunodominant mycobacterial epitopes. Collaborators isolated 
the HLA-A*0201-restricted D454 T-cell clone specific to the LLDAHIPQL epitope derived 
from the highly immunogenic Esx-G protein. The LLDAHIPQL sequence is conserved 
across mycobacterial species thus offering potential for pan-mycobacterial vaccination. I 
aimed at proving that D454 TCR binds to HLA-A*0201-LLDAHIPQL. I successfully 
obtained an HLA-A*0201-LLDAHIPQL crystal structure, the first bacterially-derived 
HLA-peptide complex, and identified the key mechanisms involved in the molecular 
recognition of HLA-A*0201-LLDAHIPQL by a conventional TCR. 
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CHAPTER 1. INTRODUCTION 
1.1 Overview of the immune system 
Environmental pressures drive evolution of the human immune system to guarantee 
the protection and homeostasis of the host. Like an army, the immune system is 
composed of different regiments of cell subsets with intrinsic missions and functions. 
Each regiment encodes a specific arsenal of probes and weapons to seek and destroy 
pathogenic microorganisms and abnormal cellular activity. 
The first-line regiment – termed the innate immune system – is composed of phagocytic 
cells and the blood proteins that make up the complement system. The cell types of the 
innate immune system include monocytes, macrophages, dendritic cells and natural 
killer (NK) cells. These cells interact directly with pathogenic microorganisms at the 
portal of entry. The recognition receptors used by innate immune cells are germline 
encoded and exhibit limited diversity. Recognition by innate immune cells is confined 
to compounds and structures that are shared between groups of microorganisms (e.g. 
membrane, cell wall or nucleic acid components). These ‘universal’ antigens are called 
pathogen associated molecular patterns (PAMPs) (Janeway and Medzhitov, 2002). 
PAMPs are recognised by the pattern recognition receptors (PRRs) found at the surface 
of innate immune cells. PRRs are designed to quickly scan for the presence of microbes. 
Considered the sentinels of the body, innate immune cells intimately communicate with 
the second line of immune defence: the adaptive immune system. In contrast to the 
innate immune system, the adaptive immune system is able to adapt to hypervariable 
antigens, memorise their structure and regulate the magnitude of response at each 
successive exposure to the same antigen. The key to adaptive immunity is held by the 
vast array of different antigen receptors that the body makes and expresses on the 
surface of cells called lymphocytes. The adaptive immune system is divided into two 
main sub-regiments; humoral immunity and cellular immunity. Humoral immunity is 
mediated by B-cells (or B-lymphocytes) that secrete antibodies, promote inflammation 
and neutralise antigens. Cellular immunity is mediated by T-cells (or T-lymphocytes) 
that recognise small parts of pathogens presented at the cell surface by molecules called 
major histocompatibility complex (MHC) molecules. Some T-cells act to orchestrate the 
entire immune response using soluble messenger molecules called lymphokines while 
others act to seek and destroy infected or neoplastic cells directly. 
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1.2 Adaptive immune system 
The adaptive immune system is composed of lymphocytes. The lymphoid lineage 
accounts for up to 30% of the total leukocytes found in the human body. Lymphocytes 
are split into two main subsets: B-cells and T-cells. 
1.2.1 B-cell lineage 
B-cells express somatically encoded soluble or membrane bound immunoglobulin 
receptors termed antibodies and B-cell receptors (BCRs) respectively. BCRs and 
antibodies are highly specific for an antigenic epitope and bind with high affinity. BCRs 
serve as cell receptors and deliver intracellular activating and survival signals upon 
interaction with a pathogenic antigen. BCRs mediate B-cell activation, division, 
survival, promote the secretion of inflammatory cytokines and control antibody 
secretion. Antibody is a soluble form of the BCR. Antibodies are able to coat viruses 
and bacteria by binding strongly to surface epitopes and contribute to their clearance in 
three ways. First, antibodies bind to pathogens and prevent anchorage to target cells 
preventing the invasion of virus, bacteria and associated toxins. Second, antibodies 
facilitate the uptake of pathogens by binding via the fragment crystallisable (Fc) 
receptors to phagocytic cells promoting phagocytosis of invaders. Third, proteins of the 
complement system interact with antibodies bound to pathogens and mediate their lysis. 
My work was oriented towards T-cells hence B-cells will not be considered further here. 
The rest of this thesis will focus on the T-cell lineage of lymphocytes. 
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1.2.2 T-cell lineage 
T-cells express a somatically encoded, cell surface, heterodimeric protein: the T-cell 
receptor (TCR). The TCR comes in either of two forms: One is made by the 
combination of a γ- and a δ-chain (γδTCR) and the other by the combination of a α- and 
β-chain (αβTCR). These receptors define the lymphocytes that express them as either γδ 
or αβ T-cells. 
1.3 T-cell biology 
1.3.1 γδ T-cells  
The frequency of γδ T-cells in human is low at around 0.5-10% of circulating T-cells 
(Kalyan and Kabelitz, 2013) however it is much higher in certain tissues such as 
mucosa and the gut where they can reach 25-60% (Groh et al., 1989, Kalyan and 
Kabelitz, 2013). At the current time, rather little is known about the exact nature of 
human γδ T-cell antigens. Studies have mainly focused interest on two members of the 
CD1 MHC-like molecule – the CD1c and CD1d platforms – which presents lipids such 
as phosphatidylethanolamine (Hayday and Vantourout, 2013), phospholipids including 
cardiolipin (Dieude et al., 2011) and α-galactosyl-ceramide compounds (Uldrich et al., 
2013) to γδ T-cells. However, other molecules have been described to bind to human γδ 
T-cells such as the non-polymorphic butyrophilin 3A1 (Harly et al., 2012) and the 
endothelial protein receptor C (EPCR) (Willcox et al., 2012). Although the field of γδ 
T-cell ligands is in its infancy, recent molecular findings have stimulated a renaissance 
in γδ T-cell research and it is expected that the molecular mechanisms behind how these 
interesting lymphocytes contribute to human immunity will be revealed soon. 
My work concentrated on the far better characterised  T-cell subset that constitutes 
the vast majority of human T-cells. 
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1.3.2 αβ T-cells 
αβ T-cells are the most common of T-cells in humans (Kalyan and Kabelitz, 2013). 
Most αβ T-cells recognise short peptides presented at the cell surface by MHC class I 
(MHC I) or class II (MHC II) molecules (describe in section 1.4). Peptide-MHC 
(pMHC) molecules represent the conventional ligands of αβ T-cells and T-cells that 
recognise pMHC are said to be ‘conventional’. Recent discoveries have described how 
some αβ T-cells can recognise lipids and bacterial metabolites presented by MHC class 
I-like molecules. These newly discovered T-cell subtypes are broadly described as being 
‘unconventional’ T-cells and will be reviewed in section 1.7.  
Most αβ T-cells express either the CD4 or CD8 co-receptors on their surface. These 
surface glycoproteins define the two major αβ T-cell subsets. CD4 T-cells recognise 
pMHC II ligands and are termed ‘helper’ T-cells while CD8 T-cells recognise pMHC I 
ligands and are called ‘cytotoxic’ or ‘killer’ T-cells. I will describe these two 
populations in turn. 
1.3.2.1 CD4 helper T-cells 
T helper cells (TH) mainly orchestrate and maintain the homeostasis of immune 
responses. TH subsets express the CD4 co-receptor at the cell surface and are activated 
upon interaction of the TCR with pMHC II molecules (Konig et al., 1995, Konig et al., 
2002). TH cells are characterised by the production of cytokines that drive innate and 
adaptive effector functions and lead to an efficient immune response. Six TH cell subsets 
have been described so far TH1, TH2, TH9, TH17, TH22 and follicular helper cells each 
defined by a cytokine “signature”. 
TH1 cells are characterised by release of IFNγ and generally drive cell-mediated 
cytotoxicity against intracellular bacteria. IFNγ promotes macrophage and cytotoxic T-
lymphocyte (CTL) activation (Swain et al., 2012). TH2 cells characteristically express 
interleukin-4 (IL-4) and are specialised in driving the immune system towards the 
elimination of extracellular pathogens by recruiting basophils and activating eosinophils 
(Okoye and Wilson, 2011). Similar roles have been reported for the TH9 cell subset. 
However, the latter cells mainly play a role in immunity against intestinal parasites 
(Kara et al., 2014).  
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TH17 and TH22, secrete IL-17 and IL-22 respectively. TH17 and TH22 cells mediate 
anti-microbial activity against extracellular pathogens by promoting phagocytosis by 
monocytes and macrophages (Yu and Gaffen, 2008, Liang et al., 2006). In addition, 
TH22 cells are involved in tissues regeneration by promoting epithelial cell growth 
(Witte et al., 2010). T follicular helper cells promote the humoral response against 
extracellular pathogens by triggering B-cell survival, maturation and proliferation (Kara 
et al., 2014) (see Table 1.1). Interestingly, TH cells can acquire different effector roles 
under certain cytokine environments (Wan, 2010). The TH effector function plasticity 
permits precise tailoring of the response to different pathogens.  
Effector 
T-cell
Type Function antigen MHC 
restriction
Phenotype/chemokine 
receptor and ligand
Major effector 
molecules release
CD4 helper
T-cells (Th)
Th 1 -Promote macrophage activation
-mediate cytotoxic response 
against intracellular infection
Peptides MHC-II • CD3, αβTCR, CD4
• CXCR3, 
CXCL9/10/11
IFNγ, TNFα/β,
IL-21
Th2 -Promote humoral response and 
macrophage activation
-mediate host response against 
extracellular pathogens
Peptides MHC-II • CD3, αβTCR, CD4,
• CCR3/4/8, 
CCL1/11/13/17
IL-4, IL-5, IL-13
Th9 -mediate host response against
intestinal microbial infection
Peptides MHC-II • CD3, αβTCR, CD4
• CCR3/6. CXCR3, 
CCL11/13/20,
CXCL9/10/11
IL-9, IL-10
Th17 -promote immune response 
against microbial infection
-enhance neutrophils and 
macrophages recruitment and 
activation
Peptides MHC-II • CD3, αβTCR, CD4
• CCR2/6/4, 
CCL2/20/17
IL-17A, IL-17F,
IFNγ, IL-4, IL-13
Th22 -mediate immune response against 
bacterial infection at epithelial 
barriers
- Induce epithelial cell 
proliferation (tissue regeneration)
Peptides MHC-II •CD3, αβTCR, CD4
• CCR4/10, CCL17/28
IL-22, IL-13, 
TNF-α
Follicula
r helper 
(TFH)
-Promote B-cell antibody 
production and memory 
phenotype acquiring
Peptides MHC-II • CD3, αβTCR, CD4
• CXCR5, CXCL13
IL-21
 
Table 1.1 CD4 helper T-cell subsets. 
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1.3.2.2 CD8 “killer” T-cells 
Upon interaction with pathogenic antigens, naive CD8 T-cells mature and expand into 
cytotoxic CD8 ‘killer’ T-cells or cytotoxic T lymphocytes (CTLs). CTLs are specialised 
for the detection and elimination of intracellular pathogens and tumours. CTLs secrete 
perforin that perforates the target cell membrane. These killer cells also secret 
granzymes that gain entry through the perforin pores and induce apoptosis in the target 
cell. Moreover, CTLs express high levels of the cell surface molecule CD95 ligand that 
interacts with the CD95 receptor on target cell driving apoptosis. Studies have 
highlighted the critical role of the co-receptor during activation of most CD8 T-cells 
(Purbhoo et al., 2001). Indeed, the CD8 co-receptor enhances the engagement of low 
affinity antigens loaded on MHC I by the TCR (Holler and Kranz, 2003, Cole et al., 
2012). 
1.4 αβ T-cell ligands 
As described above, conventional αβ T-cell recognition occurs when αβ TCRs bind to a 
foreign peptide displayed by the cellular presentation platforms called MHCs. MHCs 
are divided into two major classes: MHC I and MHC II. MHC II molecules are 
expressed by leukocytes and present peptides of 10 to 34 amino acids in length 
(Rudolph et al., 2006) to CD4 T-cells. MHC II are encoded by HLA-DP, -DQ and -DR 
genes. In contrast, MHC I molecules are expressed at the surface of almost all nucleated 
cells and present shorter peptides ranging from 8 to 13 amino acids in length to CD8 T-
cells. In humans, MHC I are encoded by the highly polymorphic HLA-A, -B and -C 
genes.  
1.4.1 Peptide-MHC class II 
1.4.1.1 Structure 
MHC class II molecules consist of an α chain (comprised of α1 and α2 domains) 
associated with a β chain (comprised of β1 and β2 domains). α1 and β1 are respectively 
folded into a β sheet and an α-helix and form a peptide-binding platform. The α and β 
chains of MHC II are linked by a disulphide bond (Brown et al., 1993) (Figure 1.1). I 
detail in the next section the manufacturing and presentation processes of exogenous 
peptide onto MHC II.  
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Figure 1.1 The structure of MHC II molecules.  
MHC II is composed of an α chain and a β chain both divided into two subunits, α1 and 
α2 are shown in orange and β1 and β2 chains coloured in yellow. The peptides loaded 
into the two MHC II groove is shown in red. A schematic cartoon of the structure that 
will be used in subsequent diagrams is inset. 
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1.4.1.2 Peptide processing onto MHC II 
MHC II presents peptides from exogenous proteins to CD4 T-cells. Exogenous proteins 
or microorganisms are internalised by leukocytes and transported within the cell by 
membrane bound vesicles where they are digested by hydrolyse proteases. These 
vesicles fuse with endosomes providing further proteolytic enzymes that complement 
the digestion process producing small peptides fragments. 
MHC II α and β chains are co-expressed with a third protein called the invariant chain 
(Ii) (Bakke and Dobberstein, 1990). The Ii chain is composed of an endocytic targeting 
domain that retains the αβ heterodimer inside the endoplasmic reticulum (ER). The 
class II associated invariant chain peptide (CLIP) domain or CLIP peptide of the Ii is 
nestled inside the MHC II groove thereby maintaining the assembly of the MHC II α 
and β chains together and preventing the binding of endogenous peptides. The complex 
exits the ER and travels first through the Golgi and endolysosome to endosomal 
compartments. The high acidity inside endolysosome releases the CLIP peptide 
allowing the binding of peptides with higher affinity for the MHC II groove (Roche and 
Cresswell, 1991). The Cathepsin enzyme and HLA-DM molecule facilitates peptide 
loading onto MHC II (Stebbins et al., 1995). The newly formed αβ MHC II heterodimer 
loaded with an exogenous peptide is transported to the cell surface and ultimately fuses 
with the cell membrane where it is available for interrogation by CD4 T-cells (Wolf and 
Ploegh, 1995) (Figure 1.2). The MHC II processing pathway is leaky as it has been 
shown that exogenous peptide can be presented by MHC I particularly in dendritic cells 
and monocytes. This phenomenon is called cross presentation (Albert et al., 1998, 
Goodridge et al., 2013, Qu et al., 2009). 
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Figure 1.2 Processing and presentation of exogenous T-cell antigens onto MHC II 
molecules.  
Phagocytised proteins are degraded by enzymes inside lysosomes into small peptides 
(1) and transported into a special MHC II compartment where they are loaded onto 
MHC II. In the meantime, MHC II molecules are assembled in the ER to be transported 
in the MHC II compartment (2). Peptide-MHC II then leaves then the compartment (3) 
to be directed to the cell surface to be presented to CD4+ T-cells (4). 
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1.4.2 Peptide-MHC class I 
1.4.2.1 Structure 
MHC I molecules are composed of an α chain (or heavy chain) comprised of three 
domains (α1, α2 and α3). The α1/α2 domain consists of a β sheet supporting two α helixes 
that cradle the bound peptide cargo. The α3 domain is associated non-covalently with 
β2-microglobulin (β2m) (Figure 1.3). Each α chain is internally linked by a disulfide 
bond (Bjorkman et al., 1987). MHC I molecules look very similar to MHC II, reflecting 
their common role of presenting peptides to the TCR. 
 
Figure 1.3 The structure of MHC I molecules.  
MHC I α heavy chain (shown in blue) is comprised of three α chain subunits (α1, α2 
and α3) and is associated to the β2 microglobulin (β2m) shown in salmon. The peptide 
loaded into the MHC I groove is shown in red. A schematic cartoon of the structure that 
will be used in subsequent diagrams is inset. 
I detail in the next section the manufacturing and presentation processes of endogenous 
peptides onto MHC I. 
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1.4.2.2 Peptide processing onto MHC I 
The majority of MHC I-associated peptides are produced in the cytoplasm by a large 
multi-subunit protease complex called the proteasome. The proteasome is composed of 
multiple ATP-dependant proteases that cleave nuclear/cytosolic proteins into small 
peptide fragments (Rivett et al., 1992). After cleavage by the proteasome, peptides are 
chaperoned by several heat shock proteins (HSP) and shuttled toward the ER. The 
heterodimeric transporter associated with antigen processing (TAP) protein translocates 
peptides into the lumen of the ER (Lauvau et al., 1999). The protein cluster formed by 
TAP, ERp75 and tapasin proteins is called the peptide loading complex and catalyses 
the loading of the peptide onto the MHC I groove (Cresswell, 2000) (Figure 1.4). The 
folding of MHC I α-chains and β2m begins in the ER. The association of the α-chains 
and β2m chains is mediated by two ER bound proteins: calnexin and calreticulin.  
Calreticulin retains the newly formed MHC I heterodimer inside the ER until an 
endogenous peptide is transferred into the groove of the MHC I (Degen and Williams, 
1991, David et al., 1993) .The peptide-MHC class I complex then dissociates from the 
peptide loading complex and is transported by chaperones towards the surface of the 
cell.
Chapter 1 
12 
 
Figure 1.4 Processing and presentation of endogenous T-cell antigens onto MHC I 
molecules.  
Intracellular proteins are degraded by the proteasome into small peptides (1) and 
transported by the TAP complex into the ER to be loaded onto the MHC I molecule (2). 
The peptide-MHC complex is then conveyed toward the cell surface to be presented to 
CD8 T-cells (3).  
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1.5 Structure of the αβ T-cell receptor 
A clonotypic αβ T-cell expresses multiple copies of a single αβ TCR that is able to 
recognise peptides presented by MHC I or MHC II. The TCR is a glycosylated 
heterodimeric membrane-bound protein that is composed of an α-chain (TCRα) and a β-
chain (TCRβ). The TCR is highly architecturally similar to the fragment antigen binding 
(Fab) of an immunoglobulin molecule. Each TCR chain is composed of a constant 
domain (Cα and Cβ) and a variable domain (Vα and Vβ). The variable domains possess 
three flexible hypervariable regions called complementarity-determining region (CDR) 
loops and named CDR1, CDR2 and CDR3. CDR1 and CDR2 loops have been shown to 
engage principally with solvent exposed residues of the MHC while the CDR3 loops 
engage with residues of both the MHC and the bound peptide (Rudolph et al., 2006) 
(Figure 1.5). Hyper variability of CDR3 loops is conferred by the recombination of the 
3 genes from the V, D and J loci during T-cell development. This mechanism is called 
V(D)J recombination (described in section 1.5.3) and allows many different CDR3 loop 
shapes which in turn can engage many different peptide-MHC combinations. 
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Figure 1.5 Co-crystal structure of an αβ TCR in complex with HLA-A2 presenting 
an epitope from the telomerase reverse transcriptase (ILAKFLHWL).  
A. The αβ TCR is composed of an α chain shown in red and β chain shown in green. 
Each chain is composed of a constant domain (C) and a variable domain (V). B. An 
expanded view to show that each variable domain makes contact with the pMHC I 
molecule via 3 CDR loops (CDR1-3) (pdb: 4MNQ). 
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1.6 Manufacture of TCR genes 
1.6.1 T-cell development and TCR education 
T-cell development begins with the differentiation of pluripotent hematopoietic stem 
cells into lymphoid precursors in the bone marrow. These then migrate to the thymus 
and differentiate into thymocytes. Thymic development entails genetic and phenotypic 
maturation steps leading to the generation of a quality controlled TCR and the 
designation to the CD4 or CD8 T-cell subsets. Expression of the co-receptors CD4 and 
CD8 defines steps of T-cell development.  
Lymphoid precursors are known to express neither CD4 or CD8 co-receptor nor TCR 
and are called triple negative thymocytes (TN) (Blom and Spits, 2006). TN thymocytes 
first undergo recombination of the TCRβ chain gene locus by VDJ recombination 
(described in 1.6.2) and are then defined as CD4/CD8 double negative thymocytes 
(DN). The newly formed TCRβ chain associates with a pre-TCRα chain (pTα) (Fehling 
et al., 1995) and the CD3 complex (CD3εδ, CD3εγ and CD3εζ) implicated in TCR 
signal transduction. This immature TCR is called the pre-TCR. Following the 
expression of the pre-TCR/CD3 complex, DN thymocytes express both CD4 and CD8 
co-receptors (Spits, 2002). Thymocytes are thenceforth called double positive (DP) 
thymocytes. Signalling through the pre-TCR/CD3 complex triggers the gradual 
downregulation of the pTα and initiates the VJ rearrangement of TCRα gene locus. 
Following successful rearrangement of the TCRα chain a fully functional αβTCR/CD3 
complex is expressed at the surface of the cell.  
Newly formed αβ thymocytes undergo selection in the thymic environment. This quality 
control process ensures that thymocytes are likely to be useful but unlikely to be self-
reactive. This auditioning procedure consists of both positive and negative selection. 
Thymocytes bearing TCRs with a high affinity for self pMHC are culled while those 
with a low affinity for pMHC survive and proceed to the next step of maturation. This 
process ensures that only T-cells expressing TCRs that exhibit weak affinity for self 
pMHC populate the periphery. Thymocytes that bear TCRs that fail to recognise self 
pMHC do not receive a survival signal and are said to ‘die by neglect’. T-cells that 
successfully negotiate thymic auditioning have the capacity to react strongly to non-self 
peptides in the context of autologous MHCs. This requirement for an autologous MHC 
is termed ‘MHC-restriction’. 
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Overall, it is estimated that only about 3% of all the thymocytes generated from the 
lymphoid progenitor survive thymic selection to become naive T-cells (Shortman et al., 
1991). DP thymocytes that pass through thymic editing express either CD4 or CD8 co-
receptor (Figure 1.6). The mechanisms involved in the development of these single 
positive (SP) thymocytes are not yet fully understood. 
Thymus Periphery
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TN
thymocyte
TCR-CD8-CD4-
DP
thymocyte
preTCR CD8+CD4+
DP
thymocyte
αβTCR, CD8+CD4+
CD4+ T-cell
CD8+ T-cell
TCRβ VDJ
gene segment 
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CD8
CD4
CD8
CD4
CD4
CD8
Pre TCR signalling αβTCR signalling
pTα
β-chain αβ TCR
 
Figure 1.6 Steps of cell surface marker expression during T-cell development. 
After migrating from the bone marrow, the lymphoid precursor cell differentiates into a 
TCR/CD4/CD8 triple negative (TN) thymocyte. During this phase, TN thymocytes 
rearrange the TCRβ VDJ gene segments to produce a functional TCRβ chain and 
express a pre TCRα chain (pTα) forming a pre-TCR. Subsequently, TN thymocytes 
upregulate expression of both CD4 and CD8 co-receptors to become double positive 
(DP) thymocytes. Signalling through the pre-TCR triggers the rearrangement of the 
TCRα V and J gene segments to produce a functional TCRα chain. DP thymocytes now 
express a fully functional αβ TCRs on cell surface which is quality controlled during a 
process called thymic positive/ negative selection. The DP thymocyte downregulates 
one of the co-receptor to become single positive (SP) thymocytes. SP thymocytes exit 
the thymus to colonise the periphery. 
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1.6.2 V(D)J recombination 
The diversity of the TCR repertoire is acquired during the thymic selection of 
thymocytes when the gene segments V, (D) and J from the TCRβ and TCRα chain gene 
loci are recombined. This step of TCR gene rearrangement is called somatic 
recombination or V(D)J recombination. As mentioned in section 1.6.1, the germline 
TCRβ chain gene locus in thymocytes is the first to be rearranged. The TCRβ locus is 
located on chromosome 7 and is composed of 54 variable (Vβ), 2 constant (Cβ), 2 
diversity (Dβ) and 13 junction (Jβ) gene segments (Rowen et al., 1996). The somatic 
rearrangement of the TCRβ involves the ‘shuffling’ of the V, D and J gene segments by 
juxtaposition and rejoining of their sequences. This mechanism is assisted by 
recombination activation genes (RAGs) encoding for two enzymes RAG-1 and RAG-2. 
The somatic recombination starts with the joining of the Dβ with the Jβ segment 
forming the segment DβJβ which is then recombined with the Vβ segment. The 
VβDβJβ segment produced constitutes the variable region of the future TCRβ chain. 
The VβDβJβ is then joined to the Cβ gene segment and, if the rearrangement is 
productive, this gene is transcribed and translated to produce a fully functional TCRβ 
chain containing all four segments. The TCRβ chain assembles with the pTα chain to 
produce the first TCR expressed by the DN immature thymocytes (called the pre-TCR). 
If the pre-TCR provides a complete activation signal to thymocytes, the TCRα gene loci 
rearrangement is initiated in order to produce a TCRα chain.  
The TCRα gene locus is found on chromosome 14 and contains 47 variable (Vα), 57 
junction (Jα) and 1 constant (Cα) gene segments. The rearrangement of the TCRα locus 
is similar to the TCRβ however there is no D gene segment. The process starts first with 
the joining of the Jα and the Vα segment. If rearrangement of the TCRα gene on the 
first chromosome does not produce a functional TCR in terms of producing a positive 
selection signal then rearrangement can take place on the second chromosome. This 
results in the possible expression of two different TCRαβ with an identical TCRβ chain 
in the periphery (Padovan et al., 1993, Petrie et al., 1993). Unsuccessful rearrangement 
of a functional TCRα gene from either chromosome leads to apoptosis. Overall, V(D)J 
rearrangement of human αβ TCR genes can theoretically produce over 1018 TCR 
combinations (Sewell, 2012). In reality, the number of  αβ TCRs  in vivo is much 
smaller than this theoretical possibility and the human TCRαβ repertoire is estimated to 
be 2.5x107 (Arstila et al., 1999). 
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Figure 1.7 Steps of the V(D)J gene section recombination to produce a functional 
αβ TCR heterodimer.  
The somatic TCR gene arrangement starts with the recombination of the V and D gene 
segments. This step occurs only in the TCRβ locus as the D gene segment is inexistent 
in the TCRα locus. Newly formed VD segment rearranges with the J segment to form 
the VβDβJβ in the TCRβ locus and VαJα in the TCRα locus and are incorporated in the 
respective C segment. Newly rearrange TCRβ and TCRα genes formed are expressed at 
different stage of the T-cell development to form a fully functional αβ TCR 
heterodimer. 
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1.7 Unconventional T-cells 
Recent studies have described T-cells that do not recognise conventional pMHC 
ligands; these T-cells are described as being ‘unconventional’. In some cases, there is 
compelling structural evidence for the recognition of unconventional T-cell ligands 
(Uldrich et al., 2013, Kjer-Nielsen et al., 2012). Some unconventional T-cells recognise 
lipids presented by the CD1 family proteins. This family is composed of two groups. 
Group 1 CD1 comprise CD1a, CD1b and CD1c while CD1d is in group 2. Recent 
structural studies have documented how some αβ TCRs can recognise lipids presented 
by the non-classical MHC (MHC1b) molecule CD1d (Uldrich et al., 2013). Other αβ 
TCRs are restricted by another MHC1b molecule called MR1 (Kjer-Nielsen et al., 
2012). MR1-restricted T-cells are called mucosal associated invariant T-cells (MAITs). 
It is not yet clear how many types of different unconventional T-cell types there are. 
Some key, recently discovered, unconventional T-cells are described below. 
1.7.1 CD1d-resricted T-cells (NK T cells) 
Classical type I NK T-cells are restricted by the group 2 CD1 molecule CD1d and 
express an invariant TCRα chain Vα24 Jα18 paired with Vβ11 chain in human 
(Bendelac et al., 2007). The first antigen discovered for type I NK T-cells was the 
glycosphingolipid α-galactosylceramide (α-GalCer) loaded on CD1d (Bendelac et al., 
1995, Borg et al., 2007). However, other ligands have been identified such as bacterial 
glycolipids also presented by the CD1d platform (Godfrey et al., 2010b). 
Another NK T-cell class has been identified in the last decade. Type II NK T-cells are 
also known to be restricted by CD1d. Type II NK T-cells recognise hydrophobic 
compounds including sulfatides (Jahng et al., 2004) and non lipid molecules (Godfrey et 
al., 2010a). Type II NK T cells also express an invariant αβ TCR (Vα3.2 Jα9 or Vα8Jα9 
associated with Vβ8).  
NK T-cells are mainly specialised in cytokine production. Interestingly, the nature of 
the cytokine released depends on the tissues and microenvironment (Godfrey et al., 
2000). Recent studies have highlighted that some NK T-cell are involved in suppression 
of tumour rejection (Berzofsky and Terabe, 2008) and the inhibition of autoimmunity 
(Jahng et al., 2004). 
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1.7.2 Group 1 CD1-restricted T-cells 
While, numerous studies have been aimed at unravelling the mysteries of NK T-cells, 
relatively few have explored the T-cell subsets restricted by group 1 CD1 family 
molecules (CD1a, CD1b and CD1c). Interestingly, this population is surprisingly 
important in peripheral blood. Indeed, they can represent from 1/300 to 1/10 of 
peripheral T-cells and are known to be present in the CD4 and CD4-/CD8- double 
negative (DN) population (Bendelac et al., 2007, de Lalla et al., 2011). Their role has 
only been assessed recently and was shown to share features with TH1 cells.  
1.7.3 MR1-restricted T-cells MAITs 
This recently discovered group of unconventional T-cells possess an invariant TCR 
designed for the detection of bacterially-infected cells through the monomorphic MHC 
Ib molecule MR1 (Gold et al., 2010). Mucosal associated invariant T-cells (MAITs) are 
classified as innate cells due to their restricted TCR repertoire but share characteristics 
of adaptive immunity such as acquirement of memory phenotype (Martin et al., 2009), 
cytolytic activity (Bendelac et al., 2007) and undergo thymic selection (Gold et al., 
2013). MAITs are also found in high frequencies in the liver (~45%) and low 
frequencies in peripheral blood (1-4% of the total lymphocytes) (Martin et al., 2009). 
Like NK T-cells, they express an invariant TCRα chain Vα7.2 Jα33 that associates 
chiefly with Vβ2 and Vβ13 chains. MAIT biology is discussed in detail in chapter 4. 
1.8 Mycobacteria 
My work aimed at examining T-cell responses to intracellular bacteria with special 
emphasis on mycobacteria. I will describe these bacterial species including their 
phylogenetic nomenclature, the diseases they cause and how the immune is system 
intimately involved in their transmission. 
1.9 Mycobacteria classification 
Mycobacteria are gram-positive, aerobic bacteria that belong to the family of 
Mycobacteriaceae and to the genus Mycobacterium. The Mycobacterium genus contains 
more than 120 species. The vast majority of these species are non-pathogenic such as 
the well-studied Mycobacterium smegmatis (M. smegmatis).  
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However, certain species such as Mycobacterium tuberculosis (M. tuberculosis), 
Mycobacterium bovis (M. bovis) and Mycobacterium leprae (M. leprae) are virulent 
human and animal pathogens. Mycobacterium species can be classified into two major 
groups – slow growing and fast growing species. There are also several different 
Mycobacterium subclasses (Grange and Yates, 1986). (see Table 1.2). I will describe 
details of the three pathogenic Mycobacterium species below as these important species 
have been studied extensively. 
Slow growing  species Fast growing species
Mycobacterium 
Tuberculosis 
complex
Mycobacterium 
Avium
complex
Ungrouped
Mycobacterium 
fortuitum
clade
Mycobacterium 
parafortuitum
clade
Ungrouped
-M. Tuberculosis
-M. bovis
- M. affricanum
- M. avium
- M. avium
paratuberculosis
-M leprae
- M. marinum
-M. fortuitum
-M. senegalense
- M. brisbanense
- M. parafortuitum
- M. fortuitum
- M. smegmatis
- M. elephantis
 
Table 1.2 Categorisation of important Mycobacterium species. 
1.10 Mycobacterium tuberculosis 
1.10.1 M. tuberculosis infection 
M. tuberculosis is an important human pathogen that is transmitted between individuals 
via air droplets. Once inhaled, M. tuberculosis targets phagocytic cells found in the lung 
alveoli. M. tuberculosis infection is mainly characterised by an intense cough, fever and, 
in advance stages of the disease, severe diarrhoea. The disease associated with M. 
tuberculosis infection is called Tuberculosis (TB). TB severity varies with the dose of 
infection and the efficiency of an individual’s immune system. 10 to 25 % of TB 
infections are extra-pulmonary and affect mainly people with weakened immune 
systems particularly HIV-infected individuals. This form of TB infection is 
characterised by the dissemination of M. tuberculosis toward other organs such as 
lymph node, pleura and osteoarticular sites (Golden and Vikram, 2005).  
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Even though TB mortality has steadily decreased since 1990, it still represents a major 
global disease burden. In 2012, the World Health Organisation estimated that 1.3 
million people died and more than 8.7 million fell ill as a result of M. tuberculosis 
infection. Moreover, co-infection with HIV has dramatically escalated in the developing 
countries. Pockets of TB infection can be found in the United States, Europe, some 
areas of former Soviet Union and the UK (WHO Global tuberculosis report 2014-
Executive summary). M. tuberculosis infection is characterised by different steps that I 
will briefly described in the following sections. 
1.10.2 M. tuberculosis transmission 
The human immune system plays a key role in M. tuberculosis transmission. As 
previously mentioned, M. tuberculosis is transmitted via the airways and infects mainly 
phagocytic cells such as monocytes, neutrophils, dendritic cells and macrophages 
located in the lungs (Kang et al., Wolf et al., 2007). As such, the recruitment of 
neutrophils during the first stage of the infection is beneficial to the expansion of M. 
tuberculosis. Progressive accumulation of dead neutrophils and live bacteria forms 
structures called granulomas in the lungs (Davis and Ramakrishnan, 2009). The bacilli 
remain in the granulomas and are excreted via the airways for transmission. After entry 
in the lung, M. tuberculosis and macrophages compete against each other for survival. 
In about 15% of M. tuberculosis infected patients, the bacilli can traffic to other organs 
leading to the development of an acute disease called extra-pulmonary TB (Peto et al., 
2009). M. tuberculosis infection is often divided in different stages as described below. 
1.10.2.1 Phagocytosis of M. tuberculosis by monocytes/ macrophages 
Recognition of M. tuberculosis by innate immune cells is initiated by the binding of M. 
tuberculosis PAMPs to cell surface Toll-Like Receptors (TLRs) (Banaiee et al., 2006, 
Bafica et al., 2005). Upon M. tuberculosis recognition, these cells release cytokines and 
chemokines to produce a pro-inflammatory environment that promotes recruitment of 
monocytes and macrophages at the site of infection (Cooper et al., 2011). Once 
recruited, macrophages phagocytose the bacteria through interactions between M. 
tuberculosis cell surface glycoproteins and cell surface complement receptors or 
mannose receptors (Schlesinger et al., 1994) or via Fc receptor binding to antibody 
opsonised bacteria (Cosma et al., 2003). This interaction results in the phagocytosis of 
the bacillus by specialised vesicles called endosomes (Cohn, 1963).  
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The survival of M. tuberculosis requires the inhibition of certain macrophage 
intracellular pathways specialised in the maturation of phagolysosomes. These 
pathways include disruption of endosome trafficking towards lysosomes (Hart et al., 
1972); the fusion of phagosomes with lysosomes (Hart et al., 1972); and inhibition of 
macrophage apoptosis which is beneficial for M. tuberculosis persistence in host 
(Blomgran et al., 2012). Once these pathways are inhibited, M. tuberculosis resides and 
multiplies in early endosomal compartments until macrophages enter apoptosis and are 
targeted by innate immune cells that are in turn infected; thereby spreading the 
infection. M. tuberculosis is propagated via a vicious circle that transmits infection from 
macrophage to macrophage by manipulating their life cycle. 
1.10.2.2 Equilibrium between M. tuberculosis and the adaptive immune system 
A delayed onset of the adaptive immune response is observed during TB infection. 
Lymphocytes can take up to 40 days before being recruited and activated by M. 
tuberculosis epitopes (Poulsen, 1950). This delay could be partially explained by the 
inhibition of M. tuberculosis-infected DC migration toward lymph nodes delaying the 
presentation of M. tuberculosis epitopes to CD4 T-cells (Blomgran and Ernst, 2011). 
Moreover, a large population of M. tuberculosis specific regulatory T-cells (Treg) can be 
detected during M. tuberculosis infection and could delay CD4 and CD8 T-cell 
migration toward the lungs (Shafiani et al., 2010). Boosting of adaptive immune cells 
with M. tuberculosis decreases bacterial load and TB symptoms in most individuals. 
This phase is called TB latency and is characterised by the control of the bacillus 
growth by the immune system but a failure to clear it.  
Studies have highlighted various mechanisms involved in the persistence of M. 
tuberculosis in the host. It is thought that inhibition of MHC II expression by M. 
tuberculosis infected macrophages could delay the presentation of M. tuberculosis 
epitopes to CD4 T-cells (Egen et al., 2011, Noss et al., 2001). Individuals with latent TB 
are not thought to transmit infection. However, ~10% of individuals with latent TB 
infection will go on to develop active TB later in life (Schwartzman, 2002) and can then 
spread infection. 
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1.10.2.3 Reactivation of M. tuberculosis 
M. tuberculosis-infected individuals can develop an active disease after an 
asymptomatic period due to disruption of M. tuberculosis latency. M. tuberculosis 
reactivation produces an active, transmissible disease state and occurs in around 5-10% 
of latently infected individuals (Schwartzman, 2002). Various conditions are known to 
increase the risk of reactivation. The main risks of M. tuberculosis reactivation are 
associated with immuno-suppression due to HIV virus (Kwan and Ernst, 2011), 
chemotherapy or immunotherapy (Nadkarni et al., 2007). There is also an enhanced risk 
of reactivation in elderly patients thought to be due to the ageing of the immune system. 
1.10.3 Clearance of M. tuberculosis 
Most patients infected with M. tuberculosis do not exhibit symptoms of TB and either 
live with a latent asymptomatic TB disease or clear the bacterium. Efficiency of the 
immune system in the clearance and containment of the bacterium is mediated by the 
inflammatory environment that drives anti-microbial innate and adaptive immunity. 
Studies have described the role of IFNγ, TNFα and vitamin D as crucial for M. 
tuberculosis containment. Indeed, an IFNγ-mediated immune response promotes the 
activation of macrophages and CTLs. In macrophages, IFNγ promotes maturation of 
phagolysosomes and favours antigen presentation to T-cells (MacMicking et al., 2003) 
and the production of nitric oxide (NO) (Chan et al., 1992) essential for degradation of 
bacteria. Furthermore, vitamin D induces expression of a protein called LL-37 by 
macrophages. LL-37 contributes to the lysis of the bacterium (Martineau et al., 2007). 
Interestingly, vitamin D deficiency has been shown to be associated with active TB. 
Thus a combination of cytokines and vitamins is thought to aid the clearance of M. 
tuberculosis by the innate immune system. Unfortunately 5-10 % of infected patients 
still develop active TB disease. 
1.10.4 Treatment of M. tuberculosis infection 
The introduction of antibiotic treatments has decreased M. tuberculosis prevalence 
worldwide. M. tuberculosis infection is mainly treated with combinations of antibiotics 
such as isoniazid/rifampicin/pyrazinamide/ethambutol cocktails. However, the extensive 
use of these antibiotics has triggered multidrug resistance M. tuberculosis strains 
(MDR-M. tuberculosis).  
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A prophylactic M. tuberculosis vaccine was developed in the beginning of the 20th 
century by a French research group using an attenuated strain of Mycobacterium bovis 
(M. bovis) called Bacille Calmette-Guerin (BCG) vaccine. The vaccine, its efficacy and 
limitations will be discussed in section 1.10.6. 
1.10.5 Mycobacterium bovis 
M. bovis is a slow growing Mycobacterium closely related to M. tuberculosis. M. bovis 
mainly infects animals including cattle, badgers and cats where it induces a TB disease. 
Transmission of M. bovis from animal to human was a major problem prior milk 
pasteurisation and still represents one of the biggest challenges facing the cattle farming 
industry. Indeed, M. bovis can contaminate humans via aerosols, meat and faeces. M. 
bovis related-TB symptoms in animals are very similar to those triggered by M. 
tuberculosis in human. An attenuated form of M. bovis called BCG has been used as a 
human TB vaccine for almost 100 years. 
1.10.6 BCG vaccine  
The Bacillus Calmette Guerin (BCG) vaccine is an attenuated strain of M. bovis 
developed in the early 1920’s by Calmette and Guerin at the Pasteur institute in France 
to prevent TB infection. The vaccine was obtained after subculturing M. bovis for 39 
passages in potato media. BCG vaccine effectively reduces transmission of M. bovis 
between animals (Calmette, 1931, Wedlock et al., 2007, Hope et al., 2011). During 
attenuation the bacillus has been shown to have lost several immunogenic virulence 
factors necessary for survival inside macrophages. 
BCG vaccine efficacy has been mixed and disappointing in preventing TB in adult 
populations (varies between 0% in south India and 80% in the UK) (Rodrigues and 
Smith, 1990, Colditz et al., 1994)). Nevertheless, the vaccine is believed to have 
contributed to the eradication of tuberculosis in Europe and has shown good protection 
in infants (Zodpey et al., 1998, Colditz et al., 1995). BCG vaccine is protective against 
Mycobacterium leprae (Merle et al., 2010). Different hypotheses have been suggested to 
explain the low efficacy of BCG vaccination in TB. It has been suggested that exposure 
to environmental Mycobacterium species could confer protection against M. 
tuberculosis.  
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Thus, the benefits of BCG vaccination could be masked by the natural exposure to TB 
antigens (the masking hypothesis) (Palmer and Long, 1966, Andersen and Doherty, 
2005).  
Another hypothesis postulates that a previous natural immunisation to M. tuberculosis-
like antigens could prevent the replication of BCG bacilli after injection. Thus, the load 
and duration of BCG antigen presentation to the immune system is decreased resulting 
in reduced potency (the blocking hypothesis) (Brandt et al., 2002). Studies have also 
shown that the efficacy of the BCG vaccine is dramatically reduced in M. tuberculosis-
HIV co-infected individuals where immune integrity is compromised (Arbelaez et al., 
2000). 
1.11 Mycobacterium leprae 
Mycobacterium leprae is the causative agent of Leprosy and currently affects 1 in 
10,000 of the global population (W.H.O.-leprosy). Leprosy has highly variable clinical 
manifestations that oscillate between two polar forms. Interestingly, the adaptive 
immune system signature varies within this spectrum of leprosy forms. The first form is 
known as tuberculoid leprosy and is characterised by the generation of granulomas in 
the lungs and nerve damage due to the immune-mediated destruction of M. leprae 
infected Schwann cells in peripheral nerves. This forms triggers a high cell-mediated 
TH1 immune response that maintain minimum symptoms and possibly clear the bacilli. 
However, at the other end of the spectrum, the more pathogenic clinical form is called 
lepromatous leprosy. Lepromatous leprosy induces mainly a TH2 response and fails to 
activate a TH1 response resulting in severe symptoms such as numerous skin lesions and 
nerve destruction (Britton and Lockwood, 2004, Cosma et al., 2003). Dissection of the 
T-cell subsets patients with leprosy showed the presence of many unconventional T-
cells such as CD1 restricted and γδ T-cells (Layre et al., 2009, Willcox et al., 2007). 
Due to its slow growth and host dependency, M. leprae is difficult to expand ex vivo. 
However, M. leprae can be cultivated in the footpads of mice and armadillos providing 
good source of bacilli (Shepard, 1960, Kirchheimer and Storrs, 1971). The development 
of multidrug therapies such as antibiotic cocktails has dramatically decreased leprosy 
prevalence worldwide. However, leprosy is still a health problem in developed countries 
where more than 200,000 new cases emerge every year (W.H.O.-leprosy). 
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1.12 Aims 
T-cells orchestrate immunity and are pivotal to the removal of cells infected with 
intracellular pathogens. When I initiated my thesis studies there was renewed interest in 
the study of T-cell responses to Mycobacterium tuberculosis (M. tuberculosis). In 
particular, new ‘innate-like’, ‘unconventional’ T-cell populations such as MAITs were 
being strongly implicated as key immune cells during M. tuberculosis infection. My 
work was aimed at studying T-cell responses to mycobacteria. I used Mycobacterium 
smegmatis (M. smegmatis) as a model of M. tuberculosis infection as I was able to 
openly work with this non-pathogenic mycobacterium in the laboratory. I was 
particularly interested in documenting the breadth of T-cell responses raised against M. 
smegmatis and the division of these responses between conventional (HLA-restricted, 
peptide-recognising) and unconventional (non-HLA restricted, non peptide-recognising) 
T-cell populations. I believe that unconventional T-cells are particularly interesting 
because they do not rely on the HLA molecules that are known to vary widely 
throughout the population as described above. Unconventional T-cells recognise 
bacteria via non-polymorphic MHC-like molecules such as CD1a, CD1b, CD1c, CD1d 
and MR1. These molecules are invariant in the human population and therefore offer 
opportunities for pan population vaccination. The specific aims of this thesis are: 
1. To define the frequency of conventional and unconventional T-cells generated during 
direct ex vivo exposure to intracellular mycobacteria. 
2. To investigate the molecular and cellular mechanism by which unconventional MAIT 
cells recognise cells infected with Mycobacterium. 
3. To undertake the first dissection of the molecular recognition of M. tuberculosis by a 
conventional TCR. 
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Cell culture 
2.1.1 Mammalian culture media 
R0 medium: RPMI (Invitrogen) supplemented with 100 international units (iu) of 
Penicillin and 100 µg of streptomycin (Invitrogen), 2mM L-glutamine (Invitrogen). 
R2 medium: R0 medium supplemented with 2% Foetal Calf Serum FCS (Inactivated 
FCS; Life technology).  
R10 medium: R0 medium supplemented with 10% FCS (Inactivated FCS; Life 
technology).  
T-cell culture medium: R10 supplemented with 100 iu/mL of interleukin-2 (Novartis) 
and 25 μg/mL of interleukin-15 (Peprotech). 
T-cell expansion medium: R10 supplemented with 20 iu/mL of interleukin-2 (IL-2; 
Novartis), 25 μg/mL of interleukin-15 (IL-15; Peprotech) and 1 μg/mL of purified 
phytohemagglutinin (PHA; Alere). 
Red blood cell lysis buffer (pH 7.2-7.4): 155 mM NH4Cl, 10 mM KHCO3, 0,1 mM 
EDTA. 
MACS buffer: D-PBS no MgCl2, no CaCl2 (Life Technology), 5 g/L BSA, 0.74 g/L 
EDTA. 
Freezing buffer: 90% of FCS (Life Technology) and 10% of Dimethyl sulfoxide 
(DMSO; Sigma). 
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2.1.2 Preparation of human peripheral blood mononuclear cells (PBMCs) from blood 
Peripheral blood was collected from healthy donors by venepuncture into a sterile 
falcon tube (Corning Life Science) containing heparin (LEO Laboratories Ltd) at a final 
concentration of 100 iu/mL of blood. Blood was layered onto an equal volume of a 
LymphoPrep (Sigma) solution (density 1.077 +/- 0.001 g/mL; Progen) and centrifuged 
for 20 minutes at 537 x g (Hareaus megafuge, 1.0 R) with the centrifuge brake turned 
off. PBMCs were layered above the LymphoPrep and collected with a 3 mL Pasteur 
pipette. PBMCs were washed with R10 medium (section 2.1.1) and centrifuged at 435 x 
g for 10 minutes. Red blood cells were lysed using the red blood lysis buffer (section 
2.1.1) and incubated at 37 °C for 10 minutes then washed with R10 medium and 
centrifuged 5 minutes at 300 x g.  
2.1.3 Origin of T-cells used in this thesis 
CD8 T-cell clones used throughout this thesis are listed below in Table 2.1. D426 B1 
and D454 CD8 T-cell clones were provided by Prof. David Lewinsohn, Oregon Health 
and Science University, Portland. Morpheus was extracted from D426 B1. 
Name 
clone 
HLA 
Restriction 
Natural 
Epitope 
TCR 
(Arden) 
Origin :Organism/Protein 
(owner) 
D426 B1 MR1 unknown 
Defined in 
chapter 4 
M. tuberculosis 
(Lewinsohn, D. et al.) 
D454 A*0201 LLDAHIPQL 
Vα 2.1 
Vβ 16.1 
M. tuberculosis/Esx-G 
(Lewinsohn, D. et al.) 
Morpheus - - 
Vα 1.4 
Vβ 24.1 
Originate from the D426 B1 
line/M. tuberculosis/Esx-G 
(Lewinsohn, D. et al) 
NLV4-10 A*0201 NLVPMVATV V β 13.1 
Cytomegalovirus pp65 
protein (Garry Dolton et al.) 
 
Table 2.1 List of human CD8 T-cells used throughout this thesis. 
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2.1.4 Expansion and maintenance of CD8 T-cell clones 
CD8 T-cell clones were expanded from existing culture or cryopreserved stocks in a T-
25 tissue culture flask (Greiner bio-one) at a concentration of 1 x 106 CD8 T-cell clones 
into 15 mL of an expansion mixture. The expansion mixture was prepared as follows: 
15 x 106 allogeneic PBMCs (obtained from a minimum of three healthy donors) were γ-
ray irradiated at 3000 centi-gray (Caesium source) and washed with 50 mL of R10 
medium at 300 x g for 10 minutes. The allogeneic PBMCs were then resuspended in 15 
mL of T-cell expansion media (section 2.1.1) and added to 1 x 106 CD8 T-cells. The 
cells were incubated at 37°C and 5% CO2. After 5 days, half of the media was 
exchanged with T-cell culture media (section 2.1.1). CD8 T-cell clones were used in 
assays after a minimum of 8 days following the expansion protocol to allow TCRs to be 
up-regulated to the T-cell membrane. 
2.1.5 Extraction of IRAPVLYDL specific T-cells from D426 B1 by IFNγ secretion 
assay and limiting dilution 
2.1.5.1 IFNγ secretion assay 
IRAPVLYDL specific T-cells were extracted from D426 B1 clone using IFNγ secretion 
assay, Cell enrichment and detection kit (PE) from Miltenyi Biotec. Before proceeding 
to the IFNγ secretion assay, D426 B1 cells were washed once in R0 medium (section 
2.1.1) and centrifuged at 300 x g for 5 minutes, resuspended into R2 medium and rested 
overnight at 37 °C and 5% CO2. 1 x 10
6 cells were plated in a single well 96 round 
bottom well plate (Greiner bio-one) in R2 medium, pulsed with 50 μM of IRAPVLYDL 
and incubated 4 hours at 37˚C and 5% CO2. The cells were washed with 10 mL of cold 
MACS Buffer and centrifuged at 300 x g for 10 minutes. The supernatant was removed 
and the pellet was resuspended in 80 μl of cold R2 medium and 20 μl of IFNγ Catch 
Reagent (anti-IFNγ monoclonal antibody; (mouse IgG1) conjugated to cell surface 
specific monoclonal antibody (mouse IgG2a); Miltenyi Biotec). The cells were mixed 
thoroughly and placed on ice for 5 minutes. 10 mL of 37°C warm R2 medium were 
added and the cells were incubated 45 minutes at 37˚C and 5% CO2, whilst rotating. 
Antibody treated cells were washed with cold MACS buffer and centrifuged at 300 x g 
for 10 minutes.  
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The pellet was treated with 80 μl of cold MACS buffer and 20 μl of IFNγ Detection 
antibody (PE) (anti-IFNγ monoclonal antibody (mouse IgG1) conjugated to R-
phycoerythrin (PE); Miltenyi Biotec) and were placed on ice for 10 minutes. Another 
wash with MACS buffer followed by a centrifugation step at 300 x g for 10 minutes 
was performed. The cell pellet was re-suspended in 80 μl of cold MACS buffer and 20 
μl of anti-PE micro-beads (Miltenyi Biotec). Cells were incubated at 4°C whilst rotating 
for 15 minutes. Cells were washed with 10 mL of cold MACS buffer and centrifuged at 
300 x g for 10 minutes. The supernatant was removed. Cells were then resuspended in 
500 μl of cold MACS buffer and run through an MS column (Miltenyi Biotec). IFNγ 
specific labelled cells were extracted through the MS column using a magnetic field 
(Miltenyi Biotec). IFNγ specific labelled and unlabelled cells were rested separately in 
T-cell culture medium overnight. 
2.1.5.2 T-cell limiting dilution  
Post sorting as described above, both IFNγ specific and unspecific T-cells were cloned 
at a concentration of 0.5 cells per single well of a round bottom-well plate (Greiner bio-
one) and expended in T-cell expansion media as detailed in section 2.1.1. Cells were 
incubated at 37 °C and 5% CO2 for 5 days before the medium was changed for the T-
cell culture media. 
2.1.6 Boosting of PBMCs with M. smegmatis  
2.1.6.1 Phagocytosis of M. smegmatis by antigen presenting cells 
Chosen antigen presenting cells (APCs) were incubated with R10 medium lacking 
penicillin/streptomycin. APCs were incubated with M. smegmatis for 2 hours at a 
concentration of 3.5 x 106 APC to 35 x 106 cfu M. smegmatis (MOI 10 x M. smegmatis 
cell for 1 x APC (10:1)) in 10 mL of R10 medium lacking penicillin/streptomycin in a 
T-75 (Greiner bio-one) to allow phagocytosis. Following the phagocytosis, the cells 
were incubated for 2 hours with 100 units/mL of penicillin and 100 µg/mL of 
streptomycin (Life technology). APCs were washed 3 times with R10 medium and 
treated with PBS supplemented with 2 mM EDTA prior to removal from the tissue 
culture plastic. Cells were than washed twice with R10 medium and centrifuged at 300 
x g for 5 minutes and resuspended in R10 medium to be used in assays. 
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2.1.6.2 Boosting of PBMCs with M. smegmatis infected autologous dendritic cells 
PBMCs from a healthy donor were extracted from peripheral blood. Half were 
cryopreserved into 1 mL of freezing buffer. Monocytes were extracted from the other 
half and used to generate dendritic cells (DCs). 
Monocyte differentiation into dendritic cells 
Monocytes were extracted from healthy PBMCs obtained from peripheral blood using 
anti-CD14 antibody magnetic beads (Milteny biotec). CD14 positive cells were cultured 
at 2 x 106 per well in a 6 well plate in 5 mL of R10 medium supplemented with 100 
ng/mL of recombinant human GM-CSF (Peprotech), 50 ng/mL recombinant human IL-
4 (Peprotech). After 3 days, half of the medium was renewed. After 6 days of 
incubation, the differentiation status of monocytes into DCs was assessed by flow 
cytometry by measuring the expression of the following cell surface markers: CD209, 
CD1a and CD14. Cells were stained with 2μL of anti-CD209 (eBioscience), 2μL of 
anti- CD1a (eBioscience) and 2μL of anti-CD14 (eBioscience) antibodies and analysed 
by flow cytometry (Figure 2.1). DCs were then co-cultured with M. smegmatis using 
the protocol detailed in section 2.1.6.1. 
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Figure 2.1. Differentiation “status” of monocytes into dendritic cells. 
Monocytes (A.) extracted from PBMCs as explained above were tested for their 
expression of CD14 marker before differentiation (B. top quadrant) and after 
differentiation (C. top quadrant) protocol was applied. The expression of CD209 and 
CD1a marker was tested for CD14+ monocytes before differentiation (B. bottom 
quadrant) and CD14- monocytes after differentiation (dendritic cells C. Bottom 
quadrant). The red percentage on C. Bottom quadrant correspond the percentage of 
dendritic cells. 
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Boosting of PBMCs with autologous DCs 
Cryopreserved PBMCs were thawed out and were plated into 24 well plate at a 
concentration of 3.5 x 106 cells per 2 mL of T-cell culture media, one day before 
boosting. Cells were then counted and plated at 5 x 106 cells per well in a 24 well plate 
and co-cultured with 2 x 105 M. smegmatis infected DCs in R10 medium supplemented 
with 20 iu/mL IL-2. Half the media was replaced every 3 days for 13 days. 
2.1.6.3 Boosting of PBMCs with M. smegmatis infected A549 cells 
PBMCs were extracted from blood and plated in R10 medium at a concentration of 5 
x106 PBMCs for 2 x105 M. smegmatis infected A549 cells per well of a 24 well plate in 
R10 supplemented with 20 iu/mL IL-2. Half the media was replaced every 3 days. 
2.1.7 Origin and culture of lymphoblastoid cell lines 
The Hmy.2.C1R cell line, called C1R in this thesis, is a class I negative EBV 
transformed B cell line. A HLA-A*0201 expressing C1R (C1R-A2) cell line was 
generated in-house by colleagues (Wooldridge et al., 2005). C1R-A2 were cultured in 
R10 medium (section 2.1.1). 
A549 is lung adenocarcinoma epithelial adherent cell line and can be cultured in R10 
medium in flask (Greiner bio-one). Cells were scraped off the flask using EDTA 2 mM 
for 10 minutes at 37 °C. Cells were then washed with R10 medium and resuspended in a 
new flask at a concentration of 1 x 104 cells/cm2. This step was repeated when the cell 
reached 90 % confluent. 
Cell name HLA expression Source 
C1R-A2 A*0201 
C*4 (small amount expressed) 
(Wooldridge et al., 2005) 
A549 A*2501/3001 
B*18/4403 
C*1203/1601 
More information:(Adams et al., 
2005) 
 
Table 2.2 Lymphoblastoid cell lines used in this thesis. 
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2.1.8 Confocal Microscopy 
Coverslips (Warner Instruments) were added to the wells of a 24 flat bottom-well plate 
and treated with 500 µL of poly-L-lysin (Sigma Aldrich) for 5 minutes at RT. The 
solution was then removed from the well and the coverslips were washed twice with 
sterile water and dried at 37°C for 2 hours. 5 x 104 ± M. smegmatis A549 cells were 
added to each well and incubated for 3 hours in 500 µL of R10 to allow adherence of 
A549 cells to the coverslips. After incubation, cells were treated with 500 µL of a 2%-
formaldehyde-PBS solution for 20 minutes followed by a wash with water. The 
coverslips were then removed from the plate and cells were put in a drop of Mowiol 
(Sigma Aldrich) between coverslip and a glass slide (Thermo Scientific). The slide was 
stored at 4°C in the dark and analysed for the GFP protein fluorescence emission at a 
wavelength of 495 nm using a Leica TCS SP5 confocal microscope (Leica 
Microsystems). 
2.2 T-cell activation assays 
2.2.1 Single peptide activation assay 
CD8 T-cells were washed with R0 medium and rested in R2 medium overnight before 
being used in an activation assay. In single well of an 96 round bottom-well plate, 3 x 
104 T-cells were primed with 6 x 104 APCs per 100 µL of R2 medium and a titration of 
peptide from 10-4 to 10-15 M for 13 hours at 37˚C and 5% CO2. The 96 well plate was 
centrifuged at 35 x g to sediment cells to the bottom of the wells. 60 µl per well of 
supernatant was harvested and diluted with 60 µl of R2 medium. Supernatants were 
analyzed by MIP-1β enzyme-linked immunosorbent assay (ELISA) (described in 
section 2.2.4). 
2.2.2 Combinatorial peptide library screening assays 
2.2.2.1 Description of a nonamer combinatorial peptide library (CPL) 
The nonamer CPL (Pepscan Presto) contains 180 nonamer peptide mixtures. Each 
mixture contains nonamer peptides with one amino acid fixed at one position and an 
equimolar mix of the 20 proteinogenic amino acids in all other positions. The cysteine 
residue was omitted from the random positions to avoid formation of disulphide bonds 
between peptides within the mixture and peptide aggregation.  
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Each mixture is composed of 1.7 x 1010 peptides and the whole library contains 5 x 1011 
peptides and encompasses almost all possible nonamer peptides. T-cells were 
challenged with a nonamer library and their activation towards each mixture was 
evaluated by the release of MIP-1β chemokine or the IFNγ cytokine and measured by 
ELISA. 
2.2.2.2 Screening T-cell clones using a nonamer peptide library 
CD8 T-cells were washed with R0 medium and rested in R2 medium overnight. APCs 
were plated in single well of a 96 round bottom-well plate at a concentration of 6 x 104 
APCs per 45 µl and pulsed with 5 µl of peptide mixture from a nonamer peptide library 
at a final concentration of 100 µM for 1 hour at 37°C and 5% CO2. 3 x 10
4 CD8 T-cells 
per 50 µl were added to pulsed APCs. Plates were incubated overnight at 37 °C and 5% 
CO2 and centrifuged at 35 x g for 5 minutes. 60 µl of supernatant were harvested and 
diluted in 60 µl of R2 medium and analysed by MIP-1β or IFNγ ELISA. 
2.2.3 Chromium release assay 
For a chromium (Cr51) release assay, 2 x 106 APCs were washed with R10 medium. The 
dry pellet was incubated with 60 μCi of Cr51 for 1 hour at 37 °C and 5% CO2, washed 
with 10 mL of R10 medium and centrifuged at 300 x g for 5 minutes. Cells were re-
suspended into 5 mL of R10 medium and rested for an hour to release the excess of 
Cr51. APCs were then washed with R10 medium and plated at a concentration of 2,000 
APCs per 45 µl of R10 medium in single well of a 96 round bottom-well plate. Cells 
were pulsed with a titration of peptide from 10-4 to 10-15 M for 30 minutes at 37˚C. 1 x 
104 T-cells were added to the pulsed APCs and incubated for 4 hours at 37˚C and 5% 
CO2. 20 μl per well of supernatant were collected and added to 150 μl of Optiphase 
supermix scintillation cocktail (Perkin Elmer). The Cr51 radiation from the wells was 
measured using a Micro-Beta2 counter (Perkin Elmer). Percentage cytotoxicity was then 
calculated using the following equation: Specific lysis= [(experimental lysis-
spontaneous lysis)/(maximum lysis-spontaneous lysis)] x 100%. 
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2.2.4 Enzyme-linked immunosorbent assay (ELISA) 
All antibodies used during the development of MIP-1β ELISA came from the DuoSet 
ELISA/ human CCL4/MIP-1β development system kit (R&D Systems). All washes 
were performed by an AquaMax 2000 microplate washer (MFS analytical 
technologies). 
A half well flat bottom ELISA microplate (Corning Costar) was coated with 50 µl of a 
1.5 µg/ml of mouse anti-human MIP-1β antibody (capture antibody) and incubated 
overnight at room temperature (RT). The plate was washed 3 times with 190 µl of 
0.05% Tween 20-PBS (wash buffer) and 150 µl of a 1% BSA-PBS (diluent buffer) 
solution was added to each well. The plate was incubated for 1 hour at RT and washed 3 
times with 190 µl of wash buffer and 50 µl of cell supernatant collected from an 
activation assay was added to wells. Furthermore, a recombinant human MIP-1β 
standard (R&D Systems) was titrated from 1,000 to 62.5 pg/ml. The plate was 
incubated 1 hour and 15 minutes at RT and washed 3 times with 190µl of wash buffer. 
The plate was then coated with 50 µl of a 50 ng/ml of a biotinylated goat anti-human 
MIP-1β antibody (detection antibody) and incubated 1 hour and 15 minutes at RT. The 
plate was washed 3 times with 190 µl of wash buffer and 100 µl of a streptavidin 
conjugated to horseradish-peroxidase was added to the wells. The plate was incubated 
20 minutes followed by 3 washes with wash buffer. 100 µl of a 1:1 ratio colour reagents 
A and B (R&D Systems) were added to the wells and incubated for a maximum of 20 
minutes. The reaction was blocked by adding 50 µl of a H2SO4 solution. The OD450 of 
each well was read using a Bio-rad iMark microplate reader with correction set to 570 
nm. 
2.2.5 Enzyme linked immunospot (ELISpot) assay for IFNγ 
All antibodies and reagents used during the development of IFNγ ELISpot came from 
the ELISpot assay kit (ALP) for human IFNγ from Mabtech. All antibodies were diluted 
in D-PBS (Life Technologies). Development buffers (alkaline phosphatase development 
buffers) came from Bio-rad. The plate was washed with 150 μl of sterile D-PBS (Life 
Technologies). 
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A PVDF-backed plate (Millipore) was coated with 50 μl of a 10 μg/ml coating antibody 
(1-D1K) and incubated 4 hours at 37˚C or overnight at 4 °C. ELISpot plates were 
washed 5 times, blocked with 100 μl of 10% FCS (Inactivated FCS; Invitrogen) and 
incubated at RT for 1 hour in foil. After the media was decanted, T-cells were added to 
each well and incubated with either M. smegmatis infected APCs or peptide overnight at 
37˚C in foil with appropriate controls. After 5 washes, 50 μl of a 1 μg/ml biotinylated 
monoclonal antibody 7-B6-1-biotin was added to each well and incubated 2 hours at RT 
in the dark. The plate was washed 5 times and incubated with 50 μl of a 1 μg/ml per 
well of a streptavidin-alkaline phosphatase and incubated 2 hours at RT in the dark. 
After 5 washes, 50 μl of substrate solution was added to the wells and the plate was 
incubated 30 to 45 minutes in the dark at RT followed by 3 washes. A mixture of 
alkaline phosphatase buffers (Bio-rad) were added to the wells to reveal the spots left by 
IFNγ secreting cells. Spots were counted using an automated ELISpot Reader System 
ELR02 (Autoimmune Diagnostika). 
2.2.6 Intracellular staining (ICS) 
Cells were washed with R0 medium and plated overnight in R2 medium. Cells were 
treated with Golgi Plug (Brefeldin A; BD) (0.5 μL per mL of cell culture), Golgi Stop 
(Monensin; BD) (0.7 μL per mL of cell culture) and CD107a-FITC antibody (5 μL per 
mL of cell culture) and plated into single well of a 96 well round bottom plate at a 
concentration of 3 x 105 cells per 100 μL of R2 medium per well. Cells were stimulated 
with either 50 μM of peptide or 3 x 105 M. smegmatis infected APCs and incubated for 
5 hours at 37°C and 5% CO2. After 3 washes with PBS, cells were then stained with 
dead cell marker Vivid-Pacific Blue (see concentration and brand in table 2.2) and 
incubated for 5 minutes in the dark and then stained with cell surface markers antibodies 
using adequate concentration (table 2.2) and incubated for 20 minutes at 4 °C. 
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Marker Color Brand Clone 
concentration 
per 300 000 
cells/50μL 
PBS 
CD8 
APCCy7 Miltenyi Biotec 
BW135/80 (mouse 
IgG2a) 2 μL 
APC Miltenyi Biotec 
BW135/80 (mouse 
IgG2a) 2 μL 
PE Miltenyi Biotec 
BW135/80 (mouse 
IgG2a) 2 μL 
Vioblue 
(PB) 
Miltenyi Biotec 
BW135/80 (mouse 
IgG2a) 2 μL 
Brill Vio 
421 
Biolegend 
RPA-T8 (Mouse IgG1) 1 μL 
CD4 
FITC Miltenyi Biotec VIT4 (mouse IgG2a) 2 μL 
APC Miltenyi Biotec VIT4 (mouse IgG2a) 2 μL 
PECy7 Miltenyi Biotec VIT4 (mouse IgG2a) 1 μL 
Brill Vio 
421 
Biolegend RPA-T4 (Mouse IgG1) 
1 μL 
CD3 
PerCP Miltenyi Biotec 
BW264/56 (mouse 
IgG2a) 2 μL 
PerCP Biolegend UCHT1 1 μL 
CD19 PB Biolegend HIB19 (Mouse IgG1) 2 μL 
CD14 PB Biolegend M5E2 (Mouse IgG2a) 2 μL 
CD56 FITC Miltenyi Biotec REA196 2 μL 
MR1 - Hansen, T. et al. 26.5 (Mouse IgG2) 50 μg/mL 
Goat α-
mouse 
Ig 
FITC BD Bioscience Polyclonal 2 μL 
APC BD Bioscience Polyclonal 2 μL 
PE BD Bioscience Polyclonal 2 μL 
Vivid 
green 
PB 
Life 
Technologies 
x 
2 μL (from 
1/40 dilution in 
PBS) 
Aqua Am-cyan 
Life 
Technologies 
x 
2 μL (from 
1/40 dilution in 
PBS) 
 
Table 2.3 Cell surface marker antibodies. 
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The staining was followed by 3 washes with a solution of PBS supplemented with 2% 
FCS. Cells were treated with Cytofix/Cytoperm for 20 minutes on ice and washed with 
Perm/Wash solution (1X; BD). Cells were then stained for intracellular markers 
including cytokine (MIP-1β, IFNγ and TNFα) and other cell markers (see table 2.3 for 
concentrations). Stained cells were then washes 3 times with Perm/Wash buffer (BD) 
and then resuspended in 1% formaldehyde in PBS. Analysis of the results was carried 
out using the FACS Canto II (BD) and Flowjo software (Treestar Inc Ashland Oregon). 
Marker Color Brand Clone 
Concentration for 
300 000 cells/50μL PBS 
αβTCR 
PE Biolegend IP26 2 μL 
FITC Biolegend IP26 2 μL 
APC Biolegend IP26 2 μL 
γδTCR 
PE Miltenyi Biotec 
11F2 (mouse 
IgG1) 
2 μL 
FITC Miltenyi Biotec 
11F2 (mouse 
IgG1) 
2 μL 
APC Miltenyi Biotec 
11F2 (mouse 
IgG1) 
2 μL 
W6/32 - Abcam W6/32 50 μg/mL 
Vα 7.2 APC Lewinsohn, D. et al 3C6 2 μL 
CD107a FITC BD Biosciences H4A3 1 μL 
TNFα PECy7 BD Bioscience MAb11 0.5 μL 
MIP-1β PE BD Bioscience D21-1351 0.5 μL 
IFNγ APC Miltenyi Biotec 
45-15 (mouse 
IgG1) 
0.5 μL 
 
Table 2.4 Intracellular marker specific antibodies. 
2.2.7 Carboxyfluorescein diacetate Succinimydyl Ester (CFSE) 
CFSE powder (Invitrogen) was resuspended in ddH2O to give a 10 mM stock solution 
that was filtered and aliquoted. 1 x 106 cells were re-suspended into PBS and CFSE was 
added to a final concentration of 1 μM. Cells were incubated at 37 °C in a water bath for 
7 minutes and washed 3 times with PBS supplemented with 10% of FCS. 
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2.3 Flow cytometry 
Cell surface markers and T-cell receptor expression on T-cells and cell lines were 
monitored by antibody and pMHC tetramer staining. The analysis was carried out by 
flow cytometry using a FACSCanto II (BD) and Flowjo software (Treestar Inc). 
2.3.1 Fluorescent conjugated anti-human antibodies for detection of cell surface and 
intracellular protein expression. 
The antibody concentration used to stain 3 x 105 cells is described in tables 2.2 and 2.3. 
Cells were washed with PBS in FACS tubes and resuspended in 50 μL of PBS to be 
stained first with a dead stain dye Vivid green or Aqua for 5 minutes at RT in the dark. 
Then cell surface markers were added to cells at concentration listed in tables 2.2 and 
2.3 and incubated for 20 minutes on ice. Cells were then washed with PBS 
supplemented with 2% FCS and resuspended in 150 μL of PBS/2% FCS prior to flow 
cytometry. 
2.3.2 pMHC tetramer staining of T-cell clones and PBMCs 
3 x 105 cells were washed, re-suspended into 50 μL of PBS in a FACS tube. Cells were 
treated with 50 nM of the protein kinase inhibitor PKI dasatinib (Axon Medchem) for 
30 minutes at 37 °C and 5% CO2. Cells were then stained with 0.5-1 μg of PE -
conjugated pMHC I tetramer for 30 minutes on ice followed by a wash with PBS 
supplemented with 2% FCS. After washing, cells were resuspended in 150 μL of 
PBS/2% formaldehyde and analysed by flow cytometry. 
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2.4 Bacterial culture and assays 
2.4.1 Bacterial culture media and reagents 
Luria-Bertani (LB) medium: 10 g/L tryptone (Fisher Scientific), 5 g/L yeast extract 
(Fisher Scientific), 5 g/L NaCl (Fisher Scientific) and supplemented with 50 mg/L 
carbenicillin (Sigma-Aldrich). 
LB agar plate medium: 15 g/L agar bacteriological (Oxoid), 10 g/L tryptone (Fisher 
Scientific), 5 g/L yeast extract (Fisher Scientific), 5 g/L NaCl (Fisher Scientific) and 
supplemented with 50 mg/L carbenicillin (Sigma-Aldrich). 
TYP media: 16 g/L tryptone (Fisher Scientific), 16 g/L yeast extract (Fisher Scientific), 
5 g/L potassium phosphate dibasic (Acros organics). 
Lemco culture media: 5 g/L Lemco powder (Oxoid), 10 g/L tryptone (BD), 5 g/L 
NaCl (Fisher Scientific), 0.5 mL/L Tween 80 (Sigma-Aldrich). 
Lemco agar plate: 5 g/L Lemco powder (Oxoid), 10 g/L tryptone (BD), 5 g/L NaCl, 15 
g/L agar bacteriological (Oxoid). 
TFB1 solution: 30 mM KOAc, 50 mM MnCl2, 100 mM KCl pH 5.8, 10 mM CaCl2 
and 15% v/v glycerol. 
TFB2 solution: 10 mM Na-MOPS pH7, 10 mM KCl, 75 mM CaCl2 and 15% v/v 
glycerol. 
2.4.2 Bacterial strains 
2.4.2.1 Escherichia coli strains 
Rosetta 2 (DE3) pLysS Escherichia coli (E.coli) (Novagen) competent cells were used 
for protein expression and were grown in TYP medium. 
One Shot (TOP10) E.coli (Invitrogen) competent cells were used as host for DNA 
amplification and were grown in TYP medium. 
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2.4.2.2 Mycobacterium smegmatis strains 
Mycobacterium smegmatis (M. smegmatis) (mc2155 strain) was offered by Prof Tim 
Walsh and Dr Matthias Eberl. 
M. smegmatis-gfp+ (mc2155 strain expressing GFP (pFLAME7)) was offered by Prof 
Tim Walsh and Dr Matthias Eberl. 
2.4.3 Mycobacterium smegmatis culture 
10 mL of Lemco media was inoculated using a sterile loop. The growth curve was 
assessed as described in chapter 3 to evaluate the M. smegmatis expansion phases by 
measuring the OD600 at 3 to 10 hours intervals. A sample of culture was plated onto 
Lemco agar plate to evaluate the concentration of bacteria. The optimum time of culture 
was taken during the expansion phase and chosen according to the growth curve.  
2.4.4 Escherichia coli culture 
2.4.4.1 Making competent E. coli cells 
E. coli cells were plated onto an LB agar plate and incubated at 37°C overnight. A 
single colony was picked and added to 200 mL of LB medium to be cultured to an 
OD600 of 0.4-0.6. Cells were then centrifuged at 1333 x g for 20 minutes at 4°C and the 
pellet was washed in 40 mL of ice cold TFB1 solution and centrifuged. Cells were then 
resuspended in 20 mL of ice cold TFB2 solution and aliquoted into pre-chilled 
eppendorf tubes and stored at -80°C.  
2.4.4.2 Transformation of competent bacteria 
Transformation of either TOP10 or Rosetta E.coli strains was performed by thawing 25 
μL of competent cells on ice for 5 minutes. 50-100 ng of plasmid DNA was added to the 
bacterial aliquot and incubated for 5 minutes on ice. The cells were then heat shocked in 
a water bath at 42°C for 2 minutes and placed directly on ice for a 5 minute recovery 
period. Cells were then streaked onto a LB agar medium plate (supplemented with 50 
mg/L carbenicillin) and grown overnight at 37 °C. Several colonies that grew on the 
plate were then picked and cultured overnight in LB medium (supplemented with 50 
mg/L carbenicillin). 
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2.5 Protein manufacture 
2.5.1 Buffers and reagents 
Lysis buffer: 10 mM TRIS pH8.1, 10 mM MgCl2, 150 mM NaCl, 10% Glycerol. 
Triton wash buffer: 0.5% Triton X, 50 mM TRIS pH8.1, 100 mM NaCl, 2 mM EDTA. 
Re-suspension buffer: 50 mM TRIS pH8.1, 100 mM NaCl, 2 mM EDTA. 
Guanidine buffer : 6 M guanidine, 50 mM TRIS pH8.1, 100 mM NaCl, 2mM EDTA.  
pMHC I refold buffer: 50 mM TRIS pH8 (Fisher scientific), 2 mM EDTA pH8 
(Fisher scientific) and 400 mM L-arginine (SAFC). 
TCR refold buffer: 2.5 M Urea (Fisher scientific), 50 mM TRIS pH8, 2 mM EDTA 
pH8 and 400 mM L-arginine (SAFC). 
Biomix A: 0.5 M Bicine buffer, pH8.3. 
Biomix B: 100 mM ATP, 100 mM MgO(Ac)2, 500 μM Biotin. 
BIAcore buffer: 10 nM HEPES pH7.4, 150 nM NaCl, 3 mM EDTA and 0.005% (v/v) 
Surfactant p20. 
Crystal buffer: 10 mM TRIS pH 8.1 and 10 mM NaCl. 
2.5.2 Protein expression vectors 
MHC constructs: The sequence that encodes for the alpha chain of HLA-A*0201 and 
MR1 (residues 1-248: α1, α2, and α3 domains) and β2m chain were designed according 
to previous work performed by Jonathan Boulter (Boulter et al., 2003) and synthesised 
and inserted into a plasmid by Geneart. The N-terminus of the α chain of HLA-A*0201 
was tagged with a biotinylation sequence (GGGLNDIFEAQKIEWH) (Altman et al., 
1996, O'Callaghan C et al., 1999) allowing tetramerisation of pMHC monomer or 
adherence to streptavidin BIAcore chips. Proteins were expressed without the 
biotinylation tag for crystallisation studies. 
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TCR construct: D454 TCR α chain (residues 1-207) and D454 β chain (residues 1-
247) DNA sequences were designed according to previous work to introduce an 
artificial inter-chain disulfide located on the α and β constant domain (Boulter et al., 
2003). 
pGMT7 vector: pGMT7 vector contains a penicillin/ carbenicillin resistance cassette 
and the T7 RNA polymerase promoter inducible by Isopropyl β-D-1-
thiogalactopyranoside (IPTG) (Garboczi et al., 1996). 
2.5.3 Cloning of DNA construct into pGMT7 vector 
The MHC α chain, β2m, αTCR and βTCR chains sequences were inserted into the 
pGMT7 expression plasmid allowing protein expression under the control of the T7 
RNA polymerase promoter, within a Rosetta DE3 E.coli system. Quality control of the 
plasmid sequence was performed by DNA sequencing by Central Biotechnology 
Services at Cardiff University (CBS). The steps of the cloning are described below. 
2.5.3.1 Enzymatic digestion 
DNA plasmids and pGMT7 vector required an enzymatic digestion with BamH1 and 
EcoR1 restriction endonucleases (New England Biolabs). The digestion was performed 
in a final volume of 20 μL with 1μg of target DNA and 1-2 μL of restriction enzyme. 
After 2 hours incubation at 37°C, fragments obtained were separated by agarose gel 
electrophoresis. 
2.5.3.2 Agarose gel purification and ligation 
The enzymatic digestion samples were mixed with a DNA loading buffer (Bioline). The 
DNA fragments were loaded and separated by electrophoresis at 100 V for 1 hour in a 
1% agarose gel (Invitrogen) containing 1X SYBR safe DNA gel stain (Invitrogen) 
diluted with TRIS-acetate-EDTA buffer. To estimate the size of the DNA fragments 
obtained from the enzymatic digestion, a molecular weight marker (HypperLadder I, 
Bioline) was loaded on the gel. Inserts and vectors were extracted and purified from the 
agarose gel using the QIAquick gel extraction kit (Qiagen) according to the 
manufacturer’s recommendations. Insert and vectors concentration were measured using 
a NanoDrop ND 1000 (Thermo Scientific). 
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Gel extracted inserts were ligated with pGMT7 vector using 1 μL of T4 DNA ligase 
(New England Biolabs) and 50 ng of pGMT7 vector with a molecular ratio of vector to 
insert of 1:1, 1:3 and 1:5 in a final volume of 10 μL of DNA ligase buffer (New 
England Biolabs). The mixture was incubated at room temperature for 30 minutes. 
2.5.3.3 Plasmid amplification in TOP10 E.coli 
Ligation products were transformed and amplified overnight into TOP10 E.coli. The 
plasmids were purified from the bacteria using the QIAquick PCR DNA extraction kit 
(Qiagen) according to the manufacturer’s instructions. 
2.5.4 Expression of inclusion bodies in Rosetta E. coli  
Expression plasmids were transformed into Rosetta E.coli and plated onto agar plate 
supplemented with 50 μg/mL of carbenicillin. A starter culture was set up to verify the 
expression of the plasmid by picking and culturing a single colony in 30 mL of TYP 
media supplemented with 50 μg/mL of carbenicillin. The starter culture was grown at 
37°C and shaken at 220 rpm until the suspension reached an optical density (OD600) 
between 0.4 and 0.6. The expression of the plasmid was induced with or without IPTG 
at a final concentration of 0.5 mM for 3 hours. 20 μL of suspension cultures was 
analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
The gel was stained with SimplyBlue SafeStain (invitrogen) and destained in ddH2O. 
After verifying the quality and quantity of the protein expression of the starter culture 
on the SDS-PAGE gel, the IPTG free starter culture was added to 1 L of TYP media 
supplemented with 50 μg/mL of carbenicillin and incubated at 37°C and shaken at 220 
rpm to reach an OD600 of 0.4-0.6. The culture was induced with 0.5 M of IPTG (final 
concentration 0.5 mM) for 3 hours.  
Cells were harvested and centrifuged at 4000 rpm for 20 minutes with a Legend RT 
centrifuge (Sorvall) with a Heraeus 6445 rotor. The cell pellet was re-suspended in 40 
mL of lysis buffer and sonicated on ice at 50-60% power for 20 minutes using 2 second 
interval using a MS73 probe (Bandelin). The sonicated pellet was incubated with 200 
μL of 20 mg/mL DNAase (Sigma) for over an hour and then resuspended with 100 mL 
of Triton wash buffer and centrifuged for 20 minutes at 10,000 rpm using an Evolution 
RC ultracentrifuge and a SLA-1500 rotor (Sorvall). The supernatant was discarded and 
the pellet was scraped and resuspended into 100 mL of triton wash buffer.  
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The pellet was then centrifuge again for 20 minutes at 10,000 rpm, the supernatant was 
discarded and the pellet was washed with 100 mL of Resuspension buffer and 
centrifuged 20 minutes at 10,000 rpm. The pellet was resuspended in 10 mL of 
guanidine buffer. The concentration of inclusion bodies was measured using a 
NanoDrop ND 1000 (Thermo Scientific) and were stored at -20°C. A 20 μL sample was 
harvested at each wash to be analysed by SDS-PAGE gel electrophoresis to assess the 
purity of the inclusion bodies. 
2.5.5 Manufacture of soluble pMHC I and TCR monomers 
2.5.5.1 Refolding of soluble pMHC I 
For the refolding of inclusion bodies in one litre of refold buffer , 30 mg/L of the heavy 
chain HLA-A*0201 with (if used for tetramerisation) or without biotin tag and 30 mg/L 
of β2m inclusion bodies were denaturated in 6 mL of a solution of 8 M guanidine buffer  
supplemented with 10 mM Dithiothreitol (DTT; Sigma) for 30 minutes at 37 °C. The 
refold was initiated by transferring first 200 μL of peptide (20 μg/mL in DMSO, 
Proimmune, UK) then the denaturated heavy chain and β2m into 1L of 4 °C pMHC I 
refold buffer supplemented at the last minute with the 4 mM cystamine (Sigma) and 6 
mM cysteamine (Sigma). The mixture was incubated overnight at 4 °C under gentle 
stirring. The following day, the refold buffer was transferred into a 12.4 kDa molecular 
weight cut-off (MWCO) dialysis tube (Sigma) and dialysed in 20 L of water 
supplemented with 10 mM TRIS pH8 bucket for 24 hours at 4 °C. Dialysed refold 
mixture was then filtered through a 0.45 μm filter membrane (Millipore) and analysed 
by ion exchange chromatography and gel filtration (described in section 2.5.6.1 and 
2.5.6.2). 
2.5.5.2 Biotinylation of pMHC I 
Refolded and purified pMHC I was concentrated to a final volume of 700 μL using a 20 
mL Vivaspin column with a 10 kDa cut off (Sartorious). The biotinylation process 
consists on the addition of 100 μL Biomix A, 100 μL Biomix B, 100 μL d-Biotin 500 
μM (Avadin) and 2 μL BirA enzyme (Avadin) to the concentrated pMHC I. The mix 
was incubated overnight at RT. Excess of biotin was removed by centrifuging the mix 
using a Vivaspin column (10 kDa MWCO: Sartorious). 
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2.5.5.3 Refolding of soluble αβ TCR 
For a 1 L TCR refold, 60 mg/mL α chain and 30 mg/mL β chain were denaturated 
individually at a final concentration of 10 mg/mL in guanidine buffer supplemented 
with 10 mM DTT for 30 minutes. The denaturated chains were added dropwise to a 4 
°C TCR refold buffer supplemented at the last minute with the 4 mM cystamine 
(Sigma) and 6 mM cysteamine (Sigma). The refold was mixed for 3 hours at 4°C and 
then transferred into 12.4 kDa MWCO dialysis tubing (Sigma), and dialysed in 20 L of 
10 mM TRIS pH 8.1 until refold conductivity was under 2000 μS/cm. Dialysed TCR 
refolds was then filtered and purified as described for the pMHC I refold protocol in 
section 2.5.5.1. 
2.5.6 Purification of pMHC I and αβTCR monomers  
2.5.6.1 Anion exchange chromatography 
pMHC I and αβTCR refold products were purified initially by anion exchange 
chromatography followed by a gel filtration using a ÄKTA Fast Protein Liquid 
Chromatography (FPLC) using a Poros 50HQ column (Applied Biosystems) in 
conjunction with Unicorn software. The column was equilibrated with a buffer A (10 
mM TRIS) at a flowrate of 20 ml/min. The refold product was loaded onto the column 
and fractionally eluted with a salt gradient (0-1M NaCl in 10 mM TRIS). The collected 
fractions were analysed by Coomassie-stained SDS-PAGE gel. The fractions containing 
the protein of interest were pooled and concentrated down to 500 μL in a 10 kDa 
MWCO Vivaspin 20 or Vivaspin 4 (Satorius) by centrifugation 20 minutes at 1200 x g. 
Protein concentration was determined using a NanoDrop ND1000 (Thermo Scientific). 
2.5.6.2 Size exclusion chromatography 
After a first purification by anion exchange, pMHC and αβTCR monomers were 
purified by size exclusion on a 24 mL Superdex 200 10/300 GL column (GE 
Healthcare) pre-equilibrated with PBS buffer (for pMHC tetramerisation) or BIAcore 
buffer (BIAcore analysis) or crystal buffer (for crystallisation). Elution was performed 
at 0.5 mL/min and fractions of 1 mL were collected to be analysed on Coomassie-
stained SDS-PAGE gel. The pooled fractions of interested were concentrated down as 
described above. 
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2.5.7 Tetramerisation of pMHC I 
The tetramerisation of pMHC I was carried out on ice and in the dark using R-
phycoerythrin (PE) (Molecular probes) conjugated streptavidin. Streptavidin contains 
four binding sites for biotin therefore four biotinylated pMHC can be added to one 
streptavidin-PE molecule. The concentration of Streptavidin-PE was calculated to 
obtain an equimolar ratio of 1 streptavidin-PE for 4 biotinylated pMHC I monomers 
(1:4 ratio). 5 aliquots of equal volume of streptavidin-PE was added at 20 minutes 
intervals by gentle mixing. 5 aliquots were enough to ensure full saturation of all four 
biotin-binding sites of the streptavidin. The pMHC I tetramers were stored at 4 °C for a 
maximum of a week prior to cell staining. 
2.5.8 Structural methods 
2.5.8.1 Crystallisation using the sitting drop vapour diffusion technique 
In order to ascertain optimum concentration buffer for target protein, variation of pH, 
salt concentration and precipitant were evaluated using commercial screens such as JBS 
basic screen (JenaBioscience), PACT premier (Molecular Dimensions) and in-house 
designed screen (Bulek et al., 2012). Protein was concentrated to 10 mg/mL in 10 mM 
TRIS, pH 8.1 and 10 mM NaCl. 0.2 μL of protein and 0.2 μL of crystallisation buffer 
were dispensed into each small reaction well of a 96 well Intelli-plates (Art Robbins 
Instruments-ARI) using the crystal Phoenix robot (ARI). 60 μL of crystallisation buffer 
were dispensed into each large reservoir. Intelli-plates were sealed, incubated at RT and 
analysed for crystal formations at 48 hours, 1 week and thereafter every 2 weeks. 
Selected crystals were cryoprotected with 25% ethylene-glycol and flash cooled in 
liquid nitrogen in Litho loops (Molecular Dimensions) to be analysed at Diamond light 
source, Oxford. 
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2.5.8.2 HLA-A*0201-LLDAHIPQL and HLA-A*0201-MIDAHIPQV diffraction data 
collection and model refinement 
Diffraction data were collected at beam-line I04.1 at a fixed wavelength of 0.9163Å at 
Diamond light source in Oxford, with a Pilatus 2M detector. Using a rotation method, 
200 frames were recorded each covering 1° of rotation. Reflection intensities were 
estimated with the MOSFLM package (McCoy et al., 2007) and the high resolution 
HLA-A*0201 structure published by my laboratory (pdb reference 4I4W) was used as a 
model for molecular replacement. Refinement and rebuilding of HLA-A*0201-
LLDAHIPQL and HLA-A*0201-MIDAHIPQV was carried out using the modelling 
programme, COOT (Emsley and Cowtan, 2004) and the data scaled, reduced and 
analysed with the CCP4 package (Krissinel et al., 2004, Murshudov et al., 1997). 
2.5.9 Surface plasmon resonance 
2.5.9.1 Preparation of the gold sensor chip 
D454 TCR binding assay was performed using a BIAcore 3000 (GE Healthcare). 
Briefly, an CM5 sensor chip (GE Healthcare) was activated by using an amine coupling 
solution (GE Healthcare) containing 10 mM N-(3-dimethylaminopropyl)-N3-
ethylcarbodiimide (EDC) and 400 mM M-hydroxysuccinimide (NHS). The sensor chip 
was coated with a solution of streptavidin (200 μg/mL in 10 mM acetate pH 4.5 (Sigma-
Aldrich)). The chip was finally washed with 1 M ethanolamine hydrochloride in order 
to deactivate any remaining reactive groups left on the sensor chip surface. 
2.5.9.2 Equilibrium-binding assay 
About 1 μM of either biotinylated HLA-A*0201-LLDAHIPQL and biotinylated HLA-
A*0201-MIDAHIPQV soluble molecules in BIAcore buffer were coupled to individual 
streptavidin coated CM5 sensor chip. The pMHCs were injected to coat the CM5 sensor 
chip. The equilibrium binding assay was performed by injecting 10 serial dilutions of 
D454 TCR over the sensor chip at 45 μl/min at 25°C. Results were analysed using 
BIAevaluation 3.1 and Origin 6.1 softwares. The constant of dissociation (KD) values 
were calculated assuming a 1:1 molecular interaction ( ) by plotting 
specific equilibrium-binding responses against protein concentrations followed by non-
linear least squares fitting of the Langmuir binding equation . 
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CHAPTER 3. GENERATION OF T-CELL RESPONSES TO 
MYCOBACTERIUM SMEGMATIS 
3.1 Introduction 
3.1.1 T-cell responses to bacteria 
A successful immune response to bacteria is characterised by the development of a 
tailored network of innate and adaptive immune cells that efficiently communicate with 
each other to eradicate or suppress bacteria in order to maintain homeostasis. Certain 
bacterial species have evolved to actively seek host immune cells for their survival and 
propagation. These bacteria have the ability to survive and persist within the body by 
manipulating the cellular pathways and immune responses deployed against them by the 
host. This evasion and manipulation is often to the detriment to the host. Certain species 
of Mycobacterium such as M. tuberculosis and M. bovis, as well as other gram positive 
and negative bacteria, induce the down-regulation of MHC II at the surface of an 
infected host cell (Barrionuevo et al., 2012, Ibana et al., 2011, Pecora et al., 2009), 
thereby evading optimal T-cell responses. Moreover, during M. leprae infection an 
inhibitory environment is created by the induction of regulatory T-cell subsets, thereby 
reducing cytotoxicity towards infected cells (Bobosha et al., 2014). 
A range of T-cell subsets are deployed by the immune system during bacterial 
challenge. Cytotoxic and TH cells recognise bacterial peptides presented by classical 
MHC I and II and provide some defence against bacterial threat, although delayed in 
certain infections, such as M. tuberculosis (Blomgran et al., 2012, Wallgren, 1948). 
Furthermore, bacterial-derived antigens are also recognised by innate-like T-cell subsets 
such as γδ T-cells, natural killer (NK) T-cells and mucosal associated invariant T-cells 
(MAITs). γδ T-cells play a role during bacterial challenge, especially during the early 
phases, both directly and indirectly by influencing the inflammatory response and other 
T-cell subsets (Ladel et al., 1996). Moreover, murine models have shown that γδ T-cells 
curb bacterial dissemination post infection (Zachariadis et al., 2006, Hiromatsu et al., 
1992). CD1d-restricted NK T-cells have been shown to play a role in tailoring immune 
responses towards a TH1 or a TH2 phenotype depending on the type of bacterial antigen 
(Venkataswamy and Porcelli, 2010).  
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The newly characterised MHC class I-related protein 1 (MR1) restricted T-cell subset, 
MAITs, play an important role in early bacterial infection and especially in respiratory 
bacterial infection (Le Bourhis et al., 2010, Gold et al., 2010, Chua et al., 2012). 
Overall, it is thought that unconventional T-cells, present during the early stage of 
infection, play a role in bridging the innate and adaptive immune systems (Meierovics 
et al., 2013) and are therefore instrumental in host defence. 
The understanding of T-cell responses to bacteria is an important and currently active 
area of research. A greater understanding of the T-cell subsets involved and their roles 
during bacterial challenge would help to develop strategies to overcome sub-optimal 
immunity to certain species of bacteria and the rise of drug resistant strains. In this 
chapter, I dissected the T-cell response raised against APC that had phagocytosed M. 
smegmatis.  
3.1.2 Mycobacterium smegmatis as a model to study T-cell responses to bacteria 
M. smegmatis is a fast growing non-pathogenic bacterium that was first isolated from 
human penis smegma (Brown-Elliott and Wallace, 2002). M. smegmatis is rapidly 
phagocytosed and processed by APC, with antigens being presented on MHC I and II 
(Bohsali et al., Harriff et al., Jondal et al., 1996). Importantly for my studies, M. 
smegmatis could be handled in the Bio-safety level 1 facilities (Singh and Reyrat, 2009) 
that were available in the Institute of Infection and Immunity at Cardiff University. M. 
smegmatis grows rapidly, in a host cell independent fashion, allowing easy culture and 
availability for experiments. Additionally, M. smegmatis shares close homologues to 12 
virulent factors from M. tuberculosis (Reyrat and Kahn, 2001). 
3.1.3 Aims 
The purpose of the first component of my studies was to dissect the CD3+ T-cell subsets 
generated during the boosting of PBMC with APC that had phagocytosed M. 
smegmatis. I aimed to optimise the boosting parameters to trigger a sufficient T-cell 
response to M. smegmatis, thus allowing the responding T-cells to be characterised with 
monoclonal antibodies, against cells surface markers, and flow cytometry. I wanted to 
assess the distribution of αβ and γδ TCR usage as well as their CD4 and CD8 co-
receptor expression.  
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3.2 Results 
3.2.1 Experimental Approach 
Multiple parameters needed to be optimised in order to establish whether it was feasible 
to routinely elicit T-cell responses to M. smegmatis in vitro as described in Table 3.1. 
Both the multiplicity of infection (MOI) (1:10 APC:M. smegmatis) and PBMC to APC 
ratio (10:1) were based on previous literature (Connelly et al., 2007, Verma et al., 1979, 
Bohsali et al., 2010) and advice from Dr Matthias Eberl (Institute of Infection and 
Immunity, Cardiff University). Other parameters required more in depth optimisation: 
Firstly, M .smegmatis growth was assessed to define the kinetics of expansion allowing 
it to be used at optimal health and to achieve the desired MOI. Secondly, APCs were 
tested for their ability to trigger a T-cell response against M. smegmatis, without high 
background when APCs were used alone. Thirdly, I explored two assay outputs for 
identifying responding T-cells by flow cytometry. 
Mycobacterium 
smegmatis
• Growth curve
• Multiplicity of infection 
(MOI)
• Time of phagocytosis
Antigen 
presenting cell
• Nature of the APC
• Autologous DCs
• A549 cells
• PBMC: APC ratio
PBMCs
• Analysis of Expansion 
by CFSE
• Analysis of activation 
by IFNγ intracellular 
staining (ICS)
 
Table 3.1 The parameters optimised in order to dissect T-cell responses to M. 
smegmatis.  
The parameters optimised in this study are highlighted in red and those based on current 
literature shown in black. 
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3.2.2 Monitoring growth of M. smegmatis in culture 
The different phases of M. smegmatis growth were determined by measuring the optical 
density (OD: 600 nm) at different time points during culture over 75 hours (Figure 3.1 
A) in Lemco media. The OD600 readings were accompanied by growing time-point 
matched samples on Lemco agar plates for 48 hours to establish the number of colony 
forming units (CFU) per mL of culture (Figure 3.1 B). This allowed the OD600 of the 
culture to be related to the number of bacteria present (Figure 3.1 C) allowing M. 
smegmatis to be harvested from culture at a given time-point and co-cultured with an 
APC to give the desired MOI. M. smegmatis could not be readily detected by reading 
the OD600 during the initial phase of growth (0-30 hours) (Figure 3.1 A). Bacterial 
growth could be measured during this phase by the number of CFUs formed on agar 
plates (Figure 3.1 B). Exponential growth could be measured between 30 and 55 hours 
by OD600 (Figure 3.1 B). After 55 hours OD600 plateaued and declined due to dormancy 
and/or death (Figure 3.1 B). The rapid growth phase seemed the most appropriate time 
to harvest M. smegmatis for the phagocytosis, as they were still duplicating and were 
likely to be in good condition. Based on these observations M. smegmatis was harvested 
between 40-50 hours with an OD of 0.25 to 1 and the actual number of M. smegmatis 
enumerated retrospectively by agar culture. 
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Figure 3.1 Monitoring M. smegmatis growth in culture by reading optical density.  
M. smegmatis was grown in 10 mL of Lemco media (Chapter 2) for 75 hours. (A) The 
optical density (OD: 600 nm) was taken at the times indicated. (B) A matched sample 
was also plated on antibiotic free Lemco agar plates to establish the number colony 
forming units (CFU) after 48 hours. (C) The CFU/mL were plotted versus OD for the 
time points when the M. smegmatis were growing most rapidly and appeared healthy. A 
linear regression curve and associated equation (displayed on the plot in C) were used to 
establish the CFU/mL from OD600 readings. This standardisation was performed for 
each M. smegmatis culture.  
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3.2.3 Using DC to present M. smegmatis antigens 
Dendritic cells (DCs) are considered to be professional APCs (Corinti et al., 2000) and 
prime naive T-cells by presenting antigens on MHC I and II (Pozzi et al., 2005). DCs 
efficiently phagocytose M. smegmatis (Bohsali et al., 2010). DCs can be generated in 
vitro by the culture of blood-derived monocytes in GM-CSF and IL-4 as described in 
Chapter 2. T-cell responses to M. smegmatis-loaded APC were monitored by dilution of 
carboxyfluorescein succinimiydyl ester (CFSE) using flow cytometry (Quah et al., 
2007). CFSE is passively taken up by cells and converted to a fluorescent molecule by 
cell intrinsic esterases (Wang et al., 2005). The fluorescent intensity of the CFSE is 
diluted as the cells divide as it shared between daughter cells (Quah et al., 2007). 
During a pilot experiment, autologous DCs were generated from two donors and 
subsequently incubated with or without (±) M. smegmatis and then co-cultured for 8 
days with CFSE labelled PBMC from the same donors. I chose day 8 for flow 
cytometric analysis based on prior experience of generating antigen-specific T-cell 
lines, as it allows sufficient duration for responding T-cells to proliferate at least once 
and then be detected by CSFE dilution. At day 8, cells were labelled with a viability dye 
(Vivid) and anti-CD3 and were sequentially gated as shown in Figure 3.2 A and B, 
with CFSE low (responding) CD3+ T-cells appearing in all cultures. Donors 1 and 2 
(Figure 3.2 C and D) gave background T-cell responses (DCs alone) of 3.51% and 
0.89%, and M. smegmatis specific T-cell responses (% seen with DCs with M. 
smegmatis minus the % seen with DCs alone) of 11.79% and 18.01% respectively. T-
cells responding to DCs loaded with M. smegmatis gave a stereotypical CFSE dilution 
profile, with clearly defined populations of T-cells with varying CFSE fluorescence 
intensities. I intended to add more conditions during the pilot experiment but the DC 
yield at the end of the procurement process restricted my plans. Ideally, sufficient 
PBMC needed to be set-up at the start of the assays so the number of cells available for 
analysis allowed all the necessary controls to be included for robust dissection of any 
responding T-cells. Efforts to scale up the approach using DCs were made by taking 
more blood from each donor, although there were ethical limitations imposed on how 
much blood could be taken. I therefore examined the use of an alternative, immortalized 
APC. 
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Figure 3.2 Autologous dendritic cells were capable of eliciting specific CD3+ T-cell 
responses to M. smegmatis.  
PBMC from two donors were labelled with carboxyfluorescein succinimiydyl ester 
(CFSE) and incubated for 8 days with autologous DCs that had been co-cultured ± M. 
smegmatis. Cells were also stained for viability and CD3 and sequentially gated based 
on forward and side scatter (A) followed by viable/CD3+ cells (B) and displayed as 
pseudocolour dots plots with CD3 versus CFSE fluorescence (C and D). The degree of 
T-cell proliferation was assessed by the loss of CFSE fluorescence as shown by the 
gates in C and D. The percentage of cells residing in the proliferating gate is shown 
inset for each dot plot. 
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3.2.4 A lung epithelial cell line phagocytoses M. smegmatis 
The immortalised epithelial cell line, A549, has been used in studies involving 
phagocytosis of bacteria (de Astorza et al., 2004, Kim et al., 2011) and made a good 
candidate APC. The use of A549 cells means that large amounts of uniform APC can be 
generated easily but also has some potential disadvantages. First, using a potentially 
HLA-mismatched APC for presentation to donor PBMC runs the risk of generating 
allo-reactive T-cell responses. Alloreactivity arises when T-cells recognise self peptides 
bound to non-self MHC. By definition, such complexes are not encountered in the 
thymus and are therefore considered as foreign (Felix and Allen, 2007, Kourilsky and 
Claverie, 1989). Allo-reactivity is dramatically demonstrated when HLA mismatched 
donated organs are rejected after transplantation (Benichou et al., 1999). Second, using 
HLA mismatched APC can exclude boosting of responses through classical HLA and 
therefore result in an underestimation of such responses. Non-HLA matched APC 
should still be capable of antigen presentation to unconventional T-cells. I first 
confirmed that A549 cells could phagocytose M. smegmatis, before using them for this 
study. 
Based on a previous study (Davey et al., 2011) M. smegmatis phagocytosis by A549 
cells was set-up to evaluate the percentage of bacterial uptake over time. A549 cells 
were co-cultured for 0.5, 1, 1.5 and 2 hour(s) with M. smegmatis constitutively 
expressing green fluorescent protein (GFP) (M. smegmatis-gfp+). After 2 hours >17% of 
A549 cells stained for GFP (Figure 3.3). This value is likely to be an underestimate as 
once phagocytosed, M. smegmatis is degraded, thereby halting GFP gene expression. 
Furthermore, studies have shown that the half-life of GFP inside fibroblasts is 2.8 hours 
(Halter et al., 2007). However, I considered that a confirmed uptake of bacterium by 
~20% of APC was acceptable for this study as this value is similar to that that has been 
reported using DCs (M. Eberl, personal communication). 
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Figure 3.3 A549 cells cultured with M. smegmatis expressing green fluorescent 
protein (GFP) appeared GFP+.  
A549 cells were cultured ± M. smegmatis-gfp+ at a MOI of 10:1 and incubated for 0.5, 
1, 1.5 and 2 hour(s). To stop the phagocytosis, M. smegmatis-gfp+ were washed off the 
A549 cells 5 times using PBS and low speed centrifugation. The samples were then 
analysed by flow cytometry. The gates shown were set on the sample of A549 cells that 
had not been cultured with M. smegmatis-gfp+. The percentage of cells residing in the 
GFP+ gate is shown for each dot plot. Cells were also stained with the viability dye 
(Vivid) and gated based on their forward and side scatter and viability. 
Although it was encouraging that a proportion of A549 cells co-cultured with M. 
smegmatis-gfp+ was GFP+ by flow cytometry it was imperative to confirm that the 
fluorescence seen was due to phagocytosis and not simply due to M. smegmatis 
association with the cell surface of A549, In order to confirm that the bacterium were 
intracellular, I examined the 2 hour sample using confocal microscopy. A representative 
image is shown in Figure 3.4, with 2 (28.6%) of the 7 clearly visible cells showing GFP 
fluorescence in discreet intracellular compartments. No fluorescence was seen to be 
associated with the A549 cell membrane even though > 1000 individual cells were 
visualised. These data confirmed that A549 cells were phagocytosing M. smegmatis, 
making this cell line suitable for use as an APCs in this study. 
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Figure 3.4 A549 cells co-cultured with M. smegmatis expressing green fluorescent 
protein (GFP) had discreet areas of GFP fluorescence when imaged by confocal 
microscopy. 
M. smegmatis-gfp+ were added to A549 cells at an MOI of 10:1 and co-cultured for 2 
hours. The cells were subsequently washed 5 times to remove excess bacteria and 
imaged by confocal fluorescence microscopy at 489 nm (emission at 518 nm). A 
representative image is shown (scale in bottom right hand corner) in a plane that shows 
the GFP fluorescence most clearly. 
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3.2.5 M. smegmatis-loaded A549 cells induce specific T-cell responses 
Once the ability of A549 cells to phagocytose M. smegmatis was confirmed I proceeded 
to using these cells (± M. smegmatis) as targets for T-cell boosting from the PBMC of 
two donors. As the number of A549 cells was not limiting, T-cell boosting was analysed 
at 3, 8 and 13 days post-boosting to assess how responses developed over time in vitro. 
Additionally, cells were stained with antibodies for the co-receptors, CD4 and CD8. No 
M. smegmatis responding T-cells (CFSE low) were present at day 3 (Figure 3.5 C and 
F), suggesting a relatively low precursor frequency in the peripheral blood of donors or 
that cells were slow to respond. The responding T-cells accumulated as the assay 
progressed with the greatest proportion of cells being seen in the dividing gate at day 13 
(Figure 3.5 E and H). I did not have enough cells to continue the time course beyond 
day 13. On day 8, the percentage of T-cells responding to M. smegmatis-loaded A549 
cells (minus background T-cell responses to A549 cells alone) was similar to that seen 
when DCs were used for boosting: 8.21% and 15.6% with A549 cells (donors 3 and 4 
Figure 3.5) and 11.8% and 18% with DCs (donors 1 and 2 Figure 3.2). At day 13, the 
donors gave specific T-cell responses of 13.4% (donor 3 Figure 3.5 E) and 58.6% 
(donor 4 Figure 3.5 H) of the CD3+ T-cells residing in the responding, CFSE low gate. 
The background T-cell response (A549 cells without M. smegmatis) for donor 3 
increased dramatically to 28.2% at day 13 (Figure 3.5 E), from 3.29 % at day 8, 
possibly due to allo-reactivity. This reduced the fold-difference between the background 
and M. smegmatis-specific T-cell responses from 3.5 at day 8 to 1.5 at day 13. In 
comparison, the fold-difference for donor 4 increased from 8.3 at day 8 (Figure 3.5 G) 
to 11 (Figure 3.5 H) at day 13. 
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Figure 3.5 A549 cells cultured with M. smegmatis were capable of inducing specific 
T-cell responses.  
PBMC from two donors were labelled with CFSE and incubated for 3 (C and F), 8 (D 
and G) and 13 (E and H) days with A549 cells that had been cultured with and without 
M. smegmatis. The cells were also stained for viability, CD3, CD4 and CD8, and 
sequentially gated based on their forward and side scatter (Figure 3.2 A) followed by 
viable/CD3+ cells (Figure 3.2 B) and displayed as pseudocolour dots plots with CD3 
versus CFSE fluorescence. The degree of T-cell proliferation was assessed by the loss 
of CFSE fluorescence as shown by the black (A549 cells alone) and red (A549 cells 
with M. smegmatis) gates. The cells residing in the dividing gates (black and red) were 
further gated as indicated (arrows) and displayed as CD8 versus CD4 pseudocolour 
plots. The percentage of cells residing in the proliferating and quadrant gates are shown 
inset for each dot plot. 
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An equivalent T-cell growth was observed when exposed to M. smegmatis-loaded A549 
cells and DCs at day 8 (Figure 3.2 and 3.5). However a vast majority of CFSE low 
cells resided in one population when stimulated with M. smegmatis-loaded A549 cells 
rather than distinct T-cell populations seen when stimulated with M. smegmatis-loaded 
DCs. In each case there was some background division of T-cells. This background 
could be due to many factors including prior exposure to antigen in vivo or response to 
mitogens present in the media, that were either constitutive (e.g. IL2) or produced by 
the target APC. Additionally, alloreactivity could be responsible when A549 cells were 
used due to the potential for HLA mismatching. Overall, from the pilot studies, DCs and 
A549 triggered M. smegmatis-specific T-cell expansion far above the background seen 
with uninfected APCs. The limitations associated with using DCs meant that the A549 
cells offered a more attractive option as the APC of choice going forward. 
3.2.6 Dissection of M. smegmatis-specific T-cell responses in multiple donors 
Once boosting parameters were optimised, I extended my studies to further donors and 
initiated the dissection of T-cell responses to M. smegmatis (a summary of all the 
donors used for this study and the various parameters used can be found in appendix 
A1). I also extended my studies beyond proliferation (CFSE dilution) to include 
Intracellular Cytokine Staining (ICS). PBMC from six donors were set-up in the same 
manner as previously described but without pre-labelling the cells with CFSE, cultured 
for 13 days and restimulated with A549 cells ± M. smegmatis, for 5 hours prior to ICS. 
All six donors produced IFNγ-secreting cells in response to re-stimulation with M. 
smegmatis with an average response of 6.3% of CD3+ cells (range of 1.8-12.9 %, 
Figure 3.6) with a greater difference between the background and M. smegmatis 
specific T cell responses when compared to the CFSE experiments (12.6 versus 3.6 
fold). Across all the experiments (CFSE and ICS data), using A549 cells as the APC, all 
of the donors exhibited induction of M. smegmatis-specific T-cells above background 
(p=0.03, 2-tailed, paired T-test). Collectively, the M. smegmatis-specific T-cell 
responses ranged from 1.6% to 56.4% of CD3+ cells at day 13, with an average response 
of 12.9%.  
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Figure 3.6 Multiple donors elicit specific T-cell responses to M. smegmatis and the 
responding cells had a skewed distribution of CD4 and CD8 expression. 
PBMC from six donors were incubated for 13 days with A549 cells that had been cultured with 
M. smegmatis. Subsequently, T-cells were restimulated with A549 cells that had been cultured 
with and without M. smegmatis and stained for IFNγ (intracellular), viability, CD3, CD4 and 
CD8. The cells were sequentially gated based on their forward and side scatter (A), for single 
(B) and viable/CD3+ cells (C) and displayed as pseudocolour dots plots with CD3 versus IFNγ 
fluorescence as shown. The degree of T-cell response was assessed by the appearance of IFNγ+ 
cells as shown by the black (A549 cells alone) and red (A549 cells with M. smegmatis) gates. 
The percentage of cells residing in the responding gate is shown inset for each dot plot. The 
cells residing in the responding gates were further gated as indicated (arrow) and displayed as 
CD8 versus CD4 pseudocolour plots with large dots. The percentage of cells residing in the 
quadrant gates are shown inset for each dot plot. 
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3.2.7 Co-receptor phenotyping of M. smegmatis-specific T-cells 
Of the 10 donors that gave M. smegmatis-specific T-cell responses in previous 
experiments, 8 (2 with CSFE and 6 from the ICS experiments) were also analysed for 
CD4 and CD8 co-receptor expression (stained for viability, CD3, CD4 and CD8 and 
sequentially gated as described in Figures 3.6), All four possible subsets: CD4+, CD8+, 
CD4+CD8+ (double positive: DP) and CD4-CD8- (double negative: DN), appeared in the 
cultures to varying degrees. CD3+ T-cells in the responding gates (CFSE low or IFNγ+), 
where compared for CD4 and CD8 expression between PBMC exposed to A549 cells ± 
M. smegmatis. In comparison to PBMC cultured with A549 cells alone, CD4+ and DP 
T-cells (relatively low frequency for the latter) had a significantly reduced frequency 
than with A549 cells with M. smegmatis (p=0.0095 and p=0.034 respectively, Figure 
3.7). This suggests that these CD4+ and DP T-cells present with A549 cells alone may 
either be responding to the A549 cells or they had a survival advantage in vitro over the 
other T-cell subsets, when antigenic stimulation is absent. In contrast, the DN T-cell 
subset was significantly enriched when A549 cells were loaded with M. smegmatis 
compared to A549 cells alone (p=0.024 Figure 3.7): six of the donors (3 (Figure 3.5), 
5, 6, 7, 8 and 10 (Figure 3.6)) exhibited this skew, with 4.6-30 fold (mean of 10.4) 
more DN T-cells residing in the responding gates when compared with A549 cells 
alone. There was also a significant (p=0.005) skewing towards CD8+ T cells with 6 of 
the 8 donors (3, 4 (Figure 3.5), 5, 6, 8 and 9 (Figure 3.6)) exhibiting the shift when M. 
smegmatis was present, with an average 3-fold increase. 5 of 8 donors gave a skewing 
towards both CD8+ and DN T-cells. 2 out of 8 donors were skewed towards just CD8+ 
T-cells (donors 4 (Figure 3.5) and 9 (Figure 3.6)). The remaining donor (10) exhibited 
an expansion towards the DN population only (Figure 3.6). 
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Figure 3.7 Statistically significant skewing of CD4 and CD8 expression of CD3+ T-
cells following culture of PBMCs with M. smegmatis-loaded A549 targets.  
CD3+ T-cells from 8 donors PBMC exposed to A549 cells ± M. smegmatis, as assessed 
by T-cell proliferation (Figure 3.5) or production of IFNγ (Figure 3.6), were analysed 
for CD4 and CD8 co-receptor expression. The proportion of CD3+IFNγ+ or 
CD3+CFSElow that were single positive for CD8+ or CD4+, DN: or DP were compared 
statistically (2-tailed, paired T-test) between A549 cells without (–) and with (+) M. 
smegmatis. 
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3.2.8 M. smegmatis-specific T-cells are enriched for γδ TCR 
There were enough cells from donors 5, 7 and 10 (indicated by * in Figure 3.6) to 
further dissect the responding population in terms of αβ and γδ TCRs (Figure 3.8). Pan-
TCR antibodies were used to stain the cells alongside antibodies for CD3, CD4 and 
CD8. Donors 5 and 7 had a greater proportion of CD3+ IFNγ+ γδTCR+ in the A549 cells 
with M. smegmatis cultures, compared to the A549 cells alone cultures, with 91% and 
72.9% of CD3+IFNγ+ cells expressing γδTCR (background of 19.5% and 12.1%) 
respectively. For both donors 5 and 7 the γδTCR+ T-cells were predominately DN T-
cells. The DN phenotype γδ T-cells is consistent with the fact that they are not HLA-
restricted (Yachie et al., 1989). Despite a decrease in the proportion of αβTCR+ T-cells 
in the presence of M. smegmatis for donor 5, the distribution of CD4 and CD8 was 
skewed towards CD8+ T-cells (56.7% with and 4.79% without M. smegmatis). The data 
for donor 10 shows responding cells were enriched for αβTCR+ T-cells, with 88.1% 
versus 74.4% for A549 cells with and without M. smegmatis respectively. Despite the 
relative neutrality for donor 10, there seems to be a skewing towards DN T-cells in the 
γδTCR+ gate (52.8% versus 12.3 % for A549 cells with and without M. smegmatis), and 
perhaps for αβTCR+ gated cells (7.5 % versus 0 % for A549 cells with and without M. 
smegmatis). T-cells could not be cleanly divided into γδ T-cells and αβ T-cells based on 
antibody staining. There might be several reasons for this such as the lack of separation 
by flow cytometry including down-regulation of TCR during ICS and steric hindrance 
between anti-CD3 and anti-TCR antibodies  
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Figure 3.8 Gamma delta T-cells were enriched in two out of three donors following 
culture with A549 cells pre-incubated with M. smegmatis. 
PBMC from three donors (* in Figure 3.5) were incubated with A549 cells that had been 
cultured with M. smegmatis for 13 days and restimulated with and without M. smegmatis prior 
to staining for IFNγ (intracellular), viability, αβTCR, γδTCR, CD3, CD4 and CD8. The cells 
were sequentially gated based on forward and side scatter, single, viable CD3+IFNγ+ cells and 
displayed as pseudocolour dots plots with αβTCR versus γδTCR fluorescence as shown. The 
cells in the green (CD3+αβTCR+) and red (CD3+γδTCR+) gates were further gated as indicated 
(arrow) and displayed as CD8 versus CD4 pseudocolour plots with large dots. The percentage 
of cells residing in the quadrant gates are shown inset for each dot plot. 
Chapter 3 
69 
3.2.9 Vα7.2 Jα33 TCRs are enriched in PBMCs primed with M. smegmatis 
Mucosal associated invariant T-cells (MAITs) are characterised by usage of an invariant 
TCRα chain. This chain is made from Vα7.2 (Arden nomenclature) or TRAV1-2 
(IMGT nomenclature), with junction (J) region 33. MAITs can be CD8α+ or DN 
(Reantragoon et al., 2013, Gapin, 2009). In order to examine whether M. smegmatis 
induced MAITs, I set up further experiments with two donors as above but stained with 
an antibody for the Vα7.2 TCR. PBMCs were primed with M. smegmatis-loaded A549 
cells and cultured for 30 days prior to exposure to A549 cells ± M. smegmatis and ICS. 
Addition of Vα7.2 TCR antibody to the polychromatic phenotyping panel was highly 
sensitive to antibody concentration and it took me several weeks to optimise the 
protocol (hence the 30 day time point for this experiment). Post boosting with M. 
smegmatis, PBMCs were stained for viability and with monoclonal antibodies for 
αβTCR, CD4, CD8 and Vα7.2 TCR (Figure 3.9). Minimal background T-cell responses 
of 0.42% and 0.82% were seen for donor 11 and 12 respectively. In the presence of M. 
smegmatis, the proportion of CD3+IFNγ+ cells were the highest generated throughout 
this study, with 25.5% and 34.6% for donor 11 and 12 respectively (Figure 3.9). The 
increase in reactive T-cells could be due to donor differences, an increased 
accumulation of expanding T-cells with time (30 versus 13 days) and/or the steady 
demise of T-cells that did not get a survival signal, as they did not respond to antigen 
during the initial boosting. Both donors had a greater proportion of CD3+IFNγ+Vα7.2+ 
T-cells (78.4% and 31.3% for donor 11 and 12 respectively) with M. smegmatis-loaded 
A549 cells compared to A549 cells alone (10.9% and 5.3% for donor 11 and 12 
respectively) (Figure 3.9). The M. smegmatis responding Vα7.2+ T-cells were enriched 
for a CD8+ phenotype when compared to the A549 cells alone cultures. The 
discrimination of Vα7.2+ from Vα7.2- was not clean, and it is possible that some Vα7.2 
expressing T-cells, but temporarily low or apparently null, reside in the negative 
population due to TCR down regulation. Frustratingly, the pan αβTCR antibody did not 
perform as previously seen in section 3.2.8, possibly for reasons already discussed. For 
these reasons it is hard to interpret the data for the CD3+IFNγ+Vα7.2- population 
without improved resolution and/or by using antibodies against other cell surface 
markers, such as the γδTCR. The distribution of CD4 and CD8 on the Vα7.2- T-cells 
was not that dissimilar between A549 cells ± M. smegmatis, with only a slight skew 
towards CD8+ and DN T-cells for donor 11 and CD8+ T-cells for donor 12 with M. 
smegmatis.  
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Figure 3.9 Mucosal associated invariant T-cells were enriched in M. smegmatis 
primed PBMC.  
PBMC from two donors were incubated for 30 days with A549 cells that had been 
incubated with M. smegmatis. The cells were restimulated with A549 cells that had been 
incubated ± M. smegmatis and stained for IFNγ (intracellular), viability, αβTCR, CD3, 
CD4, CD8 and a monoclonal antibody against the variable alpha segment 7.2TCR 
(Vα7.2), which is associated with MAITs. The cells were sequentially gated based on 
forward and side scatter, single cells and displayed as pseudocolour dots plots with CD3 
versus IFNγ (PE) then αβTCR versus Va7.2 (APC). The CD4 and CD8 expression was 
assessed on the Vα7.2 negative (blue) and positive (purple) cells as indicated by the 
associated gate colour, with percentages shown inset. Donor 11 was also stained with a 
monoclonal antibody against CD161 and the percentage of T-cells staining with CD161 
shown inset (red) for the Vα7.2 negative and positive cells. 
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3.3 Discussion 
The aim of this chapter was to dissect the T-cell populations generated during M. 
smegmatis antigen presentation by APCs. M. smegmatis was chosen for its ease of 
handling in the laboratory as well as its ability to be phagocytosed by specialised APCs 
such as DCs (Bohsali et al., 2010) and the lung epithelial cell line A549. T-cells are 
known to expand upon stimulation with cognate antigen. This expansion can be viewed 
by flow cytometry when cells are labelled with CFSE as this dye dilutes between 
daughter cells. CFSE dilution was used to observe T-cell responses to M. smegmatis-
loaded autologous DCs and A549 cells. Both APC produced similar results but as DCs 
were limited in number, I continued with A549 targets. 
A549 cells were used to present M. smegmatis antigens to two donor PBMCs stained 
with CFSE. T-cell expansion was analysed at 3, 8 and 13 days. On average, T-cell 
expansion at day 13 was higher than at 8 days (39% compared to 11.9% of CFSE low 
CD3+ T-cells respectively). Subsequent experiments were performed after 13 days of 
exposure to M. smegmatis antigens. A high background of CFSE dilution in response to 
A549 cells was observed, therefore I examined another readout; IFNγ ICS. Background 
activation was considerably less with ICS. An IFNγ ICS was performed on 6 donor 
PBMCs to analyse the phenotype of M. smegmatis-specific T-cells. Interestingly, IFNγ 
+CD3+ T-cells skewed towards a CD8 and DN phenotype (Figure 3.7). Analysis of M. 
smegmatis responsive αβ and γδ T-cells populations for three of the 6 donors showed a 
significant enrichment of γδ T-cells mostly exhibiting a DN phenotype which is 
concordant with the literature (Brenner et al., 1987, Groh et al., 1989). The αβ and γδ T-
cell populations were not clearly separated due to a very low anti-αβTCR and -γδTCR 
antibody staining. The low TCR antibody staining observed could be due to antibody 
steric competition between the anti-CD3 and -TCR antibodies that stain the same 
protein complex: CD3-TCR. However, in the case of the αβTCR antibody, this 
possibility has been tested for and ruled out by the manufacturer (Biolegend). I obtained 
clear separation with the anti-αβTCR and anti-CD3 antibodies used in my stainings with 
unstimulated PBMC. To conclude, the most likely reason for the poor separation was 
TCR down-regulation upon stimulation. 
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Two separate donor PBMCs were analysed for their distribution of Vα7.2 J33 TCR 
expressing population generated during M. smegmatis boosting of naive T-cells. A 
Vα7.2 J33 TCR is indicative of MAIT cells. There was a clear expansion of 
IFNγ+CD3+Vα7.2TCR+ population stimulated by M. smegmatis-loaded A549 cells with 
both donor PBMC. These results make it likely that M. smegmatis induced MAITs. 
MAITs and their specificity are explored in more detail in Chapter 4. 
The aim of this chapter was to dissect the T-cell subsets generated during exposure to 
M. smegmatis antigens. To this end I used IFNγ as a readout of T-cell activation as it is 
the classic TH1 cytokine. It is possible that the choice of this cytokine skewed my 
results. However similar results were seen when examining T-cell proliferation by 
CFSE dilution and flow cytometry. I would also have liked to have simultaneously 
examined NK T cell populations by staining with CD56 and/or an antibody specific for 
the NK T Type 1 Vα24 invariant TCR chain. However, I was limited by the number of 
channels of the flow cytometer I had available to me. The use of other flow cytometers, 
such as the BD FACSAria II, allows the detection of 15 parameters simultaneously and 
could be used to include NK T-cell markers and isolate them from other T-cell subsets. 
Moreover, the development of new flow cytometers such as the Cytometer by Time of 
Flight (CyTOF) allows the detection of as many as 100 markers. This technology 
consists on using antibody labelled with heavy metals to stain single cells. Heavy metal 
time of flight is measured by mass spectrometry. This technology permits to combine 
multiple antibodies to look at T-cell polyfunctionality, memory phenotypes and specific 
markers and therefore improve the stringency of T-cell subsets dissection (Newell et al., 
2012, Bendall et al., 2011, Ornatsky et al., 2006).  
In conclusion, this study provides a preliminary insight into some of the T-cell subsets 
induced by ex vivo exposure to M. smegmatis-loaded cells. Due to the expression of 
certain analogous M. tuberculosis proteins, its low pathogenicity and high 
immunogenicity, M. smegmatis has become an attractive bacterium to use for the design 
of M. tuberculosis vaccines (Zhao et al., 2012, Sweeney et al., 2011). My results 
indicate that both conventional and unconventional “HLA-restricted” T-cells contribute 
to mycobacterial immunity. I next planned to examine these two types of T-cell 
responses in detail. 
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CHAPTER 4. RECOGNITION OF MYCOBACTERIA BY AN 
UNCONVENTIONAL T-CELL 
4.1 Introduction 
4.1.1 Mycobacterium tuberculosis-specific unconventional T-cells 
The last five years has seen an increase in the number of studies examining the role of 
unconventional T-cells in infectious disease, particularly in M. tuberculosis infection. 
These studies include examination of the role of CD1-restricted T-cells, γδ T-cells and 
MAITs. Lipid-specific, CD1-restricted T-cells (described in Chapter 1) have an 
important role in immunity to mycobacteria. Circulating CD1-restricted T-cells from 
skin lesions of leprosy patients expressed a TH1 profile (Sieling et al., 2000) and 
exhibited cytotoxic activity (Rosat et al., 1999). Downregulation of CD1a, CD1b and 
CD1c molecules at the surface of M. tuberculosis infected cells emphasises their likely 
importance in the control of M. tuberculosis infection (Stenger et al., 1998).  
CD1d-restricted, NKT type 1 (formerly iNK) T-cells are now known to play a central 
role during various bacterial infections by producing a cytokine environment necessary 
for the recruitment of innate and adaptive cells (Kinjo et al., 2006, Nieuwenhuis et al., 
2002). In TB infection, activity of iNK T-cells was shown to be characterised by the 
secretion of GM-CSF, a soluble factor that promotes maturation of M. tuberculosis 
infected macrophages in vitro leading to the inhibition of M. tuberculosis growth 
(Rothchild et al., 2014).  
γδ T-cells also participate to the TB-specific immune response (Kasmar et al., 2011). 
The Vγ9/Vδ2 T-cell subset is known to be reactive to phospho-antigens including the 
(E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP) produced by 
mycobacteria species and other bacteria (Eberl et al., 2003). Elevated numbers of 
Vγ9/Vδ2 T-cells have been observed in the peripheral blood and cerebrospinal fluid of 
TB infected patients (Kabelitz et al., 1990, Dieli et al., 1999).  
While some inroads have been made in understanding unconventional T-cell biology 
during TB infection, much remains to be discovered. In this chapter, I will focus on an 
anti-microbial unconventional T-cell subset that has recently come to the forefront of T-
cell biology: the Mucosal Associated Invariant T-cell (MAIT). 
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4.1.2 Mucosal Associated Invariant T-cells (MAITs) 
4.1.2.1 MAIT cells have a specific phenotypic signature 
The first evidence of MAITs existence was described by Porcelli and team in the 1990’s 
where they observed a peripheral CD8/CD4 DN population expressing a semi-invariant 
TCR Vα chain (TRAV1-2/ TRAJ33 (IGMT nomenclature) or Vα7.2/Jα33 (Arden 
nomenclature) pairing preferentially with biased Vβ chain usage (Vβ2, Vβ11 and Vβ13) 
(Porcelli et al., 1993). The high conservation of the TCRα sequence combined with 
biased TCRβ usage indicated that MAITs recognize a very limited spectrum of antigens 
compared to conventional αβ T-cells. Interestingly, further TCR sequencing revealed a 
low degree of variation in CDR3α loop sequence that likely resulted in minor 
degeneracy in ligand recognition by the TCRα chain (Treiner et al., 2005). Collectively, 
these studies suggested that MAITs must be a functionally specialized T-cell subset.  
Since 2003, the number of studies focusing on MAITs has rapidly increased and we are 
finally unravelling the biology of this mysterious T-cell subset. In 2003, Treiner and 
team found that MAITs were restricted to the non polymorphic ubiquitously expressed 
molecule MHC-Related Protein 1 (MR1) (Treiner, 2003). As shown in Chapter 3, 
MAIT cells can be CD8+, CD8- and CD8-/CD4- DN (Tilloy et al., 1999). A small 
frequency of CD4+ MAITs was also detected in Chapter 3. MAITs express the C-lectin 
CD161 marker (Dusseaux et al., 2011) known to be highly expressed on T-cells that 
express IL-17 pro-inflammatory molecule such as the TH17 subset (Walker et al., 2012). 
Moreover, MAITs possess a memory phenotype of CD45RA-, CD45ROhi, CD95hi, 
CD62Llo (Dusseaux et al., 2011).  
4.1.2.2 MAIT cell biology 
MAIT cells constitute about 5-10% of T-cells in a healthy human blood. MAITs are 
enriched in some tissues such as liver, lung alveoli and gut epithelia where they can 
reach >50% of total T-cells (Dusseaux et al., 2011, Treiner et al., 2003). Like 
conventional T-cells, MAITs are generated in the thymus where they undergo positive 
and negative selection (Treiner et al., 2003, Martin et al., 2009). Germ free mice exhibit 
a marked depletion of peripheral MAITs suggesting that they have an important role in 
bacterial infections (Martin et al., 2009). In vitro studies have shown that MAITs can 
recognise gram positive and gram negative bacteria as well as fungi (Le Bourhis et al., 
2010).  
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The role of MAITs in host defence has been demonstrated in vivo in mice where they 
are important in establishing and maintaining an inflammatory environment (Meierovics 
et al., 2013). Furthermore, peripheral MAITs have the ability to release granzyme A and 
B conferring cytotoxic activity (Le Bourhis et al., 2010, Aaltonen et al.). 
4.1.2.3 MAITs in TB 
MAITs are a major T-cell population in the lungs of healthy humans and are capable of 
recognizing M. tuberculosis antigen regardless of any previous exposure to the 
bacterium (Gold et al., 2008). MAIT frequency is low during acute TB infection but 
elevated during the TB latency (Gold et al., 2008) phase suggesting that MAITs are 
involved in the containment of M. tuberculosis expansion during latency.  
4.1.3 MHC class I related protein-1  
The gene for MHC related protein-1 (MR1) was discovered by a Japanese team in the 
1990’s, when they detected mRNA transcript of an MHC-related gene located on 
chromosome 1 outside the conventional HLA locus (Hashimoto et al., 1995). The MR1 
gene sequence is highly conserved between individuals as well as between mammalian 
species suggesting that it has an important evolutionary role. MR1 shares strong 
sequence homologies with classical MHC class I molecules. MR1 is composed of a 
heavy chain subdivided in three α domains (α1, α2, α3). Like classical MHC I, MR1 
heavy chain associates with β2m (Miley et al., 2003). The percentage of amino acid 
homology in the peptide-binding groove between classical MHC I and MR1 is 40-50%. 
Overall, MR1 is significantly more related to MHC I than other MHC related molecules 
such as the CD1 family of molecules suggesting that it is more likely to present a 
peptide than a lipid-based antigen (Hashimoto et al., 1995). MR1 is ubiquitously 
expressed on almost all nucleated cells and is essential for the recognition of bacteria by 
MAITs (Riegert et al., 1998). Interestingly, MR1 is up-regulated on pathogen infected 
cells which increases the activity of MAITs during active infection (Le Bourhis et al., 
2013). MR1 is required for the positive selection of MAITs in the thymus (Gold and 
Lewinsohn, 2013). The level of MR1 expression on the cell surface is usually low 
compared to classical MHC I.  
At the outset of my studies, I was provided with a MAIT clone raised from a patient 
with latent TB infection that killed M. tuberculosis-infected DCs via MR1. My goal was 
to determine the mechanism of this important molecular recognition. 
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4.1.4 Aims 
When I started my studies with MAITs the ligand they recognised was unknown. The 
shape and function of the MR1 molecule suggested that it presented parts of bacteria to 
MAITs and there was speculation about this ligand being a peptide due to the strong 
homology between MR1 and conventional MHC class I molecules. The focus of this 
chapter was to characterise the ligand recognised by M. tuberculosis-specific MAITs. I 
was provided with a MAIT clone termed D426 B1 by Prof. David Lewinsohn at the 
University of Oregon. At the beginning of this work my goals were to:  
-  Test whether MR1 molecule presented a peptide ligand to MAITs. 
-  Refold MR1 monomers and produce MR1 tetramers. 
-  Stain D426 B1 cells with MR1 tetramer. 
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4.2 Results 
4.2.1 Mycobacterium tuberculosis-reactive MAIT clone 
Professor David Lewinsohn provided me with a MAIT cloned from the peripheral blood 
of a TB infected patient (patient D426). This MAIT clone was termed D426 B1. The 
D426 B1 TCR had been sequenced to verify expression of the invariant MAIT TCRα 
Vα7.2/Jα33 and D426 B1 clonality. D426 B1 expressed a Vβ 13.5 chain (Gold et al., 
2010), the most common Vβ chain expressed by MAIT cells in the peripheral blood 
(Porcelli et al., 1993).  
4.2.2 D426 B1 MAIT clone effector functions 
4.2.2.1 D426 B1 clone effector functions in response to M. smegmatis 
T-cell effector function is characterized by the release of specialized cytokines upon 
TCR interaction with an infected cell. MAITs are known to exhibit a TH1 cytokine 
profile as well as a cytotoxic function to target cells infected with Shigella flexneri (Le 
Bourhis et al., 2013) or Salmonella typhimurium (Gras et al.). My collaborators have 
demonstrated that the D426 B1 MAIT clone can be activated by M. tuberculosis 
infected DCs via MR1 presentation (Gold et al., 2010). 
In order to assess if the D426 B1 clone was able to exhibit MAIT-like effector 
functions, I examined the activity when these cells were presented with M. smegmatis-
infected DCs from an MHC-I/II mismatched donor. As mentioned in Chapter 3, I chose 
to use M. smegmatis to present bacterial antigen to MAITs as the bacterium grows 
rapidly and is relatively easy to culture. It was also possible to work with M. smegmatis 
under the containment level 2 facilities I had available to me. M. smegmatis infected 
human cells are good activators of MAITs (Chapter 3, Figure 3.7). 
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I first examined D426 B1 cytotoxic activity by chromium release assay. Chromium 
cytotoxic assays are routinely used in my laboratory to quantify 51Cr release from 51Cr-
loaded APCs following lysis by cytotoxic T-cells. The percentage of killing is directly 
deducted using the following formulas: % cytotoxicity = [(experimental release − 
spontaneous release) / (maximal release − spontaneous release)] × 100. Monocytes from 
a healthy donor PBMCs were extracted and differentiated into DCs as described in 
Chapter 2, and then infected with M. smegmatis and labelled with the radioactive 
chromium isotope 51Cr. D426 B1 T-cells were incubated with the M. smegmatis 
infected or uninfected- 51Cr-labelled DCs for 4h. Supernatants were harvested and D426 
B1 cytotoxicity was analysed by measuring the 51Cr released from M. smegmatis 
infected DCs (Figure 4.1.A.). Expression of IFNγ and MIP-1β was simultaneously 
measured by ELISA (Figure 4.1.B.). Over the 4h experiment, more than 70% of M. 
smegmatis infected DCs were killed by D426 B1 cells. These cells did not lyse 
uninfected DCs (Figure 4.1.A.). As expected, D426 B1 cells secreted MIP-1β (>600 
pg/mL) and IFNγ (>350 pg/mL) in response to M. smegmatis infected DC (Figure 
4.1.B.).
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Figure 4.1. Quantification of the cytotoxic and cytokine profile of the D426 B1 
clone to Mycobacterium smegmatis infected dendritic cells.  
Heterologous dendritic cells (DC) were labelled with Cr51 for an hour followed by a 
wash in R10. DCs were left to rest for an hour then washed in R10. 2x103 Cr51 labelled 
DCs were infected with M. smegmatis and presented to 1x104 D426 B1 MAIT clone. 
Cells were incubated for four hours and the supernatant was harvested. (A.) D426 B1 
cytotoxicity was analyzed by measuring the Cr51 release of DCs using a micro-beta 
counter. The percentage of cytotoxicity was calculated using the formula: % 
cytotoxicity = [(experimental release − spontaneous release) / (maximal release − 
spontaneous release)] × 100. (B.) Release of IFNγ and MIP-1β cytokines by D426 B1 
was measured by ELISA. 
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Since, D426 B1 clone could kill non-HLA matched DCs infected with M. smegmatis 
and produce TH1 cytokines, we hypothesized that this response was restricted by a non-
polymorphic MHC; most likely MR1.  
4.2.3 D426 B1 clone recognises short peptides 
4.2.3.1 Antigen presenting cells for MAIT profiling 
To avoid recognition through conventional MHCs two APCs, hMR1-HeLa cells and 
A549, were selected due to their mismatched HLA expression with donor D426 and 
ease of culture. Moreover, our collaborators have previously shown that D426 B1 clone 
recognises M. tuberculosis infected A549 cells (Gold et al., 2010). I therefore reasoned 
that A549 cells must efficiently present epitopes to D426 B1.  
4.2.3.2 D426 B1 clone peptide sizing scan and peptide library screening 
I next aimed to investigate whether MAIT cells could recognize and/or be activated by 
peptides. For this aim, I used different length combinatorial peptide libraries (CPLs) 
laid out in positional scanning format. Figure 4.2 shows a graphical representation of a 
nonamer CPL. 
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Figure 4.2. Representation of a nonamer combinatorial library (Wooldridge et al., 
2010).  
The nonamer CPL is divided into sub-libraries of peptide mixtures. In each peptide 
mixture, one of the 20 proteogenic amino acids (A, C, D, E, F, G, H, I, K, L, M, N, P, 
R, S, T, V, W and Y) is fixed at one position (circle) while the other are degenerate 
between the 19 natural amino acids (square) with the exception of the cysteine. Peptides 
within each mixture are present at equimolar concentration. Each sub-library 
corresponds to a complete scan of the peptide diversity at one position and is composed 
of 20 peptide mixtures each with one amino acid fixed at one position along the 9-mer 
peptide backbone. For example, the first mixture consists of peptides with alanine at 
position P1 and positions P2 to P9 are degenerate. The second mixture consists of 
peptide with alanine at position P2 with the other positions are degenerate. The nonamer 
CPL contains in total 4.9 x 1011 peptides.  
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Briefly, a CPL is series of sub-libraries that when combined that contain almost all 
possible peptides of a defined length. Each mixture is composed of peptides that have a 
fixed amino acid at a specific position and an equimolar mix of 19 amino acids at each 
other position along the peptide backbone. Cysteine is used as a “fixed’ amino acid but 
is not included as part of the equimolar mix to limit the possibilities of oxidation. Thus 
the only possible peptides known to be missing from a complete library of a given 
length are those that contain more than one cysteine. CPL screens have been used to 
map a T-cell epitope (Yin et al., 2011). My laboratory has had great success using these 
tools (Wooldridge et al., 2012, Ekeruche-Makinde et al., 2012, Ekeruche-Makinde et 
al., 2013) including mapping unknown T-cell epitopes (unpublished).  
D426 B1 clone was challenged with a single sub-library (position 4) of octamer (8mer), 
nonamer (9mer), decamer (10mer), undecamer (11mer), dodecamer (12mer) and 
tridecamer (13mer) CPLs in order to determine the optimum peptide length recognized 
by D426 B1. Unexpectedly, it has recently been shown by our group that CD8 T-cells 
are "preprogrammed" to recognize peptides of defined length (Ekeruche-Makinde et al., 
2013). hMR1-HeLa cells were pulsed with position 4 peptide mixtures from the five 
CPLs and were used as targets for D426 B1 in overnight assays. Potential alloreactivity 
of D426 B1 with hMR1-HeLa was controlled for by incubating T-cells with hMR1-
HeLa with 5% of DMSO (the solvent used to reconstitute the peptide library mixtures). 
The supernatants were harvested and analysed by MIP-1β ELISA. Interestingly, only 
the position 4 mixtures of the nonamer CPL activated D426 B1. Indeed, D426 B1 
secreted >150 pg/mL of MIP-1 when stimulated with the position 4 proline of the 
9mer CPL. These results suggested that D426 B1 can recognise a 9mer peptide with a 
proline at position 4 (Figure 4.3). 
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Figure 4.3. Screening of D426 B1 cells using position 4 mixtures of the 8mer, 9mer, 
10mer, 11mer, 12mer and 13mer combinatorial peptide libraries (CPLs). 
D426 B1 were stimulated overnight with hMR1-HeLa pulsed with position 4 peptide 
mixtures from six CPLs. The supernatants were harvested and responses to the CPLs 
were analyzed by MIP-1β ELISA. Responses are displayed as a cluster of six histogram 
plot representing a set of 20 mixtures having a define amino acid listed on the x-axis. 
Each histogram represents the position 4 along the peptide backbone of the different 
peptide length of CPLs. 
4.2.3.3 D426 B1 nonamer peptide library screenings 
D426 B1 was next challenged with hMR1-HeLa cells pulsed with the full nonamer 
peptide library. Individual D426 B1 responses were quantified by the release of MIP-1β 
by ELISA. CPL screening showed a preference for defined residues in the peptide core 
at positions P3, P4, P5, P6, P7 and P8. However, at the peptide termini such as P1, P2 
and P9, D426 B1 did not react to any of the CPL sub-mixtures (Figure 4.4 A.). The 
overall D4261 B1 response to the nonamer CPL is summarized in Figure 4.4 B.  
Chapter 4 
84 
M
IP
1-
β
(p
g/
m
L)
Fixed amino acid residue in combinatorial library mixture
0
250
500
A C D E F G H I K L MN P Q R S T V WY
P1
0
250
500
A C D E F G H I K L M N P Q R S T VWY
P2
0
250
500
A C D E F G H I K L MN P Q R S T V WY
P3
0
250
500
A C D E F G H I K L MN P Q R S T V WY
P4
0
250
500
A C D E F G H I K L MN P Q R S T VWY
P5
0
250
500
A C D E F G H I K L MN P Q R S T V WY
P6
0
250
500
A C D E F G H I K L MN P Q R S T V WY
P7
0
250
500
A C D E F G H I K L MN P Q R S T VWY
P8
0
250
500
A C D E F G H I K L M N P Q R S T V W Y
P9
M
IP
-1
β
(p
g
/m
L
)
Fixed amino acid residues in combinatorial library mixture
500
250
0
500
250
0
500
250
00
500
250
0
500
250
0
500
250
0
500
250
0
P1 P2 P3
P4 P5 P6
P9P8P7
 
A P A V
M T
N W Y
L
A
Y D
2 3 4 5 6 7 981
MIP-1β (pg/mL) colour code:
125-250  Red
63-125  Green
5- 63  Blue  
Figure 4.4. Complete nonamer combinatorial peptide library (CPL) screen on the 
D426 B1 MAIT T-cell clone.  
hMR1-HeLa cells were pulsed with the nonamer peptide library mixtures and presented 
to D426 B1. The response to the library mixtures was measured by MIP-1β ELISA. A. 
The nine histograms represent the nine amino acid positions along the peptide backbone 
(from N-term to C-term) numbered as P1 to P9. Each histogram represents D426 B1 
MIP-1β responses to 20 set of CPL sub-mixtures with a define amino acid fixed at each 
position and plotted on the x axis. B. Shows a summary of the data in A. Each mixture 
is characterized by the single letter nomenclature of the amino acids fixed within the 
mixtures. The magnitude of response is characterized by the MIP-1β concentration 
released by D426 B1 seen in the screen and is assigned with colour codes ranging from 
red to blue.  
B. 
A. 
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The lack of any recognition of sub-mixtures at P1, P2 and P9 might suggest that the 
MAIT TCR does not make contacts outside of the central region of the peptide and/or 
that these positions are not required for MR1-binding. It is also possible that the MAIT 
TCR might be restricted to a small number of peptides thus the concentration of 
individual immunogenic peptides within the CPL sub-mixtures may be too low to 
trigger a measurable response at P1, P2 and P9. Nonetheless, a conserved D426 B1 
immunogenic peptide sequence was retrieved from D426 B1 screening with the 
nonamer CPL: xxAPVLYDL. 
4.2.3.4 Design of D426 B1 peptide agonists 
From the D426 B1 screening with the nonamer CPL, a core 9mer immunogenic 
sequence was retrieved: xxAPVLYDL. A search with National Centre for 
Biotechnology Information (NCBI), revealed several epitopes from the M. tuberculosis 
proteome with similarity to the CPL suggested sequence. These epitopes and their 
protein origin are listed in Table 4.1. Interestingly, these sequences are often conserved 
with other bacterial species providing a potential, and exciting, explanation for how 
MAITs are able to recognise several different pathogens.  
 Protein in M. tuberculosis 
Species excluding M. 
tuberculosis 
DDLPVLYEL peptide chain release factor 2 M. avium/smegmatis/abscessus 
DHAPVLVDL exodeoxyribonuclease III protein xthA M.bovis/smegmatis/cosmeticum 
FWHKVLYDL leucyl-tRNA synthetase leuS 
Staphylococcus aureus, 
Lactobacillus delbrueckii, 
Streptococcus agalactiae, M. 
xenopi 
TSGPVNYDL conserved hypothetical protein Only M. tuberculosis 
GLEEVLYEL 
DNA-directed RNA polymerase subunit 
beta 
M. ulcerans/liflandii/africanum 
MRPPALYDT conserved alanine rich protein 
M. paratuberculosis/ 
avium/xenopi 
 
Table 4.1. Blast of M. tuberculosis protein sequences sharing identities with 
xxAPVLYDL. 
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I also designed some predicted optimal, but non-natural, peptide agonists for D426 B1. 
These sequences were: IRAPVLYDL, IRAPALYDL, IRAPVLYDI, MRAPALYD 
ISVPVLYAL, IRAPALYDI (bold letters indicate the optimal residues determined by 
CPL screen while non-bold residues are amino acids that also showed in the screen). 
For custom agonist screening, hMR1-HeLa cells were pulsed with a titration of 
individual peptides from 10-4 to 10-14 M and presented to D426 B1. Supernatants were 
analysed by MIP-1β ELISA. D426 B1 reacted to all the peptides. MIP-1β was still 
detected when D426 B1 was stimulated with a concentration as low as ~10-13 M of 
IRAPVLYDL, IRAPALYDL, IRAPVLYDI and MRAPALYDL peptides indicating 
that D426 B1 is very sensitive to these particular agonists (Figure 4.5). 
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Figure 4.5. D426 B1 TCR recognition of titrated peptides ligand suggested from 
nonamer CPL screening. 
6x105 hMR1-HeLa cells were pulsed with a titration of peptides designed predicted by 
the nonamer CPL screen and presented overnight to 3x105 D426 B1 MAITs. 
Supernatant were harvested and analyzed by MIP-1β ELISA. 
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4.2.4 D426 B1 clone does not recognize peptide through MR1 
Once I had identified potential ligands, the next step was to verify if the peptides were 
restricted by the MR1 molecule. To achieve this, two blocking antibodies were used. 
The first antibody was provided by Ted Hansen (Washington University, School of 
Medicine) and is a conformation dependant anti-MR1 blocking antibody (clone 26.5) 
(Huang et al., 2005). The second antibody was an anti-MHC I (clone W6/32) blocking 
antibody that targets the constant region found on the α chain of MHC I region 
associated to β2m molecule. W6/32 is known to bind to HLA-A, -B, -C and -E 
(Chouaib et al., 1988). 26.5 and W6/32 antibodies were used to block the D426 B1 
response to peptide in order to verify MHC restriction.  
My first attempt of blocking the D426 B1 response was performed by stimulating D426 
B1 with the IRAPVLYDL peptide in the absence of APC (T-cell-to-T-cell presentation) 
(Figure 4.6). D426 B1 cells were first treated with either, the anti-MR1 clone 26.5 
blocking antibody, W6/32 blocking antibody or no antibody and then stimulated with 
peptide overnight. Activation was measured by MIP-1β ELISA (Figure 4.6). The D426 
B1 response was not completely blocked by either of the antibodies. However, reduced 
sensitivity in the presence of W6/32 was noted. Several hypotheses can be proposed to 
explain these results. First, blocking antibodies are not optimum tools to block T-cell 
activation as they cannot provide an absolute antibody saturation of all surface bound 
MHCs. Second, MIP-1β is arguably the most sensitive read out for T-cell activation 
(Laugel et al., 2007). Highly immunogenic peptides may trigger T-cell activation 
through low numbers of pMHC "missed" by antibody blocking.  
Chapter 4 
88 
1500
1000
500
0
-9 -10 -11 -12 -13 -14 -15
Log10 (M)
M
IP
-1
β
(p
g
/m
L
)
T-cell + IRAPVLYDL
T-cell + IRAPVLYDL+ anti-MR1
T-cell + IRAPVLYDL+ anti-MHC I
 
Figure 4.6. Identifying the MHC restriction of candidate ligands through antibody 
blocking.  
3x105 D426 B1 cells were first treated with 50 μg/mL of anti-MR1 (clone 26.5) or anti-
MHC I (clone W6/32) blocking antibodies and then with a titration of IRAPVLYDL 
peptide. The cells were incubated overnight and the T-cell response was analyzed by 
measuring the MIP-1β release by ELISA. 
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In order to limit the possibility of ‘leakiness’ during antibody blocking experiments I 
decided to utilise less potent peptide antigens. To this end, I used sub-mixtures from the 
nonamer CPL instead of IRAPVLYDL to stimulate D426 B1. Indeed, the CPL sub-
mixtures appeared less sensitive than to IRAPVLYDL in my initial assays so these 
responses would be more responsive to T-cell blocking via an antibody to the restricting 
element. The chosen CPL sub-mixtures were those that best activated D426 B1 clone 
(Figure 4.4.A.). These CPL sub-mixtures were named after the number corresponding 
to the position of the fixed amino acid and the single letter amino acid code fixed at this 
position: position 3 alanine (3A), position 4 proline (4P), position 5 alanine (5A), 
position 5 valine (5V), position 6 leucine (6L), position 7 tyrosine (7Y) and position 8 
aspartic acid (8D). As detailed above, D426 B1 cells were treated with both anti-MR1 
(clone 26.5) and anti-MHC I (clone W6/32) blocking antibodies and 10 μM of nonamer 
CPL sub-mixtures. Supernatants were harvested after 24 hours incubation and responses 
to the peptide mixtures were analyzed by MIP-1β ELISA. In the absence of antibody, 
D426 B1 was activated by all CPL sub-mixtures characterized by a secretion of < 200 
pg/mL MIP-1β. However, D426 B1 responses to CPL sub-mixtures were not blocked 
after treatment with anti-MR1 26.5 blocking antibody indicating that D426 B1 
responded to the peptide in an MR1-independent manner. In contrast, the CPL sub-
mixture responses were completely abrogated when using the W6/32 MHC I antibody 
(Figure 4.7). These results indicate that D426 B1 recognizes peptide presented by a 
classical MHC class I molecule and not by MR1. 
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Figure 4.7. Blocking of the D426 B1 response to CPL sub-mixtures.  
3x105 D426 B1 cells were treated with either and an anti-MR1 (clone 26.5), anti-MHC 
class I blocking (clone W6/32) antibodies or no antibody for an hour. 10 μM of seven 
nonamer CPL mixtures were added to D426 B1 and the cells were incubated overnight 
at 37°C. Supernatants were harvested and analysed by MIP-1β ELISA.  
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These experiments pointed towards two potential conclusions. First, I deemed it was 
possible that D426 B1 could have more than one specificity such that it could see one 
ligand in the context of MR1 and a peptide ligand in context of a classical HLA 
molecule. Second, it was also possible that the D426 B1 MAIT clone was not, as 
claimed, a monoclonal population. I therefore set about further characterisations of the 
D426 B1. 
4.2.4.1 Polyfunctional profiling of the D426 B1 clone through intracellular staining 
with an agonist peptide  
The cytokine release profile of D426 B1 was measured by intracellular staining (ICS) 
upon stimulation with IRAPVLYDL peptide. ICS permits discrimination of individual 
responder cells within a population by measuring cytokine production at the single cell 
level. D426 B1 MAIT clone was stimulated with or without IRAPVLYDL peptide for 4 
h. The ability of all T-cells within the D426 B1 line to be triggered via the TCR was 
assessed using an anti-CD3 antibody. The cytokine profile of the D426 B1 line was 
measured by production of intracellular MIP-1β, IFNγ and TNFα by ICS. Additionally, 
up-regulation of CD107a, a marker of degranulation and a surrogate marker of CD8 T-
cell killing, was measured (Betts et al., 2003). Analysis was carried out by 
polychromatic flow cytometry. As expected, unstimulated D426 B1 did not stain for 
cytokines. However, upon anti-CD3 antibody stimulation D426 B1 T-cells stained for 
numerous cytokines. Importantly, these experiments identified a distinct, minority 
peptide-specific population constituting only ~10% total T-cells (Figure 4.8.B.). 
Chapter 4 
92 
A. 
C
D
4
-A
P
C
Dead-PB
77.7
85.2S
S
C
FSC
 
B. 
0.46
64.7
8.76
0.45
34.9
10.9
1.01
95.3
9.56
C
D
8
-A
P
C
 H
7
CD107a MIP-1β IFNγ TNF-α
No peptide 
stimulation
CD3 
stimulation
IRAPVLYDL
stimulation
0.45
4.53
7.35
 
Figure 4.8. Intracellular staining of D426 B1 cell line stimulated with 
IRAPVLYDL peptide. 
3x105 D426 B1 cells were treated with Golgi Stop and Golgi Plug and stimulated for 
four hours with 5% DMSO (1st line quadrants) 1 μg/mL of anti-CD3 antibody (2nd line 
quadrants) or 50 μM of IRAPVLYDL (3rd line quadrants). An ICS was performed as 
explain in Chapter 2 and cells were analysed by flow cytometry. (A.) Gating strategy. 
D426 B1 cells were first gated using the SSC vs FCS. Alive CD4 negative T-cells were 
then isolated. (B.) D426 B1 cells were stained using anti-CD107a, MIP-1β, IFNγ, and 
TNFα antibodies. 
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These results appeared to confirm the presence of a peptide-specific contaminant 
population within the well characterised D426 B1 MAIT clone (Gold et al., 2010) I 
obtained from my collaborators in Portland. In order to formally confirm this 
disappointing possibility, I sequenced the TCR chains present in the clone. 
4.2.4.2 TCR sequencing of the D426 B1 clone 
To determine the clonality of the D426 B1 clone, 5' Rapid Amplification of cDNA Ends 
(RACE)-based TCR sequencing was carried out to evaluate clonal purity. Two TCRα 
and two TCRβ chains were detected within the D426 B1 cell line. The presence of the 
Vα7.2/Jα33 α chain variant in D426 B1 confirmed that at least one population was a 
MAIT cell (Table 4.2). The presence of a Vα1.4/Jα45 clonotype in ~15% of the culture 
indicated a contaminating CD8 T-cell within the D426 B1 culture.  
A. TCRα chain sequencing 
TRAV (IMGT) Vα (Arden)  CDR3α  TRAJ Freq (%) 
1-2 7.2 CAVRDSNYQLI 33 85.71 
8-3 1.4 CAVGRGGADGLT 45 14.29 
 
B. TCRβ chain sequencing 
TRBV (IMGT) Vβ (Arden) CDR3β TRBJ Freq (%) 
6-4 13.5 CASSDSGESGTEAF 1-1 59.14 
15 24.1 CATSMMGYNEQF 2-1 40.86 
 
Table 4.2. 5'RACE TCR sequencing of D426 B1 line (kindly performed by Dr 
James Mclaren, Cardiff University).  
The TCR Vα and TCR Vβ chains and CDR3 loop sequence, J region and the frequency 
of the different populations within the D426 B1 T-cell clone.  
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The discovery that the MAIT clone I had been using in my studies was not a 
monoclonal population was a huge disappointment. In order to formally confirm that the 
clone was not a single, dual TCR population of cells I decided to attempt to clone out 
the peptide-specific population. 
4.2.5 Separation of the peptide-specific clone from the D426 B1 polyclonal culture 
In order to separate out the two clonotypes within the D426 B1 cell line, an IFNγ 
capture assay was performed (as described in Chapter 2) after 4 h stimulation with 50 
μM of IRAPVLYDL peptide. The IFNγ positive and negative fractions were rested 
overnight in T-cell culture medium prior to a cloning step in a 96-well plate at 0.5 
cell/well. Only one clone expanded well from the IFNγ negative fractions and was 
called D12. Two clones expanded well from the IFNγ positive fraction and were called 
A5 and A6 according to their position on the 96 well-plate. All clones were stimulated 
with 50 μM of IRAPVLYDL overnight and the response to the peptide was analysed by 
measuring the release of MIP-1β by ELISA. The D12 T-cell clone did not respond to 
IRAPVLYDL peptide. In contrast, clones A5 and A6 responded to this peptide (Figure 
4.9).
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Figure 4.9. D426 B1 T-cell clones specificity for IRAPVLYDL. 
A5, A6 and D12 T-cell clones extracted from the D426 B1 cell line IFNγ+ fraction and 
IFNγ- fraction separated in response to peptide were stimulated with 50 μM of 
IRAPVLYDL peptide overnight. Supernatants were harvested and analyzed by MIP-1β 
by ELISA. Dark grey bars represent T-cell clones stimulated with peptide while light 
grey bars represent unstimulated T-cell clones. 
Chapter 4 
96 
Overall, the "separation" of the D426 B1 subpopulations was successful as we 
established peptide-specific T-cell clones (A5 and A6) and a peptide unresponsive T-
cell clone (D12). Unfortunately only the A6 T-cell clone continued to expand in culture 
to sufficient number for further assays. For ease of description, this clone was renamed 
from A6 to "Morpheus". I next set about further characterising this peptide-specific T-
cell clone. 
4.2.5.1 The peptide-specific T-cell clone Morpheus is not a MAIT 
Morpheus clone was first stained with an anti-Vα7.2 antibody to verify MAIT cell 
lineage using clone 3C6 (Martin et al., 2009). A Vα7.2-positive population was revealed 
in the D426 B1 starting culture. However, Morpheus did not stain with Vα7.2 (Figure 
4.10 A). TCR sequencing of Morpheus showed just one α chain and one β chain as 
expected (Figure 4.10 B). These chains were identical to the additional chains seen in 
the starting “monoclonal” D426 B1 population. 
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Figure 4.10. Morpheus clone is not a MAIT cell.  
(A.) Vα7.2 staining of D426 B1 cell line and Morpheus clone. 3x105 D426 B1 cells or 
Morpheus cells were stained with an anti-CD8 and Vα7.2 antibodies for 30 minutes on 
ice, washed once and analysed by flow cytometry. (B.) 5'RACE TCR sequencing of 
Morpheus clone. Morpheus clone TCR was analyzed by 5'RACE sequencing by Dr. 
James McLaren. The TCR Vα and TCR Vβ chains are described using Arden et al. 
nomenclature as well as the CDR3 loop sequence and the J region usage. 
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These results indicate that the D426 B1 line was a polyclonal CD8 T-cell culture. The 
"pure" D12 clone isolated in the IFNγ negative fraction in response to peptide is likely 
to be a true MAIT. Unfortunately, this clone could not be maintained in culture long 
enough to confirm its reactivity or determine which TCR chains it expressed. 
Collectively, these data indicated that MAITs do not recognize peptides ligands. 
4.2.5.2 Morpheus is not activated by M. smegmatis infected A549 presenting cells 
A number of techniques can be used to determine the MHC restriction of a T-cell. 
Blocking antibodies are often used in studies to block T-cell responses but this approach 
can be unreliable. Cell lines without the classic MHC alleles have been extremely useful 
in determining MHC-restriction. Unfortunately, at present, there is no MR1 knockout 
cell line available to allow formal assignment of MR1-restiction to D426 B1. However, 
since MR1 is ubiquitously expressed on almost all nucleated human cell lines, I 
hypothesized that if Morpheus was MR1-restricted, it would be activated by the HLA 
mismatched A549 cell line infected with M. smegmatis. To verify this hypothesis, A549 
cells were infected with M. smegmatis and presented to the D426 B1 line (positive 
control), the NLV2-F3 T-cell clone specific for the HLA-A*0201-restricted CMV-
derived epitope NLVPMVATV (negative control) and Morpheus. MIP-1β secretion was 
then measured by ELISA. As expected, the D426 B1 line secreted MIP-1β when 
presented with M. smegmatis infected A549 target cells. However, the NLV2-F3 and 
Morpheus did not respond (Figure 4.11). These results suggest that Morpheus is not 
restricted by MR1. 
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Figure 4.11. Assessing of M. smegmatis A549 cells specificity of three CD8 T-cells. 
3x105 D426 B1, Morpheus and CMV-specific NLV2-F3 cells were stimulated overnight 
with A549 cells infected or not uninfected with different M. smegmatis:A549 MOIs 
(1:1, 10:1 and 50:1). T-cell activation was measured in the supernatant by MIP-1β 
ELISA. 
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In parallel with my studies to find the restriction element was for Morpheus, I also 
continued to study the MAIT cell ligand by attempting to manufacture soluble, biotin-
tagged MR1. 
4.2.6 Production of soluble MR1 
4.2.6.1 Production of MR1 inclusion bodies 
To produce novel multimers and determine the molecular basis of MR1 antigen 
presentation, I undertook experiments to express and refold MR1 in recombinant form. 
MR1 cDNA construct was designed with the inclusion of a biotin-tag sequence at C-
terminus, named MR1tag. BamH1 and EcoR1 restriction sites were added to 5’ and 3’ 
sequence terminus of MR1tag and β2m DNA constructs to allow cloning into pGMT7 
vector. MR1tag and β2m DNA expression constructs were separately transfected into 
Rosetta E.coli by heat shocking the bacterial cell membrane. Bacterial colonies were 
individually picked and amplified in LB media. The expression efficiency of the DNA 
constructs was assessed by activating the lac operon using Isopropyl β-D-1-
thiogalactopyranoside (IPTG) for 3 h. A sample of the bacterial culture was harvested 
before and after induction with IPTG. The samples were denaturated using DTT and run 
on a sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) for 
analysis of MR1tag and β2m expression.  
The MR1tag alpha chain is 34 kDa and 293 amino acids in length. Figure 4.12.A shows 
IPTG induced significant MR1tag alpha chain. Inclusion bodies from bacterial cultures 
were purified of bacterial impurities using a deoxiribonuclease (DNAase) treatment and 
detergent washes (protocol described in Chapter 2). Purity of MR1tag alpha chain 
inclusion bodies was assessed by running a sample denaturated with DTT on SDS-
PAGE. The MR1tag alpha chain was produced by bacteria after IPTG compared to 
IPTG unstimulated bacteria. However after the last purification step, the MR1tag 
inclusion bodies contained a small amount of bacterial impurities (Figure 4.12.B). 
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Figure 4.12. MR1 inclusion bodies (IB) production. 
(A.) MR1 expression in E. coli strain Rosetta before and after IPTG induction. SDS-
PAGE gel of DTT denaturated Rosetta E.coli extract before (left lane) and after (right 
lane) three hours of IPTG induction. MR1 protein is indicated by the red arrow. (B.) 
MR1 inclusion bodies after processing. After large scale IPTG induction of MR1 
plasmid transformed Rosetta E.coli, MR1 inclusion bodies were processed and a sample 
was run on an SDS-PAGE gel to verify purity. Bacterial culture IPTG untreated (left 
lane) and sample from the last step of IB purification (right lane) were run on the gel. 
MR1 protein is indicated by the red arrow. 
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4.2.6.2 The refolding and purification of MR1 
In order to produce MR1 protein in multimeric form, MR1tag alpha chain was refolded 
with β2m as described in Chapter 2. Briefly, MR1tag and β2m inclusion bodies were 
denaturated with DTT for 30 minutes at 37 °C and added to a 4 °C chilled refold buffer 
(50 mM Tris, 2 mM EDTA, 400 mM L-arginine and 2.5 M Urea, pH8) and agitated 
overnight at 4 °C. MR1 protein refold was first purified by anion exchange 
chromatography. The chromatogram obtained indicated a large amount of different 
MR1tag protein forms with different charges (Figure 4.13 A.). Fractions 21-42 were 
pooled and analysed as well as the individual fraction 11 by SDS-PAGE. Fraction 11 
did not contain any MR1tag protein but only the β2m chain (11.9 kDa). The pooled 21-
42 fractions contained MR1tag and β2m at ~1:1 ratio suggesting that this was correctly 
refolded MR1 protein. Unfortunately, the fraction contained minor contaminant proteins 
of different sizes mostly likely from E.coli (Figure 4.13 B.). 
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Figure 4.13. Anion exchange chromatography of MR1. (A.) Anion exchange 
chromatogram.  
Purification of MR1tag refolded product by anion exchange chromatography. The blue, 
green and brown lines represent milli-absorbance units (mAU), % of eluting buffer (1M 
NaCl, 10mM Tris, pH 8) and % of conductivity respectively. (B.) SDS-PAGE gel of 
eluted fraction 11 and pooled fractions 21-42. Samples were denaturated with DTT 
(D) or not denaturated (ND) for three minutesat 95°C and run on SDS-PAGE. Purified 
MR1tag protein is indicated by the red arrow. 
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To remove these protein contaminants, size exclusion chromatography was performed. 
The pooled fractions were first concentrated using a Vivaspin column and run on a 
Superdex 200 10/300 GL column (Figure 4.14 A). Fractions 5-8 were pooled and 
analyzed by SDS-PAGE. The gel indicated the presence of the MR1tag protein in these 
fractions and reduced levels of contaminant proteins (Figure 4.14 B.).  
A. Size exclusion chromatography B. 
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Figure 4.14. MR1 tag size exclusion chromatography.  
(A.) Size exclusion chromatogram. Purification of anion exchange chromatography 
purified pooled fractions 21-42 containing MR1tag refolded protein. (B.) SDS-PAGE 
gel of eluted pooled fractions 5-8. Samples were denaturated with DTT (D) or not 
denaturated (ND) for three minutes at 95°C and run on an SDS-PAGE. Purified MR1tag 
protein is indicated by the red arrow. 
A fully folded MR1tag protein was successfully refolded even though the concentration 
obtained was far from below that obtained during the refold of MHC I soluble 
monomers with peptide. I next planned on biotinylating the MR1 monomer so that I 
could build MR1 fluorescent tetramers. However, during the course of these studies my 
supervisor, Prof. Andrew Sewell, spoke about my results with Prof. Jamie Rossjohn 
from Monash University in Australia. Prof. Rossjohn said that they had already defined 
the MAIT ligands and that a manuscript was submitted. After this conversation I was 
advised to switch to other studies by my supervisory team. I therefore moved to 
examining conventional M. tuberculosis-specific T-cells (see Chapter 5). A few months 
later Prof. Rossjohn and team published two papers. The first study revealed the first 
structure of MR1 in complex with a vitamin B metabolite: the 6-formyl pterin (6-FP) 
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(Kjer-Nielsen et al., 2012). 6-FP does not activate MAIT cells. The second paper 
showed how MR1 could present other ligands from the riboflavin biosynthetic pathway 
and that some of these ligands acted as agonists of the MAIT TCR (Patel et al., 2013). 
Studies with MR1 tetramers appeared in October 2013 (Reantragoon et al., 2013). I am 
glad that we heard about it prior to publication as this work would have precluded 
publication of my own studies. 
4.3 Discussion 
When I started my studies, the nature of the ligand presented by MR1 to MAIT cells 
was unknown. There was widespread interest in this important topic but we believed 
that we were well placed to compete in this exciting area due to my laboratory having 
extensive expertise with T-cells, TCRs, refolding pMHC and CPL screens. Due to 
certain physiologic and sequence similarities to pMHC I and CD1, it was speculated 
that MR1 would present either peptide or lipid based antigens. Indeed, as mentioned 
earlier, MR1 shares a high sequence homology with MHC I molecules (Hashimoto et 
al., 1995). For example, MR1 has MHC-like folding and the MR1 α1 and α2 chains 
share about 40-45% homology with those from MHC I. Moreover, studies of the MR1 
antigen binding groove has shown more hydrophilic residues than in CD1 grooves 
suggesting that presentation of peptide-based ligands would be more likely than lipid-
based ligands (Hansen et al., 2007). However, in contrast to MHC I, the surface 
expression of MR1 is TAP and proteasome independent (Huang et al., 2008). This 
discovery does not refute the hypothesis that MR1 could present peptides to MAITs as 
there are many TAP-independent peptide epitopes described in the literature. Indeed one 
such group of these antigens, the so-called Cinderella epitopes (Seidel et al., 2012) 
appear to serve a function in counteracting escape mutations that result in deficiencies 
in MHC I presentation that would otherwise allow tumour escape.  My studies aimed to 
investigate whether MAITs recognized peptide bound in the MR1 groove. For this 
purpose, Prof David Lewinsohn provided me a well characterised human MAIT clone 
(D426 B1). This clone was used extensively for MAIT characterisation in a seminal 
paper published in the high impact journal PLoS Biology (Gold et al., 2010).  
The D426 B1 CD8 T-cell clone was extracted from a TB infected patient and exhibited 
MAIT-like phenotype markers such as Vα7.2 (Jα33) chain expression in complex with a 
Vβ13.5 chain, expression of IFNγ, MIP-1β and TNFα cytokines and cytotoxicity in 
response to M. tuberculosis infected DCs (Gold et al., 2010).  
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In order to determine whether a MAIT could recognise a peptide I decided to use 
combinatorial peptide libraries. A pilot screen of D426 B1 with a nonamer CPL showed 
that position 4 might be important. We have recently described how CD8 T-cells can 
exhibit a specific preference for peptides of a defined length (Ekeruche-Makinde et al., 
2013). As the peptide length recognised by D426 B1 was unknown, D426 B1 was 
challenged with position 4 CPLs sub-mixtures from 8 to 13 amino acids in length. D426 
B1 only responded to the 9mer library. Having determined the preferred peptide length I 
then proceeded to undertake a full nonamer CPL screen. D426 B1 reacted to specific 
sub-libraries at all positions except the peptide termini (P1, P2 and P9). This screen 
allowed the generation of a MAIT-specific peptide motif. This motif was used to screen 
the M. tuberculosis proteome for peptide sequences that might be recognised by D426 
B1. In total 12 out of 12 peptides generated in this way were recognised including 
TSGPVNYDL, MRPPALYDT, ISVPVLYAL real sequences derived from 
mycobacteria. Four optimal but non-natural peptides of sequence IRAPVLYDL, 
IRAPALYDL, IRAPVLYDI and MRAPALYDL were recognised at very low 
concentration (<10-13 M), indicating that D426 B1 was highly sensitive to these four 
peptides. D426 B1 was particularly sensitive to IRAPVLYDL peptide therefore I 
decided to use this peptide to confirm MR1-restriction by antibody blocking. Initial 
results gave poor blocking of D426 B1 response to IRAPVLYDL with both anti-MR1 
(clone 26.5) and MHC I (clone W6/32) blocking antibodies. Antibody blocking of 
MHC can be very “leaky” when a good ligand and sensitive effector function are used 
in combination. I therefore decided to try weaker ligands in the form of individual 9mer 
CPL sub-mixtures. Reduction of antigen potency allowed complete blocking of D426 
B1 response to peptide sub-mixtures with anti-MHC I antibody but was unaffected by 
anti-MR1 antibody. This worrying result suggested that either the D426 B1 clone had 
dual specificity for an MR1-restricted and an MHC I-restricted ligand or questioned 
whether D426 B1 was a monoclonal population. The clonality of D426 B1 was then 
examined by determining whether only a subpopulation responded to peptide using 
IFNγ ICS. Unfortunately, these experiments revealed that only ~10% of cells responded 
to peptide, suggesting that the D426 B1 clone sent by our collaborators was not 
monoclonal.  
Confirmation of D426 B1 polyclonality was performed by D426 B1 TCR sequencing 
that revealed two TCRα and two TCRβ chains. However, it still remained possible that 
D426 B1 was a dual TCR T-cell.  
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Therefore I next endeavoured to sub-clone D426 B1 after exposure to IRAPVLYDL 
peptide in order to verify if whether D426 B1 was polyclonal or a single cell bearing 
two distinct TCRs. Cells were divided into responders and non-responders by IFNγ 
capture prior to cloning by limiting dilution. One clone grew well from the non-
responding population (D12 T-cell clone) and two clones grew from the responder 
population (A5 and A6 T-cell clones). A5 and A6 clones responded to IRAPVLYDL 
peptide by MIP-1β ELISA whereas the D12 clone failed to respond. Therefore, these 
results suggested that D426 B1 was two clones. TCR sequencing of A6 (renamed 
Morpheus) showed that the clone had a non-MAIT TCRα chain. In order to determine 
where the contamination with Morpheus had arisen, I obtained a fresh early stock of 
D426 B1 clone from Portland and stained it with anti-Vα7.2 antibody. These results 
showed that this clone was 98% Vα7.2+ leading Portland to call it a monoclonal MAIT 
population. In hindsight, it seems likely that the 2% of cells that did not stain with anti-
Vα7.2 antibody were Morpheus. The percentage of Morpheus within D426 B1 clone 
was seen to expand when cultured in Cardiff in human serum while my collaborators 
from Portland used FBS.  
In parallel to the investigations above, I was interested in refolding MR1 to manufacture 
MR1 tetramers. MR1 was refolded from inclusion bodies without addition of an 
antigen. The refold yield was not nearly as impressive as some MHC I monomers. I 
believe that I was able to refold some MR1 due to the presence of residual E. coli 
impurities in the inclusion bodies that might have bound in the MR1 groove allowing it 
to refold. However, my supervisor Prof. Andrew Sewell learned from Prof. Jamie 
Rossjohn at Monash University that his team already refolded MR1 with intermediates 
in the riboflavin biosynthetic pathway and showed that these reagents specifically 
stained MAITs. Therefore, my supervisor suggested that I should shift my studies to 
looking at conventional T-cells in M. tuberculosis infection as I would be unlikely to be 
able to publish my own MAIT studies in prominent journals. Studies from the Rossjohn 
and other laboratories have substantially enhanced our understanding of MAIT cells in 
the last 12 months. These exciting discoveries will be discussed later in Chapter 6. 
Regardless the disappointment of discovery that D426 B1 was not a monoclonal MAIT 
cell, data obtained in this chapter allowed me to conclude that the M. tuberculosis 
specific MAIT cell population in D426 B1 provided by my collaborator Prof. David 
Lewinsohn does not recognise an MR1-restricted peptide. 
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CHAPTER 5. RECOGNITION OF A POTENTIAL PAN-
MYCOBACTERIUM HLA-A*0201-RESTRICTED T-CELL 
EPITOPE 
5.1 Introduction 
T-cells play a major role in clearance during acute M. tuberculosis infection and are 
largely responsible for inducing the latency phase (Urdahl et al., 2011). After M. 
tuberculosis transmission, communication between the innate and adaptive immune 
system is mainly driven by the presentation of MHC II epitopes to helper CD4 T-cells 
by M. tuberculosis infected macrophages (Green et al., 2013). Activation of M. 
tuberculosis-specific CD4 T-cells triggers secretion of cytokines including IFNγ release 
by TH1 cells that promotes and enhances CD8 T-cell activity (Green et al., 2013) in 
addition to activation and maturation of macrophages and DCs. During chronic 
infection the above functions are performed by CD8 T-cells in addition to CD4 T-cells 
(Lazarevic et al., 2005). CD8 T-cells are not the major players during acute infection 
but play an increasingly important role as infection proceeds and are believed to be 
particularly important in bringing the disease to its latency phase (Lazarevic et al., 
2005). 
Although CD8 T-cell effector activity plays a role in M. tuberculosis latency, it is 
usually insufficient to clear the bacterium. Therefore, most M. tuberculosis vaccine 
development strategies aim to trigger a more potent CD8 T-cell response. Many studies 
have focused on secreted proteins by bacteria as potential vaccine candidates. M. 
tuberculosis secreted proteins such as ESAT-6 and CFP-10 are known to be very 
immunogenic and are the focus of clinical studies (Anhui Zhifei Longcom Biologic 
Pharmacy Co., Ltd. Phase I clinical human tolerability study of recombinant 
Mycobacterium tuberculosis ESAT6-CFP10. clinicaltrials.gov). Responses to these 
proteins have also being examined as candidate diagnostics (Weldingh and Andersen, 
2008, Aagaard et al., 2006). ESAT-6 and CFP-10 trigger M. tuberculosis associated T-
cell-mediated immunity (Majlessi et al., 2003) and induce strong immune responses 
when administered in prophylactic or therapeutic vaccination (van Dissel et al., 2011, 
Hoang et al., 2013). ESAT-6 and CFP-10 are secreted by a membrane bound secretion 
system called ESX-1 belonging to the Type VII secretion systems (T7SSs) family 
(Simeone et al., 2009).  
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The T7SSs family is composed of 5 systems of secretion (ESX-1, ESX-2, ESX-3, ESX-
4 and ESX-5) that are responsible for the secretion of several proteins that serve a 
variety of functions that include roles in bacterial growth, survival inside and outside 
macrophages, and transmission (Pym et al., 2003, Gao et al., 2004). ESX-1 has been 
extensively studied; less is known about the other T7SSs and the proteins they secrete. 
Recently, there has been a rise of interest about the ESX-3 secretion system and 
associated secreted proteins. The ESX-3 system leads to the secretion of a heterodimeric 
complex formed by the Esx-G (or TB9.8) and Esx-H (or TB10.4) proteins. Recent 
studies have linked Esx-G/Esx-H heterodimer to M. tuberculosis virulence in 
macrophages as it prevents M. tuberculosis transport to lysosomes and prevents 
phagolysosome maturation thereby affecting degradation and processing of M. 
tuberculosis antigens onto MHCs (Mehra et al., 2013). The Esx-G/Esx-H complex has 
been shown to be highly immunogenic (Hervas-Stubbs et al., 2006, Skjot et al., 2002) 
and Esx-G has been shown to trigger an IFNγ response in M. bovis and BCG vaccinated 
cattle (Mustafa et al., 2006). Moreover, it has been claimed that an Esx-G-Ag85 fusion 
vaccine provides protective immunity in humans (Dietrich et al., 2005). The Esx-G and 
Esx-H sequences are conserved between Mycobacteria species indicating that these 
proteins must undertake important biological roles (Figure 5.1).  
 
 
Figure 5.1 Sequences alignment of Esx-G and Esx-H in Mycobacteria species  
The Esx-G and Esx-H amino acid sequence from M. tuberculosis, M. bovis, M. 
marinum, M. ulcerans, M. leprae and M. smegmatis. Figure reproduced from Ilghari et 
al., 2011.  
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My studies described in Chapter 4 were brought to a close by my supervisor once we 
realised that the Melbourne group had discovered the MAIT ligand and already refolded 
MR1 with agonist ligands that then stained human MAITs. As I had lost a substantial 
amount of time chasing my finding that MAITs can recognise peptide, I was advised to 
switch my studies away from unconventional T-cells towards conventional HLA-
restricted T-cells against M. tuberculosis as my laboratory has extensive experience in 
characterising these cells. I was particularly interested in studying T-cells that recognise 
the HLA-A*0201-restricted, Esx-G-derived 9mer LLDAHIPQL peptide (residues 3-11) 
(shown in Figure 5.1). The choice of LLDAHIPQL peptide as an antigen was heavily 
influenced by the work of the Lewinsohn laboratory who found that HLA-A*0201- 
LLDAHIPQL restricted CD8 T-cell clones from latent TB infected patient could be 
activated by M. tuberculosis (H37Rv)-infected dendritic cells (Lewinsohn et al., 2007) 
(Immune Epitope Database and Analysis Resource. Epitope ID: 37140/ Reference ID: 
1026754). The LLDAHIPQL sequence is conserved across Mycobacteria species 
(Ilghari et al., 2011) indicating that it might prove to be a good candidate to explore as a 
potential pan-Mycobacterial vaccine target. Prof. Lewinsohn provided me with an 
LLDAHIPQL-specific T-cell clone (D454) grown from a TB patient so I initiated 
studies on characterising this T-cell, the TCR and the antigen it recognises. 
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5.1.1 Aims 
The aim of this chapter was to characterise the D454 T-cell clone and prove that it 
bound to HLA*0201-LLDAHIPQL. Prof. Lewinsohn was particularly interested in the 
prospect of manufacturing a high affinity TCR against this antigen for use in 
therapeutics and as a potential diagnostic. After discussions between Professor 
Lewinsohn and our collaborators at Immunocore Ltd, who manufacture such TCRs, it 
was agreed that there might be an interest in designing such a reagent provided that 
there was hard proof that the D454 TCR bound to HLA*0201-LLDAHIPQL. My aim 
was to manufacture a soluble version of the D454 TCR and characterise its binding to 
HLA*0201-LLDAHIPQL. I also aimed to get a structure of HLA*0201-LLDAHIPQL 
and the D454 TCR in complex with this epitope. This structure would be the first ever 
TCR-pMHC structure for a bacterially-derived antigen. The structure would also be 
highly informative about precisely which of the six CDR loops to target during the 
phage display and directed evolution process required to enhance the affinity. The 
specific aims of this chapter were to: 
1. Manufacture HLA-A*0201-LLDAHIPQL to make pMHC multimers for T-cell 
staining 
2. Characterise D454 recognition of HLA-A*0201-LLDAHIPQL by tetramer staining  
3. Examine D454 ligand recognition by CPL screen and determine positions in the 
LLDAHIPQL peptide important for the recognition and the design of a strong agonist 
altered peptide ligand (APL) for the D454. 
4. Manufacture of D454 TCR for use in biophysical and structural studies. 
5. Produce a D454 TCR-HLA*0201-LLDAHIPQL crystal structure 
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5.2 Results 
5.2.1 D454 is specific for HLA-A*0201-LLDAHIPQL 
5.2.1.1 Manufacture of soluble HLA-A*0201-LLDAHIPQL monomers for tetramer 
production 
In order to investigate D454 recognition of HLA-A*0201-LLDAHIPQL I engineered 
soluble pMHC monomers. Biotin-tagged and un-tagged HLA-A*0201-LLDAHIPQL 
monomers were generated for use in different assays. Biotin-tagged monomers allowed 
production of tetramers using fluorochrome-conjugated streptavidin. These pMHC 
tetramers were then used to stain D454 (see section 5.2.2.3). The biotin moiety also 
allowed binding of the pMHC to streptavidin-coated BIAcore chips for surface plasmon 
resonance (SPR) analysis (see section 5.2.3.2). Biotin-tags are not particularly rigid 
structures and can interfere with protein crystallisation. I therefore also produced un-
tagged HLA-A*0201-LLDAHIPQL monomers for structural analysis (see section 
5.2.3.3). 
Tagged and untagged HLA-A*0201 and β2m inclusion bodies were produced in E. coli 
Rosetta after IPTG induction as described in Chapter 2. Tagged and untagged HLA-
A*0201 inclusion bodies were refolded with β2m inclusion bodies together with the 
LLDAHIPQL peptide. Refolded pMHC products were purified by anion exchange and 
size exclusion chromatography. I present here only the refold purification steps 
performed on tagged HLA-A*0201-LLDAHIPQL as they are identical to those 
performed on untagged HLA-A*0201-LLDAHIPQL.  
Anion exchange chromatography allows separation of proteins according to their charge 
under a gradient of salt (here NaCl) on a positively charged matrix (in this case a HQ-
Poros column). Most proteins are negatively charged at neutral pHs. The elution of 
proteins from the column was measured using UV light at a wavelength of 280 nm and 
1 mL eluted fractions were collected. Tagged HLA-A*0201-LLDAHIPQL was found in 
6 fractions at a maximum quantity of 350 mAU (Figure 5.2 A). Tagged HLA-A*0201-
LLDAHIPQL monomers fractions were collected and concentrated. The tag was then 
biotinylated overnight using the enzyme Bir-A that catalyses the transfer of biotin to the 
tag. After biotinylation of the tag sequence, excess biotin was removed by concentrating 
biotinylated pMHC monomers using a Vivaspin column. Biotinylated HLA-A*0201-
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LLDAHIPQL monomers were then purified by size exclusion chromatography (Figure 
5.2 B).  
Fractions containing biotinylated HLA-A*0201-LLDAHIPQL monomers were pooled 
to be analysed in reduced (linearised protein) using DTT or non reduced (folded 
protein) conditions on an SDS-PAGE gel in order to assess the quality and purity of 
biotinylated HLA-A*0201-LLDAHIPQL monomers (Figure 5.2 C). About 2 mg of 
biotinylated HLA-A*0201-LLDAHIPQL monomers were produced at >95% purity 
after these purification steps.  
Biotinylated HLA-A*0201-LLDAHIPQL was used for the purpose of tetramer staining 
of D454 (section 5.2.1.2) and surface plasmon resonance (section 5.2.3.2). Untagged 
HLA-A*0201-LLDAHIPQL monomers were crystallised for structural analysis (section 
5.2.3.3). 
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Figure 5.2 Steps of LLD/A2tag refold product purification.  
A. Anion exchange chromatogram of tagged HLA-A*0201-LLDAHIPQL refold. The 
blue, green and brown lines represent milli-absorbance units (mAU), % of eluting buffer (1 
M NaCl, 10 mM Tris, pH 8) and % of conductivity respectively. Red dotted lines 
correspond to the pooled fractions. B. Biotinylated HLA-A*0201-LLDAHIPQL size 
exclusion chromatogram of pooled anion exchange fractions. The blue line corresponds to 
milli-absorbance unit (mAU) and the dashed lines represent the pooled fractions. C. 
Analysis of pooled eluted size exclusion fractions by SDS-PAGE. Sample A12, A13 and 
A14 (in red) were pooled and denaturated or not denaturated with 500 mM DTT and run on 
an SDS-PAGE gel. Purified biotinylated HLA-A*0201-LLDAHIPQL monomers are 
indicated by red arrows. 
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5.2.1.2 HLA-A*0201-LLDAHIPQL tetramer staining of D454  
D454 T-cell affinity was assessed by tetramer staining using HLA-A*0201-
LLDAHIPQL tetramers. Due to a naturally weak TCR-pMHC interaction, 
multimerisation of pMHC allow the cooperative interaction with TCRs at cell surface 
resulting in an improvement of pMHC tetramer avidity compared to pMHC monomeric 
interaction. Therefore, this avidity stabilises the binding of pMHC tetramer to the cell 
surface thus the specific-T-cell staining intensity is enhanced and allows a better 
isolation of the T-cell subsets of interest (Wooldridge et al., 2009).  
HLA-A*0201-LLDAHIPQL tetramers were produced by saturating streptavidin 
tetramer backbones coupled with Phycoerythrin (PE) with soluble biotinylated HLA-
A*0201-LLDAHIPQL monomers as described in Chapter 2. A negative control staining 
was included using a CMV-specific epitope HLA-A*0201-NLVPMVATV. Cells were 
treated with 50 nM of Dasatinib prior antibody staining to prevent TCR downregulation 
upon pMHC tetramer interaction. Dasatinib is a protein kinase inhibitor (PKI) that 
targets Lck protein and prevents TCR signalling therefore downregulation of the TCR 
from the T-cell surface (Lissina et al., 2009). The gating strategy consisted of gating 
live (Vivid-PB) CD3+ (anti-CD3 antibody) and CD8+ (anti-CD8 antibody) T-cells 
(Figure 5.3 A). D454 did not stain with the CMV-specific control HLA-A*0201 
tetramer (MFI: 192 compared to MFI: 180 for no tetramer). HLA-A*0201-
LLDAHIPQL tetramer stained D454 but only weakly (MFI: 423) (Figure 5.3 B). This 
poor staining indicated that although the D454 is HLA-A*0201-LLDAHIPQL specific 
it probably binds to this antigen with relatively low affinity. 
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Figure 5.3 LLD/A2 poorly stained D454 T-cells.  
3x105 D454 T-cells were first treated with 50 nM Dasatinib for 30 minutes followed by 
0.4 μg of HLA-A*0201-LLDAHIPQL or HLA-A*0201-NLVPMVATV tetramer-PE 
for 30 min. Cells were then stained for the following markers: Dead cells (Vivid-PB), 
CD3 (anti-CD3-PerCP Cy5.5 antibody) and CD8 (anti-CD8-APC antibody) for 20 min. 
Cells were analysed by flow cytometry. A. Gating strategy consisting on staining alive 
(Vivid), CD3+ (anti-CD3-PerCP), CD8+ (anti-CD8-APC) cells. B. Staining of D454 T-
cells with HLA-A*0201-LLDAHIPQL (orange), HLA-A*0201-NLVPMVATV (blue: 
negative control) tetramers-PE or no tetramer staining (red). MFI values are indicated 
for each condition. 
Chapter 5 
115 
D454 clone was successfully stained with HLA-A*0201-LLDAHIPQL tetramer 
confirming the specificity of D454 TCR for HLA-A*0201-LLDAHIPQL. However, the 
staining was poor suggesting that the affinity of the D454 TCR might be relatively 
weak. Therefore it would be useful to have a high affinity ligand for this TCR that could 
be used as a positive control in SPR or tetramer staining. It is also substantially easier to 
produce TCR-pMHC co-crystals when the TCR affinity is KD <10 M. As these 
complexes have identical solvent-exposed surfaces to the wild type TCR-pMHC protein 
they can then be used for crystal seeding (David Cole, unpublished observations). We 
have also found that using high affinity ligands and low amounts of TCR is an efficient 
way of determining optimal crystallisation conditions for a given TCR. In order to 
optimise the LLDAHIPQL peptide I undertook a 9mer CPL screen using D454. 
5.2.2 Characterisation of D454 ligand recognition by CPL 
As described above, the aim of this section was to attempt to build an improved peptide 
agonist for D454 using the data generated from a CPL screen.   
5.2.2.1 Design of agonists predicted by CPL screen 
Combinatorial peptide libraries (CPLs) offer an insight into the optimal peptide 
sequences recognised by a TCR and are very useful for the design of high affinity, 
potent agonist peptides. D454 T-cells were challenged with a nonamer CPL and T-cell 
responses to CPL mixtures correlated with the secretion of MIP-1β were quantified by 
ELISA. As MIP-1β is already preformed in T-cells, it is secreted rapidly and in large 
quantity upon TCR activation (Wagner et al., 1998). This feature makes MIP-1β a 
sensitive readout of CD8 T-cell activation. Measurement of MIP-1β by ELISA allows 
quantification of T-cell activation by each CPL sub-library. 
The magnitude of MIP-1β secreted, and thus D454 T-cell response to the nonamer CPL, 
was overall low compared to that is observed in our laboratory with other viral or 
bacterial specific CD8 T-cell clones (Ekeruche-Makinde et al., 2013). Indeed, the MIP-
1β concentration secreted did not exceed 500 pg/mL (Figure 5.4). Moreover, D454 T-
cells were reactive to few nonamer CPL mixtures indicating that the TCR had a 
preference for relatively few specific amino acids at each position along the peptide 
backbone. These two observations indicated that D454 TCR was probably not 
particularly cross-reactive.  
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The core amino acids localised between positions P2 to P7 were mainly restricted to 
LLD cognate amino acids: XLDAHIPXX. However, at position P4 and P6 D454 also 
recognised glycine and valine as well as alanine and isoleucine respectively: 
XXXA(G)XI(V)XXX. The D454 recognition motif appeared to be more flexible at the 
N- and C-terminus of the peptide (P1, P8 and P9). These data predicted that substitution 
of wild type amino acids at these positions might produce a peptide that was a more 
potent agonist of the D454 T-cell clone than the cognate M. tuberculosis-derived 
sequence. (Figure 5.4).  
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Figure 5.4 CPL screening histogram of D454.  
6x104 C1R A2 cells were pulsed with 180 mixtures from the nonamer CPLs and were 
used to stimulate overnight 3x104 D454 CD8 T-cells. D454 T-cell responses to library 
mixtures were quantified by measuring the release of MIP-1β by ELISA. Responses are 
displayed as a cluster of 9 histograms P1-P9 representing the positions of the fixed 
amino acids along the peptides. For each position (P), a set of 20 mixtures having the 
defined fixed amino acids is represented on the x-axis. The red bars represent the 
mixtures with the fixed amino acids corresponding to the D454 cognate peptide 
(LLDAHIPQL). 
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D454 amino acid preferences along the nonamer peptide backbone observed are 
summarised in Figure 5.5 and were based on data obtained on Figure 5.4. 
1 2 3 4 5 6 7 8 9
M F L D C G A E H C V I P P L I MIP-1β (pg/ml)
I E W Q T Q M 200-500
N R S 100-200
V 50-100
L L D A H I P Q L  
Figure 5.5 Summary of the nonamer CPL screen of the D454 T-cell line. 
D454 reactivity to the mixtures is represented by the single letter amino acid code 
nomenclature for the fixed amino acid within the mixture at each position along the 
nonamer peptide backbone. The magnitude of D454 T-cell response is represented by a 
colour code where red is the highest and green the lowest responses.  
5.2.2.2 Identification of D454 potent agonists from CPL data 
A set of 30 agonist peptides were selected for testing based on the CPL data above 
Table 5.1. D454 T-cell sensitivity for these agonist peptides was tested with MIP-1β as 
readout. 
LLDAHIPQL LLDAHIPQL 
MLDGHVPQV FLDGHIPQL 
FLDGHVPLV FLDAHVPQL 
MIDAHIPQV FLDAHIPLL 
FLDAHIPQL MLDAHIPLV 
MLDAHIPQL MLDAHIPQL 
LIDAHIPQL MIDAHIPQL 
LLDGHIPQL FLDAHIPLV 
LLDAHVPQL FLDAHIPQV 
LLDAHIPLL FIDAHIPQV 
LLDAHIPQV MIDGHVPLV 
LLDGHVPQL FIDGHVPQL 
LLDGHIPQV MIDGHVPQL 
LLDGHVPQV FLIGHVPLV 
FIDAHIPQL FIDGHVPLV 
 MLDAHIPQV 
 
Table 5.1 Peptide sequences designed from D454 nonamer CPL screen.  
Residues in bold correspond to those in the cognate LLDAHIPQL. Cognate peptide is 
indicates in red at the top of each column. 
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D454 cells were challenged with C1R-A2 pulsed with a titration of individual peptides 
listed above (Table 5.1). T-cell sensitivity to an antigen was defined by the half 
maximum effective concentration EC50. It represents the peptide concentration with 
which half of the maximum T-cell response is inhibited. EC50 allows an easy 
comparison of the potency of different peptides. D454 T-cell MIP-1β release was still 
detectable by ELISA at LLDAHIPQL concentration of >10-10 M (100 pM) (Figure 5.6). 
EC50 of LLDAHIPQL peptide was calculated at 1.1x10-9 M. Most of the peptides 
tested were more potent agonists of D454 T-cells than the M. tuberculosis-derived 
sequence. However, substitution of glutamine at position 8 by leucine impact 
dramatically on the D454 sensitivity (LLDAHIPLL: EC50 7.3 x 10-9 M). D454 was 
most sensitive to the MIDAHIPQV peptide of those tested (EC50 = 1.7 x 10-11) making 
this sequence >100 more potent than the M. tuberculosis-derived LLDAHIPQL peptide. 
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Figure 5.6 D454 cells sensitivity to 30 agonist peptides.  
6 x 105 C1R A2 were pulsed with a titration of individual peptides and presented to 3 x 
105 D454 T-cells. Cells were incubated overnight and D454 cells response to the 
peptides was quantify by MIP-1β ELISA. The red line corresponds to D454 activation 
profile to LLDAHIPQL peptide titration. The green lines correspond to D454 activation 
profile to the most potent MIDAHIPQV agonist titration. 
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5.2.2.3 D454 TCR affinity for HLA-A*0201-MIDAHIPQV 
In order to compare the affinity of D454 for HLA-A*0201-LLDAHIPQL and HLA-
A*0201-MIDAHIPQV, biotinylated HLA-A*0201-MIDAHIPQV monomers were 
produced using the same protocol used in section 5.2.1.1 and were purified by anion 
exchange and size exclusion chromatographies. HLA-A*0201-MIDAHIPQV tetramers 
were produced. 
The affinity of D454 for the cognate LLDAHIPQL and optimal MIDAHIPQV peptides, 
in complex with HLA-A*0201, were evaluated using tetramer staining and analysed by 
flow cytometry using HLA-A*0201-NLVPMVATV as a negative control. The gating 
strategy consisted of gating live (Vivid) CD3+ (anti-CD3 antibody) and CD8+ (anti-
CD8 antibody) T-cells and identical to Figure 5.3 A, B and C. As expected, HLA-
A*0201-LLDAHIPQL tetramer stained weakly D454, as only 21% of T-cell clones 
were stained by tetramer. However, more than 96% of D454 were stained with optimal 
agonist HLA-A*0201-MIDAHIPQV tetramer. These data confirmed that D454 have a 
higher affinity for HLA-A*0201-MIDAHIPQV than for HLA-A*0201-LLDAHIPQL.  
A HLA-A*0201-MIDAHIPQV tetramer negative population was revealed by the 
staining representing about 4% of D454 T-cells (Figure 5.7). This population was not 
detected during the RACE TCR sequencing performed in section 5.2.3.1.a. (Table 5.2). 
Attempts to remove the tetramer negative CD8 population were unsuccessful. These 
data seem to suggest that, like the D426 B1 clone I had received from Portland, the 
D454 T-cell clone also contained a contaminant CD8 T-cell. Fortunately, on this 
occasion the polyclonal nature of D454 did not cause me any major issues. 
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Figure 5.7. Staining of D454 T-cell line with LLD-, MID- and NLV-HLA-A*0201 
tetramers.  
3 x 105 D454 T-cells were first treated with 50 nM Dasatinib  for 30 minutes followed 
by staining with 0.4 μg of HLA-A*0201-LLDAHIPQL/MIDAHIPQV/NLVPMVATV 
tetramer-PE for 30 minutes. Cells were then stained for the following markers: Dead 
cells (Vivid-PB), CD3 (anti-CD3-PerCP Cy5.5 antibody) and CD8 (anti-CD8-APC 
antibody) for 20 minutes. Cells were analysed by flow cytometry. A. Gating strategy. 
Cells of interest were live, CD3+, CD8+ and were identified by antibody staining using a 
dead cells marker (Vivid-PB), an anti-CD3-PerCP Cy5.5 antibody and an anti-CD8-
APC antibody. B. D454 T-cells were treated with a 50 nM Dasatinib (protein kinase 
inhibitor PKI) followed by 0.4 μg of HLA-A*0201-
LLDAHIPQL/MIDAHIPQV/NLVPMVATV tetramer-PE. 
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5.2.3 Characterisation of D454 TCR affinity for HLA-A*0201-LLDAHIPQL and 
HLA-A*0201-MIDAHIPQV 
5.2.3.1 Manufacture of soluble D454 TCR 
5.2.3.1.a RACE TCR sequencing of D454 TCR T-cell clone 
D454 α and β TCR cDNA sequences chains were amplified by 5’ RACE technology 
and sequenced by Cardiff University Central Biotechnology Centre (Table 5.2). 
A. D454 TCRα chain sequencing 
TRAV Vα (Arden et.al.) CDR3α  TRAJ Freq (%) 
12-1 2.1 CVVNVLYSGAGSYQLT 28 100.00 
 
B. D454 TCRβ chain sequencing 
TRBV Vβ (Arden et.al.) CDR3β TRBJ Freq (%) 
14 16.1 CASSQALGAGNTEAF 1-1 100 
 
Table 5.2. RACE TCR sequencing of D454 TCR. 
5.2.3.1.b Production of soluble D454 TCR monomers 
Production of soluble D454 TCR chains were undertaken in order to produce soluble 
D454 TCR for SPR and structural analyses. The design protocol of α and β TCR DNA 
sequences of D454 TCR was identical to the one used for the design of HLA-A*0201-
LLDAHIPQL (see section 5.2.1.3.a.). The α and β TCR IB expression was quality 
controlled by running a sample of bacteria culture denaturated with DTT on SDS-
PAGE. The α and β TCR chain molecular weights were 22.7 kDa and 27.7 kDa 
respectively and were detectable in the bacteria culture after IPTG treatment (Figure 
5.8). IBs for all chains contained impurities, probably bacterial proteins, identifiable on 
the gel as protein smears as well as individual bands of different molecular sizes 
(Figure 5.8). 
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Figure 5.8. Quality control of D454 α and β TCR chains expression by E. coli 
Rosetta assessed by SDS-PAGE gel.  
E. coli Rosetta transformed with either αTCR-pGMT7 and βTCR-pGMT7 plasmids 
were induced (right lanes) or not (left lanes) with IPTG for 3 hours. Bacterial culture 
samples were treated with DTT and denaturated at 95 °C before being run on an SDS-
PAGE. The red arrows are pointing out the TCR chain products. 
Production of soluble TCR from inclusion bodies is performed routinely by my 
laboratory and consists on re-suspending IBs in guanidine buffer (6M guanidine, 50 
mM TRIS, 2 mM EDTA, 100 mM NaCl) and individually treating the α and β TCR IBs 
with 10 mM DTT for 30 minutes and refolding both chains for 4 hours at 4 °C in a cold 
refold buffer (Chapter 2) to produce a fully folded αβ TCR heterodimer. During αβ TCR 
refolding, aggregation of unfolded α and β chains can occur. In order to remove 
aggregates, different steps of purification were required. First, αβ TCR refolds were 
purified by anion exchange chromatography and eluted according to charge using a 
NaCl gradient. Anion exchange chromatography purified αβ TCR pooled fractions were 
then purified by size exclusion chromatography to improve the purity of αβ TCR 
(Figure 5.9 A). Quality of αβ TCR monomers was assessed by running denaturated 
(DTT treatment) or non-denaturated fractions by SDS-PAGE. 
A sample of each of eight D454 αβ TCR eluted fractions were SDS-PAGE as described 
above. Under denaturating conditions, all fractions contained both α and β TCR chains 
running at ~25 kDa and ~30 kDa respectively. Under non-denaturing conditions, α and 
β TCR chains ran as a single band of ~50.4 kDa (Figure 5.9 B). Aggregates varied in 
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size and appeared as a smear on the gel in each fraction. Fraction 2 to 7 contained fully 
folded D454 αβ TCR heterodimers. However, fractions 4 and 5 were purest; I therefore 
pooled these two fractions (Figure 5.9 B).  
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Figure 5.9. Purification of D454 TCR refold product by anion exchange 
chromatography.  
A. Anion exchange chromatogram of D454 TCR refold. The blue, green and brown 
lines represent milli-absorbance units (mAU), % of eluting buffer (1M NaCl, 10mM 
Tris, pH 8) and % of conductivity respectively. Red dotted lines correspond to the 
pooled fractions. B. Analysis of 8 eluted fractions (in red) by SDS-PAGE. Sample 1, 2, 
3, 4, 5, 6, 7 and 8 (in red) were denaturated or not denaturated with 500 mM DTT and 
run on SDS-PAGE. Purified D454 proteins are indicated by red arrows. 
In order to improve the purity of D454 αβ TCR heterodimers after anion exchange the 
pooled fractions 4 and 5 were further purified by size exclusion chromatography 
(Figure 5.10 A) and analysed by SDS-PAGE. Non-denaturated fractions 5 to 7 
contained folded D454 αβ TCR heterodimers and the lowest concentration of 
aggregates therefore fractions these three fractions were pooled (Figure 5.10 B). 
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A. Size exclusion chromatography
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Figure 5.10. First purification of D454 TCR by size exclusion chromatography.  
A. D454 TCR size exclusion chromatogram of pooled anion exchange fractions. 
The blue line corresponds to milli-absorbance unit (mAU) and the dashed lines 
represent the pooled fractions. B. Analysis of the D454 TCR size exclusion fractions by 
SDS-PAGE. Sample 1, 2, 3, 4, 5, 6, 7 and 8 (in red) were denaturated or not denaturated 
with 500mM DTT and run on a SDS-PAGE gel. Purified D454 proteins are indicated by 
red arrows. 
To improve purity, size exclusion chromatography was repeated with the pooled 
fractions (Figure 5.11 A). The concentration of aggregates was greatly reduced after 
this third chromatographic separation. Fractions 3, 4 and 5 were pooled (Figure 5.11 
B).  
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A. Size exclusion chromatography B.
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Figure 5.11. Second purification of D454 TCR by size exclusion chromatography. 
A. D454 TCR size exclusion chromatogram of pooled anion exchange fractions. 
The blue line corresponds to milli-absorbance unit (mAU) and the dashed lines 
represent the pooled fractions. B. Analysis of the D454 TCR size exclusion fractions by 
SDS-PAGE. Sample 1, 2, 3, 4, 5 and 6, (in red) were denaturated or not denaturated 
with 500 mM DTT and run on a SDS-PAGE gel. Purified D454 TCR and TCR and 
TCR are indicated by red arrows. 
D454 αβ TCR heterodimer concentration was low, therefore several refolding and 
purification steps of D454 αβ TCR were necessary to produce sufficient protein for 
biophysics and crystallisation. After these laborious, cumulative steps of purification, 
the purity of D454 αβ TCR heterodimer was estimated to only be ~80%; far lower than 
for other TCRs we have refolded. 
5.2.3.2 Biophysical analysis of the D454 TCR interaction with HLA-A*0201-
LLDAHIPQL and HLA-A*0201-MIDAHIPQV 
The D454 TCR produced in section 5.2.3.1 was only ~80% pure and therefore not ideal 
for SPR where an accurate TCR concentration is required. Moreover, it is possible that 
the impurities present might inhibit TCR binding to MHC.  
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Nevertheless, I was able to use the protein I had produced to directly compare the 
binding of HLA-A*0201-LLDAHIPQL and HLA-A*0201-MIDAHIPQV; providing an 
accurate comparative affinity for the two ligands. The modification of only three amino 
acids at position P1 and anchor position P2 and P9 improve greatly the affinity of D454 
for cognate peptide. Indeed, D454 affinity was 8-fold increased for the altered peptide 
HLA-A*0201-MIDAHIPQV (Figure 5.12). 
Affinity TCR for peptide-MHC
Kd
D454 vs MIDAHIPQVD454 vs LLDAHIPQL/A2
 
Figure 5.12. Estimation of the D454 binding affinity to HLA-A*0201-LLDAHIPQL 
and HLA-A*0201-MIDAHIPQV. 
Ten serial dilution of D454 TCR were used to analyse binding to HLA-A*0201-
LLDAHIPQL or HLA-A*0201-MIDAHIPQV monomers. The constant of dissociation 
(KD) was evaluated by plotting the concentration of D454 TCR on the x-axis and the 
responses obtained unit obtained for each concentration. The equilibrium binding 
constant (KD) values were calculated assuming a 1:1 interaction ( ) by 
plotting specific equilibrium-binding responses against protein concentrations followed 
by non-linear least squares fitting of the Langmuir binding equation . 
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Even though an accurate value of the D454 TCR affinity for HLA-A*0201-
LLDAHIPQL and HLA-A*0201-MIDAHIPQV monomers could not be measured, 
these data confirm that the D454 TCR binds better to the potent agonist HLA-A*0201-
MIDAHIPQV than to the wild-type HLA-A*0201-LLDAHIPQL ligand. 
5.2.3.3 Structural studies of HLA-A*0201 in complex with LLDAHIPQL and 
MIDAHIPQL 
D454 TCR, HLA-A*0201-LLDAHIPQL and HLA-A*0201-MIDAHIPQV purified 
soluble monomers obtained in section 5.2.1.1 were used to generate protein crystals 
using the sitting drop vapour diffusion technique in multiple crystallisation screens. 
Multiple attempts to produce D454 TCR-antigen co-crystals failed. However, I was able 
to generate crystals of HLA-A*0201-LLDAHIPQL and HLA-A*0201-MIDAHIPQV in 
20% PEG 3350 and 200 mM Ammonium Nitrate. Electron diffraction patterns were 
collected for these two pMHC at Diamond Light Source synchrotron, Didcot, UK. Data 
extracted from the diffraction patterns were compared to a known HLA-A*0201 model 
using the technique of molecular replacement. Molecular replacement was successful in 
space P1211 for both HLA-A*0201-LLDAHIPQL and HLA-A*0201-MIDAHIPQV 
meaning that structures solved were consistent with the presence of one molecule per 
asymmetric unit. The resolution of the HLA-A*0201-LLDAHIPQL and HLA-A*0201-
MIDAHIPQV structures were very high at 1.72 Å and 1.63 Å respectively. The 
molecular visualisation software, PyMol, was used to directly visualise and 
superimpose the conformations HLA-A*0201-LLDAHIPQL and HLA-A*0201-
MIDAHIPQV. The data set and refinement statistics for the LLD HLA-A*0201-
LLDAHIPQL and HLA-A*0201-MIDAHIPQV structures are shown in Table 5.3. 
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Space group P 1211 
Unit cell parameters (Å,°) a=56.33, b=79.51, c=56.61 
Radiation source DIAMOND I04.1 
Resolution (Å) 47.72-1.72 
Unique reflections 47853
Completeness (%) 99.9
Multiplicity 3.8
I/Sigma (I) 14.2
Rmerge 0.08
No reflections used 47853
Rfactor (%) 17.6
Rfree (%) 21.3
Bond lengths (Å) 0.019
Bond angles (°) 1.97
Mean B value (Å
2
) 23.714
Outliers Ramachandran plot (%) 0
Overall ESU based on maximum likelihood (Å)  0.057
Data set statistics  
LLD/A2 
Refinement statistics 
 
Space group P 1 21 1 
Unit cell parameters (Å,°) a=56.56, b=79.46, c=56.77  
Radiation source DIAMOND I04.1 
Resolution (Å) 50.44-1.63 
Unique reflections 53372
Completeness (%) 99.87
Multiplicity 3.7
I/Sigma (I) 10.1
Rmerge (%) 0.133
No reflections used 53372
Rfactor (%) 16.5
Rfree (%) 18.9
Bond lengths (Å) 0.019
Bond angles (°) 2.156
Mean B value (Å
2
) 19.689
Outliers Ramachandran plot (%) 0
Overall ESU based on maximum likelihood (Å)  0.059
Refinement statistics 
Data set statistics  
MID/A2 
 
Table 5.3. Data collection and refinement statistics of LLD/A2 and MID/A2 
complex structures. 
Superposition of the LLDAHIPQL and MIDAHIPQV peptides inside the HLA-A*0201 
groove allowed comparison of how these two peptides are presented to T-cells (Figure 
5.13 A). Residues at positions P1 (leucine: Leu1 or methionine: Met1), P5 (histidine: 
His5) and P8 (glutamine: Glu8) were sticking up outside of the groove toward the 
solvent. These residues are likely to make important contacts with the TCR. The 
bulging residue histidine at position P5 is expected to play a major role in the TCR 
docking. However, positions P2 (Leu2 or isoleucine: Ile2), P6 (Ile6) and P9 (Leu9 or 
valine: Val9) were sticking down inside the HLA-A*0201 groove, therefore were more 
likely to stabilise peptide binding to HLA-A*0201 (Figure 5.13 B). Indeed, studies 
have shown that residues at P2 and P9 are the primary MHC anchors for HLA-A*0201 
in nonamer peptides (Falk et al., 1991). 
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Figure 5.13. Comparison of the conformation of LLDAHIPQL and MIDAHIPQV 
peptides inside the A2 groove. 
(A.) Superposition of LLDAHIPQL and MIDAHIPQV inside the HLA-A*0201 groove. 
Only one HLA-A*0201 groove α helix is represented here in light transparent blue. 
LLDAHIPQL is represented in yellow while MIDAHIPQL is represented in blue. 
Substituted residues on MIDAHIPQL peptide are represented in red. Arrows are 
representing amino acids that are sticking outside or inside the HLA-A*0201 groove. 
(B.) Amino acid sequence of LLDAHIPQL and MIDAHIPQV peptides and the residues 
along the nonamer peptide backbone that are sticking outside and inside the HLA-
A*0201 groove. 
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Close inspection of the peptide structures allowed me to understand how the amino acid 
substitutions in the LLDAHIPQL peptide might impact on D454 TCR binding. At 
position P1, the substitution of leucine (Leu1) with a methionine (Met1) did not 
stabilise the residue inside the HLA-A*0201 groove. Indeed, the number of contacts 
was higher between Leu1 and HLA-A*0201 groove residues than for Met1 (33 and 30 
contacts respectively) (Table 5.4). However, Met1 is a longer residue than Leu1, 
therefore Met1 extended further up away from the HLA-A*0201 groove allowing the 
possibility of more contact with D454 TCR than Leu1 (Figure 5.14 left quadrant). The 
long residue Ile2 in the MIDAHIPQV peptide made two more Van der Walls 
interactions with the HLA-A*0201 groove than LLDAHIPQL Leu2 residue making in 
total 34 contacts with the HLA-A*0201 residues compared to 31 for Leu2 (Figure 5.14 
middle quadrant). As mentioned earlier, modification of anchor residues can improve 
the docking of the peptide inside the HLA-A*0201 groove. Therefore Ile2 might 
marginally improve MIDAHIPQV interaction with HLA-A*0201 groove. At position 
P9, MIDAHIPQV Val9 residue made a similar number of contacts with the HLA-
A*0201 groove than the LLDAHIPQL Leu9 residue, even though the valine residue is 
shorter than the leucine. Interestingly, substitution of the Leu9 for Val9 has a knock on 
effect on neighbour glutamine residue at position P8 (Glu8). Indeed, Val9 seems to 
“push” Glu8 away from the HLA-A*0201 groove toward the solvent and might increase 
the number of contacts with the TCR (Figure 5.14 right quadrant). 
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Figure 5.14. Comparison of LLDAHIPQL and MIDAHIPQV residues at position 
P1, P2 and P9. 
(A.) Superposition of LLDAHIPQL and MIDAHIPQV inside the HLA-A*0201 groove. 
(B.) Close up of LLDAHIPQL and MIDAHIPQV peptide residues at position P1 (Leu1 
vs Met1 left quadrant), P2 (Leu2 vs Ile2 middle quadrant) and P9 (Leu9 vs Val9 right 
quadrant). 
 
Leu1 : A2 Leu2 : A2 Leu9 : A2 Met1 : A2 Ile2 : A2 Val9 : A2
Total contacts 33 31 29 30 34 30
VdW contacts 30 29 25 27 32 26
H-bonds 3 2 4 3 2 4
LLDAHIPQL with A2 MIDAHIPQV with A2
 
Table 5.4. Number of contact between LLDAHIPQL or MIDAHIPQV peptides 
and A2 groove residues at position P1, P2 and P9.  
This table presents the number of total contacts, Van der Walls (VdW) interactions and 
hydrogen bonds (H-bonds) between LLDAHIPQL peptide residues Leu1, Leu2 and 
Leu9 with A2 groove residues, as well as between MIDAHIPQV peptide residues Met1, 
Ile2 and Val9 with HLA-A*0201 groove residues. The full table of contacts between 
both peptides and HLA-A*0201 are presented in appendix A2 and A3.  
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5.3 Discussion 
In this chapter I aimed to characterise the recognition of the immunogenic EsxG derived 
LLDAHIPQL peptide by an HLA-A*0201-restricted CD8 T-cell clone (D454). The 
specificity of D454 for HLA-A*0201-LLDAHIPQL was confirmed by tetramer 
staining. However, HLA-A*0201-LLDAHIPQL tetramer stained D454 weakly 
indicating a low affinity of D454 TCR for HLA-A*0201-LLDAHIPQL. In order to 
investigate into the mechanism involved in HLA-A*0201-LLDAHIPQL recognition by 
D454 TCR, I decided to determine the peptide residues important for this recognition. 
To this end, I undertook a nonamer CPL screen of D454. CPLs have been widely used 
to get an insight into T-cell peptide repertoire preferences (Wooldridge et al., 2012), to 
optimise antigen and improve T-cell recognition of cognate peptide (Cole et al., 2010) 
or even to map natural ligand for T-cell clones (Yin et al., 2011). 30 peptides were 
designed based on the CPL screen were tested. Most proved to be optimal agonists. The 
MIDAHIPQV sequence performed best and was 100-fold more potent than the 
LLDAHIPQL cognate peptide in activating D454. Substitution of leucine at position P1 
and P2 for hydrophobic amino acids (phenylalanine, methionine or isoleucine) or at 
position P9 (valine) improved peptide potency. All the best three agonist peptides 
possessed a valine at position P9 indicating that this residue is optimum for the T-cell 
recognition. Structural analysis of the interaction between LLDAHIPQL or 
MIDAHIPQV peptides with HLA-A*0201 gave an insight into the impact of the amino 
acid substitution at position P1, P2 and P9 and provided a possible mechanism for the 
improved recognition of HLA-A*0201-MIDAHIPQV compared with HLA-A*0201-
LLDAHIPQL. Amino acid substitution at position P1, P2 and P9 had a minor structural 
effect on peptide anchorage to the HLA-A*0201 groove. The number of contacts 
between MIDAHIPQV with HLA-A*0201 groove residues was slightly higher than 
with LLDAHIPQL peptide. The Met1 side chain of the MIDAHIPQV peptide extends 
further outside the HLA-A*0201 groove than Leu1 in the LLDAHIPQL peptide 
providing an opportunity for enhanced contacts with the D454 TCR. Substitution of 
Leu9 for Val9 pushed the solvent exposed Glu8 residue further away from the HLA-
A*0201 groove (and towards a cognate TCR). These changes probably explain the 
enhanced potency of MIDAHIPQV. Unfortunately, I was unable to co-crystallise the 
D454 TCR with either antigen despite multiple attempts. 
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An estimation of D454 TCR affinity characterised by the constant of dissociation (KD) 
showed that D454 TCR had a ~8-fold higher affinity for HLA-A*0201-MIDAHIPQV 
than HLA-A*0201-LLDAHIPQL. These data were supported by tetramer staining of 
D454 T-cell where staining was greater with HLA-A*0201-MIDAHIPQV than with 
HLA-A*0201-LLDAHIPQL.  
Generation of potent, optimal agonist peptides by amino acid substitution of 
immunogenic cognate antigen such as MIDAHIPQV peptide could lead to the 
development of new diagnostic tools as well as new vaccine approaches. Several teams 
have already developed tetramers as a diagnostic tool for the detection of T-cell-
associated immune responses against diseases. Tetramers developed were used to target 
T-cells involved in bacterial or various infections (Gratama and Cornelissen, 2003), in 
autoimmune diseases (Brottveit et al., 2011) and in cancers and were shown to provide 
information regarding the nature of the T-cells involved, as well as their frequencies and 
location. However, due to the low affinity of certain antigens, notably self antigen 
(Wooldridge et al., 2009, Aleksic et al., 2012, Cole et al., 2007), the challenge is to 
increase the sensitivity of tetramer detection. The use of HLA-A*0201-MIDAHIPQV 
tetramers could improve the threshold of detection of M. tuberculosis/LLDAHIPQL 
specific T-cell responses in HLA-A*0201 patients. Indeed, I could detect an HLA-
A*0201-MIDAHIPQV tetramer negative population in D454 T-cell population that 
could not be detected by HLA-A*0201-LLDAHIPQL tetramer. Therefore, using HLA-
A*0201-MIDAHIPQV tetramer would allow accurate measurement of D454 specific T-
cells in patient samples that could not be detected by HLA-A*0201-LLDAHIPQL 
tetramer.  
In summary, in this chapter, I successfully characterised the recognition of an 
immunogenic M. tuberculosis epitope by a CD8 T-cell by identifying the key peptide 
residues necessary for TCR recognition and design superior agonist by using CPL 
technology. Moreover, I succeeded in crystallising and solving the first ever molecular 
structure of a real M. tuberculosis epitope in complex with an MHC class I epitope. 
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CHAPTER 6. DISCUSSION AND FUTURE WORK 
6.1 Discussion 
Understanding immune responses to bacterial infection, and notably to life-threatening 
diseases such as TB, is of major importance to the development of diagnostic tools and 
effective vaccines. T-cells orchestrate the immune system and sit at the heart of 
approaches aimed at combating M. tuberculosis infection. In this thesis, I provided an 
insight into the T-cell network involved during exposure to Mycobacterial antigens and 
showed that it involved both conventional, peptide-recognising, MHC-restricted T-cells 
and unconventional T-cells that recognise other MHC-like platforms. Understanding the 
respective roles and importance of these T-cell subsets will be pivotal to approaches for 
diagnosing and treating bacterial infection. 
In the chapter 3, I dissected T-cell responses to M. smegmatis phagocytosed by A549 
cells. I used M. smegmatis as it grows well in culture and could be used in the facilities 
that were available to me. M. smegmatis cannot multiply in the host intracellular 
environment so is not infectious. However, this bacterium can still be phagocytosed and 
degraded by specialised phagocytic antigen presenting cells (DCs) or macrophage-type 
cell lines such as A549 cells which then present bacterial antigens to T-cells (Davey et 
al., 2011). My studies identified certain actors involved in the immune response to 
mycobacterium. After exposure to M. smegmatis, the frequency of responding CD3 T-
cells was donor dependant and varied between 2 and 10 % of all T-cells. The majority 
of M. smegmatis-specific CD3+ cells were CD8 T-cells although there were also 
expanded populations of DN T-cells. The M. smegmatis-specific DN T-cell population 
consisted mainly of γδ T-cells. γδ T-cells play a major role during early bacterial 
infection and are thought to provide a bridge between the innate response and the 
classical adaptive immunity undertaken by B-cells and αβ T-cells (Ladel et al., 1996). 
Strikingly, the majority of the responding CD8 T-cell population were MAITs 
characterised by the Vα7.2 J33 markers. These results emphasise the potential 
importance of MAITs in bacterial infections (Le Bourhis et al., 2010, Gold et al., 2010, 
Chua et al., 2012).  
This study provided a preliminary insight into T-cell responses induced by exposure to 
M. smegmatis phagocytosed by an APC in vitro. It would have been interesting to 
further dissect these responses by varying parameters such as antigen load and duration 
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of exposure as well as examining different effector read-outs. My experiments used 
IFNγ secretion as a read-out of T-cell activation.  
The use of this classic TH1 cytokine obviously biased my results towards these IFNγ 
producer cells. It remains possible that other effective cells also responded but did not 
make IFNγ. In order to have a wider representation of M. smegmatis responding T-cells, 
I could have included examination of other effector markers such as CD107a, CD69, 
RANTES, TNFα and IL-2. T-cells are not restricted to the expression of only one 
cytokine. Certain T-cell populations can exhibit heterogeneity in their effector functions 
and it is becoming apparent that the range of functions that are elicited by a single T-cell 
is of vital importance to the effectiveness of an immune response. Indeed, it has been 
demonstrated that immunity to some pathogens correlates with the ability of individual 
responding cells to multitask by simultaneously responding with multiple effector 
functions. For example, ‘polyfunctional’ CD4 and CD8 T-cells are known to be 
associated with the control of HIV replication in vivo (Wherry et al., 2003, Harari et al., 
2004, Almeida et al., 2007). Other studies have aimed to examine T-cell 
polyfunctionality in bacterial infections such as TB. Recombinant TB antigen-based 
human vaccines stimulate individual T-cells to secrete IFNγ, IL-2 and TNFα (Beveridge 
et al., 2007, Scriba et al., 2010). BCG vaccination of infants is also known to trigger the 
expansion of polyfunctional T-cells (Soares et al., 2008). These studies provide 
evidence that polyfunctional T-cells might be associated with protection in chronic TB. 
Curiously, polyfunctional T-cells are highly represented during T-cell responses to 
active TB but are less frequent during TB latency (Caccamo et al., 2010). Therefore it 
has been suggested that polyfunctional T-cells could act as a biomarker of active TB 
(Caccamo et al., 2010).  
The high frequency of MAITs induced in my experiments with M. smegmatis made me 
especially keen to examine what these cells were recognising. When I started my 
studies, little was known about MAITs, their role in bacterial infection or the nature of 
the bacterial antigen they recognised. Knowledge of MAITs was limited by the 
availability of reagents for identifying these cells in ex vivo samples. I knew that several 
laboratories were trying to define the ligand presented to MAITs by MR1. The nature of 
the MR1 binding groove and its similarity to classical MHC I molecules suggested that 
it might present a peptide.  
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As my laboratory has extensive expertise with CPLs, I set out to establish whether a 
MAIT could recognise a peptide using these tools. If MAITs recognised a peptide, I was 
particularly excited by the prospect of using peptide-MR1 tetramers for tracking of 
MAITs in patient samples. 
I was provided with a well-characterised CD8 MAIT clone (D426 B1) by my 
collaborator, Prof David Lewinsohn. My studies in Chapter 4 showed that D426 B1 
could recognise peptides. These data were then used to show that this MAIT clone 
could recognise M. tuberculosis-derived peptides. Unfortunately, subsequent analyses 
revealed that this D426 B1 response was not restricted by MR1 and was attributed to a 
non-MAIT contaminant population in D426 B1 sample leading me to conclude that 
MAITs do not recognise peptide through MR1.  
I set out to continue my hunt for the MAIT ligand by attempting to refold soluble MR1. 
During these studies my supervisor heard that the Melbourne group had already 
discovered a ligand for MAITs and successfully manufactured MR1 tetramers. I was 
advised to discontinue my studies. The studies of McCluskey, Rossjohn and colleagues 
finally started to hit the press late in 2012 and revealed some fascinating insights into 
MAIT biology. The first study showed the structure of the MR1 molecule in complex 
with a folic acid (Vitamin B9) metabolite, 6-formyl pterin (6-FP) (Kjer-Nielsen et al., 
2012). Although, 6-FP fits inside MR1 groove, it is not a MAIT agonist. Subsequent 
studies have demonstrated that other metabolites from the riboflavin (Vitamin B2) 
pathway activate MAITs when presented by MR1 (Patel et al., 2013). This presentation 
of a bacterial metabolite by MR1 was highly unexpected and revealed that T-cells could 
recognise more than just foreign peptides or lipids.  
The overall conformation of MR1 is very similar to classic MHC I molecules. However, 
the antigen cavity in MR1 groove is smaller and mainly hydrophobic allowing it to 
accommodate ring-based metabolites. The MAIT TCR interacts mainly with the MR1 
groove and makes very limited contacts with the antigen (Patel et al., 2013, Lopez-
Sagaseta et al., 2013). Figure 6.1 shows a MAIT TCR in complex with MR1-6-FP and 
MR1 loaded with the MAIT agonist: 7-hydroxy-6-methyl-8-D-ribityllumazine (Ri-6-
Me-7-OH). These figures were generated using coordinates published by Prof. Jamie 
Rossjohn and colleagues in 2013 (Patel et al., 2013). Antigen recognition by the MAIT 
TCR involved mainly the Vα7.2 Jα33-encoded CDR3α loop which is diagonally 
positioned above MR1-antigen and acts as an antigen sensor. Interestingly, all MAIT 
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agonists described to date share a ribityl group that is recognised by MAIT TCR 
tyrosine residue at position 95 on the CDR3α loop (Y95α) (Patel et al., 2013).  
The ribityl group acts as a bridge that facilitates the interaction with the CDR3α loop.  
Indeed the distance between the Y95α and the terminal hydroxide of the ribityl group of 
the Ri-6-Me-7-OH (2.83 Å) is favourable for TCR binding to MR1-antigen (Figure 6.1 
B). The absence of the ribityl group in the 6-FP increases the distance to Y95α (4.93 Å) 
and explains why this interaction is too weak to activate MAITs (Figure 6.1 A). 
2.83
Y95α
Ri-6-Me-7-OH
4.93
Y95α
6-FP
Ribityl
6-Formyl pterin
(6-FP)
7-hydroxy-6-methyl-8-D-ribityllumazine
(Ri-6-Me-7-OH)
A. B.
 
Figure 6.1 MAIT TCR recognition of MR1-vitamin antigens.  
Interaction between the MAIT TCR CDR3α Tyr95α and (A.) the nitrogen hydride 
group of the 6-forym pterin (6-FP) and (B.) the terminal hydroxyl from the ribityl group 
(circled in red) of the 7-hydroxy-6-methyl-8-D-ribityllumazine (Ri-6-Me-7-OH) loaded 
in MR1 groove. Crystal structure of MAIT TCR in complex with MR1-6-FP and MR1-
Ri-6-Me-7-OH are respectively 4L4T and 4L4V respectively and were both published 
by Prof. Jamie Rossjohn and team (Patel et al., 2013). Chemical structures of 6-FP and 
Ri-6-Me-7-OH were taken from (Gapin, 2014).  
In hindsight, it is striking that the ability of MAITs to respond to different micro-
organisms corresponds to whether they possess a riboflavin-biosynthesis pathway (Le 
Bourhis et al., 2010, Gold et al., 2010, Kjer-Nielsen et al., 2012). However, much 
further work will be needed to truly dissect what MAITs recognise as riboflavin 
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metabolites are expressed by some commensal bacteria so could easily diffuse through 
epithelial layers to eventually activate MAITs leading to unwanted inflammation. 
 
The discovery of MR1 ligand has considerably improved the characterisation of MAIT-
mediated immunity. The generation of multimeric MR1-antigen has improved the 
detection of MAITs ex vivo. The combination of non-specific phenotype markers (CD3, 
CD161 and Vα7.2) with MR1-antigen tetramer strengthens the stringency of MAIT 
detection (Reantragoon et al., 2013). Interestingly, 5-15 % of MR1-antigen-specific 
MAITs were shown to express Vα7.2 Jα12 and Vα7.2 Jα20 TCR chains (Reantragoon 
et al., 2013). These results raised questions regarding the rigidity of the MAIT 
nomenclature. New data shows that the MAITs induced by Listeria, Salmonella and M. 
smegmatis express different TCRs (Gold et al., 2014). These data are highly suggestive 
of the fact that cells infected with these pathogens present subtly different antigens to 
MAITs. The important molecular details of this recognition remain to be discovered but 
may be key to how MAITs discriminate between commensal and pathogenic bacteria. 
Due to the above discoveries I was advised to switch my studies to examining 
conventional T-cell responses to Mycobacteria. I was particularly interested in T-cell 
responses to the HLA*0201-restricted epitope LLDAPHIPQL. This sequence originates 
from the immunogenic M. tuberculosis EsxG protein which triggers a strong CD8 T-cell 
response (Hervas-Stubbs et al., 2006, Skjot et al., 2002). Furthermore, LLDAPHIPQL is 
conserved between different Mycobacterial species, thereby opening up the potential 
that responses to this epitope might be broadly protective and offer pan-Mycobacterial 
immunity.  
My collaborators in Portland provided me with a T-cell clone, D454, that recognised 
HLA*0201-LLDAPHIPQL that had been isolated from the blood of a patient with 
chronic TB. This T-cell is activated by M. tuberculosis infected DCs (Lewinsohn et al., 
2007). I isolated the TCR from this clone and showed that it had a relatively low affinity 
for HLA-A*0201-LLDAHIPQL, by tetramer staining and SPR. Dissection of the 
recognition profile of D454 by CPL revealed that this clone preferred a nonamer peptide 
suggesting that better peptide agonists could be designed. I explored this avenue as such 
a ligand might have helped detection of HLA-A*0201-LLDAPHIPQL-specific T-cells. 
I also hoped that such a ligand would aid my attempts to structurally study the D454 
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TCR. 30 peptides were designed and tested as agonists of the D454 T-cell. The 
sequence MIDAHIPQV proved to be the best of those tested and was >100 fold more 
potent than the wild type LLDAPHIPQL sequence in an antigen titration experiment. 
The threshold of detection of D454 population by tetramer staining was greatly 
enhanced by using reagents folded with HLA-A*0201-MIDAHIPQV.  
Moreover, an HLA-A*0201-MIDAHIPQV negative contaminant population was 
detected using this reagent suggesting that D454, like D426 B1, was not a monoclonal 
population. I aimed at understanding the molecular mechanisms involved in D454 TCR 
interaction with HLA-A*0201-LLDAHIPQL. To this end, I attempts to crystallise 
soluble D454 TCR in complex with HLA-A*0201-LLDAHIPQL and HLA-A*0201-
MIDAHIPQV. Unfortunately, my attempts to generate a co-crystal structure were 
unsuccessful. However, I successfully solved both HLA-A*0201-LLDAHIPQL and 
HLA-A*0201-MIDAHIPQV structures. The former represents the first crystal structure 
of HLA-A*0201 presenting a bacterial antigen ever analysed. Combination of structural 
analysis of HLA-A*0201-LLDAHIPQL and HLA-A*0201-MIDAHIPQV as well as 
data generated from the nonamer CPL screen revealed the key peptide residues involved 
in D454 recognition of pMHC. Counter intuitively, two of the three positions that are 
altered in the MIDAHIPQV sequence are primary anchor positions where the amino 
acid side chain is thought to be buried within the MHC groove rather than facing the 
TCR. Indeed, the leucine to valine change at position 9 gave the biggest enhancement in 
peptide potency. Structures of HLA-A*0201-LLDAHIPQL and HLA-A*0201-
MIDAHIPQV show that the change in primary anchors had knock-on effects on 
neighbouring residues thereby altering the topography of the peptide-HLA landscape. 
My group have recently demonstrated that changes in peptide anchor positions can have 
marked effects on TCR engagement (Cole et al., 2010). These results have recently been 
backed up by structural analyses (David Cole unpublished). 
6.2 Future work 
During the course of my PhD, I have learned many lessons. The most valuable is to 
verify the quality and specificity of reagents provided by collaborators even when they 
have been used in high profile publications. Neither the D426 B1 MAIT cell clone or 
the D454 HLA-A*0201-LLDAHIPQL-specific T-cell clone were actually monoclonal. 
While this lack of clonality with the conventional T-cell did not affect my work, the 
contamination of the D426 B1 MAIT with a regular CD8 T-cell cost me dearly as it 
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resulted in me exploring the possibility that MAITs recognise peptide ligands presented 
by MR1. If I had my time over again I would certainly confirm the clonality of T-cell 
clones prior to investing major effort into them.  
My work could proceed to many future directions and I will explore some of these 
possibilities below. 
6.2.1 Comparative studies using other Mycobacteria and bacterial species 
One way of expanding my studies would be to look at the T-cell responses generated by 
other bacterial species. I used M. smegmatis due to the ease of culture and compatibility 
with the containment facilities that were available to me. Ideally, I would have also 
liked to work with pathogenic Mycobacteria such as M. tuberculosis and M. leprae. Due 
to the similarities between these organisms it is not unlikely that there might be 
crossover in the T-cell responses they induce. Any such pan-mycobacterial T-cells 
might make very good candidates to look to induce during vaccination. One candidate 
T-cell type that could potentially recognise a wide range of bacterial species is MAITs. 
A very recent study demonstrated that the MAITs raised against different 
microorganisms displayed subtly different TCRs (Gold et al., 2014). This difference 
suggests that these microorganisms present a different array of MR1-associated 
antigens. Given this evidence, it would be very interesting to isolate MR1 from cells 
infected with different microorganisms using MR1-specific antibody and then elute 
MR1-bound antigens prior to identification by mass spectrometry. Identification of 
specific MR1-associated antigens from different bacteria could prove to be especially 
important for inducing the right kind of MAITs to combat a specific infection. A similar 
approach that aimed to elute lipid moieties associated with CD1a, CD1b, CD1c and 
CD1d when cells are infected with different bacteria would also be highly informative.  
6.2.2 Clonotypic analyses of bacterially-induced T-cells 
During my studies I showed that it was possible to isolate M. smegmatis-specific T-
cells. The modern development in nucleic acid sequencing methods allows now the 
sequencing of all TCR chains available in a sample. The sequence analysis of all the 
TCR α and β chains in the M. smegmatis-specific T-cells induced from multiple 
individuals would be highly illuminating. These analyses would reveal any invariant or 
‘public’ TCR chains that occurred within these populations. 
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6.2.2.1 Invariant TCR chains 
Two invariant TCR α chains have already been identified and correspond to those used 
by NKT type 1 and MAITs. As there are invariant TCR chains associated with 
recognition of MR1- and CD1d-associated antigens it is not unreasonable to hypothesise 
that similar chains exist that are involved in recognition of other non-classical MHC 
molecules such as CD1a, CD1b, CD1c and HLA-E. It is possible that clonotypic 
analyses would reveal further unconventional T-cell subsets that have invariant or semi-
invariant TCR α or β chains. Therefore, it would be very interesting to study any such 
T-cell subsets and to establish the roles they play in bacterial infection. Deep clonotypic 
analyses of TCR chains of T-cells that target bacteria would be expected to identify 
such chains. Once identified, these unconventional T-cells could be enriched with TCR 
variable domain-specific antibody prior to cloning attempts. 
6.2.2.2 Public TCRs 
A full clonotypic analysis of the TCR chains used by M. smegmatis-specific T-cells 
from multiple individuals would also reveal any public TCR chains. Public TCRs are 
residue identical TCRs that are used to fight specific infections in all individuals with a 
given HLA type (Lim et al., 2000, Annels et al., 2000, Yu et al., 2007). Such TCRs are 
routinely found in all systems where they have been looked for. Public TCRs make 
ideal candidates for targeted vaccination (Davenport et al., 2007, Miles et al., 2006, 
Venturi et al., 2008). I could have continued my research by identifying  public TCRs 
that target HLA-A*0201-LLDAHIPQL and designed an optimal peptide agonist for it 
using CPL screening technology. My experiments and those by other members of my 
laboratory show that it is often possible to produce peptides that are 100-fold more 
potent than the natural peptide. These super peptides could be used to vaccinate 
individuals with the corresponding HLA and would be significantly better at inducing 
such responses. 
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Cell markers observed
Donor APC used
MOI
priming 
M. smeg:APC
MOI
assay
M. smeg:APC
Analysis date 
after priming
T-cell responses
measured by:
1st level 2nd level 3rd level
Donor 1
Autologous 
DCs
10:1 x D-8 CFSE staining CFSE, CD3 x x
Donor 2
Autologous 
DCs
10:1 x D-8 CFSE staining CFSE, CD3 x x
Donor 3 A549 10:1 x D-3, 8 and 13 CFSE staining CFSE, CD3 CD8, CD4 x
Donor 4 A549 10:1 x D-3, 8 and 13 CFSE staining CFSE, CD3 CD8, CD4 x
Donor 5
A549 10:1 10:1 D-13 IFNγ ICS IFNγ, CD3 αβTCR, γδ TCR CD8, CD4
Donor 6 A549 10:1 10:1 D-13 IFNγ ICS IFNγ, CD3 CD8, CD4 x
Donor 7
A549 10:1 10:1 D-13 IFNγ ICS IFNγ, CD3 αβTCR, γδ TCR CD8, CD4 
Donor 8 A549 10:1 10:1 D-13 IFNγ ICS IFNγ, CD3 CD8, CD4 x
Donor 9 A549 10:1 10:1 D-13 IFNγ ICS IFNγ, CD3 CD8, CD4 x
Donor 10
A549 10:1 10:1 D-13 IFNγ ICS IFNγ, CD3 αβTCR, γδ TCR CD8, CD4
Donor 11 A549 10:1 10:1 D-13 IFNγ ICS IFNγ, CD3 αβTCR, Vα7.2 TCR CD8, CD4
Donor 12
A549 10:1 10:1 D-13 IFNγ ICS IFNγ, CD3 αβTCR, Vα7.2TCR CD8, CD4
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/1/A/   5(MET). / CE [ C]:  /1/C/   1(LEU). / N  [ N]:   3.86 
/1/A/   7(TYR). / CZ [ C]:  /1/C/   1(LEU). / N  [ N]:   3.99 
/1/A/   7(TYR). / OH [ O]:  /1/C/   1(LEU). / N  [ N]:   2.87 
/1/A/   5(MET). / SD [ S]:  /1/C/   1(LEU). / N  [ N]:   3.78 
/1/A/ 171(TYR). / CZ [ C]:  /1/C/   1(LEU). / N  [ N]:   3.54 
/1/A/ 171(TYR). / OH [ O]:  /1/C/   1(LEU). / N  [ N]:   2.68 
/1/A/ 171(TYR). / CE2[ C]:  /1/C/   1(LEU). / N  [ N]:   3.47 
/1/A/   7(TYR). / OH [ O]:  /1/C/   1(LEU). / CA [ C]:   3.32 
/1/A/  63(GLU). / OE1[ O]:  /1/C/   1(LEU). / CA [ C]:   3.62 
/1/A/ 171(TYR). / OH [ O]:  /1/C/   1(LEU). / CA [ C]:   3.48 
/1/A/ 167(TRP). / CG [ C]:  /1/C/   1(LEU). / CB [ C]:   3.66 
/1/A/ 167(TRP). / CD2[ C]:  /1/C/   1(LEU). / CB [ C]:   3.76 
/1/A/ 171(TYR). / OH [ O]:  /1/C/   1(LEU). / CB [ C]:   3.96 
/1/A/  66(LYS). / NZ [ N]:  /1/C/   1(LEU). / CG [ C]:   3.48 
/1/A/  63(GLU). / OE2[ O]:  /1/C/   1(LEU). / CG [ C]:   3.72 
/1/A/  66(LYS). / NZ [ N]:  /1/C/   1(LEU). / CD1[ C]:   3.94 
/1/A/  59(TYR). / CE2[ C]:  /1/C/   1(LEU). / CD1[ C]:   3.76 
/1/A/  63(GLU). / CD [ C]:  /1/C/   1(LEU). / CD1[ C]:   3.82 
/1/A/  63(GLU). / OE2[ O]:  /1/C/   1(LEU). / CD1[ C]:   3.32 
/1/A/ 163(THR). / CG2[ C]:  /1/C/   1(LEU). / CD2[ C]:   3.79 
/1/A/ 167(TRP). / CD1[ C]:  /1/C/   1(LEU). / CD2[ C]:   3.93 
/1/A/ 167(TRP). / NE1[ N]:  /1/C/   1(LEU). / CD2[ C]:   3.61 
/1/A/ 167(TRP). / CE2[ C]:  /1/C/   1(LEU). / CD2[ C]:   3.82 
/1/A/  66(LYS). / NZ [ N]:  /1/C/   1(LEU). / CD2[ C]:   3.89 
/1/A/ 159(TYR). / OH [ O]:  /1/C/   1(LEU). / C  [ C]:   3.86 
/1/A/   7(TYR). / CZ [ C]:  /1/C/   1(LEU). / C  [ C]:   3.88 
/1/A/   7(TYR). / OH [ O]:  /1/C/   1(LEU). / C  [ C]:   3.28 
/1/A/   7(TYR). / CE2[ C]:  /1/C/   1(LEU). / C  [ C]:   3.81 
/1/A/  63(GLU). / OE1[ O]:  /1/C/   1(LEU). / C  [ C]:   3.69 
/1/A/ 159(TYR). / CE1[ C]:  /1/C/   1(LEU). / O  [ O]:   3.49 
/1/A/ 159(TYR). / CZ [ C]:  /1/C/   1(LEU). / O  [ O]:   3.47 
/1/A/ 159(TYR). / OH [ O]:  /1/C/   1(LEU). / O  [ O]:   2.66 
/1/A/   7(TYR). / CE2[ C]:  /1/C/   1(LEU). / O  [ O]:   3.64 
/1/A/  66(LYS). / NZ [ N]:  /1/C/   2(LEU). / N  [ N]:   3.79 
/1/A/   7(TYR). / CZ [ C]:  /1/C/   2(LEU). / N  [ N]:   3.87 
/1/A/  63(GLU). / CD [ C]:  /1/C/   2(LEU). / N  [ N]:   3.73 
/1/A/  63(GLU). / OE1[ O]:  /1/C/   2(LEU). / N  [ N]:   2.85 
/1/A/  99(TYR). / OH [ O]:  /1/C/   2(LEU). / CA [ C]:   3.73 
/1/A/  63(GLU). / OE1[ O]:  /1/C/   2(LEU). / CA [ C]:   3.81 
/1/A/  99(TYR). / OH [ O]:  /1/C/   2(LEU). / CB [ C]:   3.74 
/1/A/  66(LYS). / NZ [ N]:  /1/C/   2(LEU). / CB [ C]:   3.97 
/1/A/  63(GLU). / OE1[ O]:  /1/C/   2(LEU). / CB [ C]:   3.58 
                            /1/C/   2(LEU). / CG [ C]:   3.42 
/1/A/  67(VAL). / CA [ C]:  /1/C/   2(LEU). / CD1[ C]:   3.93 
/1/A/  63(GLU). / O  [ O]:  /1/C/   2(LEU). / CD1[ C]:   3.64 
/1/A/  66(LYS). / CB [ C]:  /1/C/   2(LEU). / CD1[ C]:   3.87 
/1/A/  67(VAL). / N  [ N]:  /1/C/   2(LEU). / CD1[ C]:   3.69 
/1/A/  63(GLU). / OE1[ O]:  /1/C/   2(LEU). / CD1[ C]:   3.75 
/1/A/  45(MET). / CE [ C]:  /1/C/   2(LEU). / CD1[ C]:   3.60 
/1/A/  67(VAL). / CB [ C]:  /1/C/   2(LEU). / CD1[ C]:   3.75 
/1/A/  99(TYR). / OH [ O]:  /1/C/   2(LEU). / CD2[ C]:   3.35 
/1/A/   9(PHE). / CZ [ C]:  /1/C/   2(LEU). / CD2[ C]:   3.68 
/1/A/   9(PHE). / CE2[ C]:  /1/C/   2(LEU). / CD2[ C]:   3.98 
/1/A/   7(TYR). / CG [ C]:  /1/C/   2(LEU). / CD2[ C]:   3.87 
/1/A/   7(TYR). / CD1[ C]:  /1/C/   2(LEU). / CD2[ C]:   3.61 
/1/A/   7(TYR). / CE1[ C]:  /1/C/   2(LEU). / CD2[ C]:   3.70 
/1/A/  99(TYR). / OH [ O]:  /1/C/   2(LEU). / C  [ C]:   3.85 
/1/A/ 159(TYR). / CE1[ C]:  /1/C/   2(LEU). / C  [ C]:   3.78 
/1/A/ 159(TYR). / OH [ O]:  /1/C/   2(LEU). / C  [ C]:   3.97 
/1/A/  66(LYS). / NZ [ N]:  /1/C/   2(LEU). / C  [ C]:   3.67 
/1/A/ 159(TYR). / CE1[ C]:  /1/C/   2(LEU). / O  [ O]:   3.88 
/1/A/  66(LYS). / CD [ C]:  /1/C/   2(LEU). / O  [ O]:   3.98 
/1/A/  66(LYS). / CE [ C]:  /1/C/   2(LEU). / O  [ O]:   3.88 
/1/A/  66(LYS). / NZ [ N]:  /1/C/   2(LEU). / O  [ O]:   2.83 
                            /1/C/   9(LEU). / N  [ N]:   3.94 
/1/A/  77(ASP). / CG [ C]:  /1/C/   9(LEU). / N  [ N]:   3.63 
/1/A/  77(ASP). / OD1[ O]:  /1/C/   9(LEU). / N  [ N]:   2.90 
/1/A/ 143(THR). / CG2[ C]:  /1/C/   9(LEU). / CA [ C]:   3.95 
/1/A/ 147(TRP). / CZ2[ C]:  /1/C/   9(LEU). / CA [ C]:   3.94 
/1/A/  77(ASP). / OD1[ O]:  /1/C/   9(LEU). / CA [ C]:   3.79 
/1/A/ 143(THR). / OG1[ O]:  /1/C/   9(LEU). / CB [ C]:   3.97 
/1/A/  77(ASP). / CG [ C]:  /1/C/   9(LEU). / CB [ C]:   3.92 
/1/A/  77(ASP). / OD1[ O]:  /1/C/   9(LEU). / CB [ C]:   3.67 
/1/A/  77(ASP). / CG [ C]:  /1/C/   9(LEU). / CG [ C]:   3.50 
/1/A/  77(ASP). / OD1[ O]:  /1/C/   9(LEU). / CG [ C]:   3.71 
/1/A/ 116(TYR). / CZ [ C]:  /1/C/   9(LEU). / CG [ C]:   3.88 
/1/A/  77(ASP). / OD2[ O]:  /1/C/   9(LEU). / CG [ C]:   3.76 
/1/A/  81(LEU). / CD2[ C]:  /1/C/   9(LEU). / CD1[ C]:   3.33 
/1/A/  77(ASP). / CB [ C]:  /1/C/   9(LEU). / CD1[ C]:   3.82 
/1/A/  77(ASP). / CG [ C]:  /1/C/   9(LEU). / CD1[ C]:   3.90 
/1/A/ 116(TYR). / CE1[ C]:  /1/C/   9(LEU). / CD1[ C]:   3.18 
/1/A/ 116(TYR). / CZ [ C]:  /1/C/   9(LEU). / CD1[ C]:   3.33 
/1/A/ 116(TYR). / OH [ O]:  /1/C/   9(LEU). / CD1[ C]:   3.58 
/1/A/ 147(TRP). / CH2[ C]:  /1/C/   9(LEU). / CD2[ C]:   3.61 
/1/A/ 147(TRP). / CZ2[ C]:  /1/C/   9(LEU). / CD2[ C]:   3.63 
/1/A/ 143(THR). / OG1[ O]:  /1/C/   9(LEU). / C  [ C]:   3.87 
/1/A/ 146(LYS). / NZ [ N]:  /1/C/   9(LEU). / C  [ C]:   3.26 
                            /1/C/   9(LEU). / O  [ O]:   2.83 
/1/A/  80(THR). / CG2[ C]:  /1/C/   9(LEU). / O  [ O]:   3.90 
/1/A/ 143(THR). / CB [ C]:  /1/C/   9(LEU). / OXT[ O]:   3.69 
/1/A/ 143(THR). / OG1[ O]:  /1/C/   9(LEU). / OXT[ O]:   2.82 
/1/A/ 143(THR). / CG2[ C]:  /1/C/   9(LEU). / OXT[ O]:   3.61 
/1/A/ 146(LYS). / NZ [ N]:  /1/C/   9(LEU). / OXT[ O]:   2.92 
 
Appendix A2. Total contacts between LLDAHIPQL peptide and HLA-A*0201 
molecule. 
 146 
/1/A/   5(MET). / CE [ C]:  /1/C/   1(MET). / N  [ N]:   3.90 
/1/A/ 167(TRP). / CB [ C]:  /1/C/   1(MET). / N  [ N]:   3.85 
/1/A/   7(TYR). / OH [ O]:  /1/C/   1(MET). / N  [ N]:   2.93 
/1/A/   5(MET). / SD [ S]:  /1/C/   1(MET). / N  [ N]:   3.91 
/1/A/ 171(TYR). / CZ [ C]:  /1/C/   1(MET). / N  [ N]:   3.42 
/1/A/ 171(TYR). / OH [ O]:  /1/C/   1(MET). / N  [ N]:   2.57 
/1/A/ 171(TYR). / CE2[ C]:  /1/C/   1(MET). / N  [ N]:   3.38 
/1/A/   7(TYR). / OH [ O]:  /1/C/   1(MET). / CA [ C]:   3.32 
/1/A/  63(GLU). / OE1[ O]:  /1/C/   1(MET). / CA [ C]:   3.45 
/1/A/ 171(TYR). / OH [ O]:  /1/C/   1(MET). / CA [ C]:   3.39 
/1/A/ 167(TRP). / CG [ C]:  /1/C/   1(MET). / CB [ C]:   3.78 
/1/A/ 167(TRP). / CD2[ C]:  /1/C/   1(MET). / CB [ C]:   3.89 
/1/A/ 171(TYR). / OH [ O]:  /1/C/   1(MET). / CB [ C]:   3.82 
/1/A/  66(LYS). / NZ [ N]:  /1/C/   1(MET). / CG [ C]:   3.23 
/1/A/  63(GLU). / OE2[ O]:  /1/C/   1(MET). / CG [ C]:   3.45 
/1/A/  66(LYS). / NZ [ N]:  /1/C/   1(MET). / SD [ S]:   3.73 
/1/A/ 167(TRP). / NE1[ N]:  /1/C/   1(MET). / SD [ S]:   3.98 
/1/A/ 167(TRP). / CE2[ C]:  /1/C/   1(MET). / CE [ C]:   3.66 
/1/A/ 167(TRP). / CZ2[ C]:  /1/C/   1(MET). / CE [ C]:   3.54 
/1/A/  63(GLU). / OE2[ O]:  /1/C/   1(MET). / CE [ C]:   3.93 
/1/A/ 167(TRP). / CH2[ C]:  /1/C/   1(MET). / CE [ C]:   3.76 
/1/A/ 159(TYR). / OH [ O]:  /1/C/   1(MET). / C  [ C]:   3.83 
/1/A/   7(TYR). / CZ [ C]:  /1/C/   1(MET). / C  [ C]:   3.86 
/1/A/   7(TYR). / OH [ O]:  /1/C/   1(MET). / C  [ C]:   3.37 
/1/A/   7(TYR). / CE2[ C]:  /1/C/   1(MET). / C  [ C]:   3.83 
/1/A/  63(GLU). / OE1[ O]:  /1/C/   1(MET). / C  [ C]:   3.66 
/1/A/ 159(TYR). / CE1[ C]:  /1/C/   1(MET). / O  [ O]:   3.50 
/1/A/ 159(TYR). / CZ [ C]:  /1/C/   1(MET). / O  [ O]:   3.50 
/1/A/ 159(TYR). / OH [ O]:  /1/C/   1(MET). / O  [ O]:   2.71 
/1/A/   7(TYR). / CE2[ C]:  /1/C/   1(MET). / O  [ O]:   3.71 
/1/A/   7(TYR). / CZ [ C]:  /1/C/   2(ILE). / N  [ N]:   3.85 
/1/A/  63(GLU). / CD [ C]:  /1/C/   2(ILE). / N  [ N]:   3.84 
/1/A/  63(GLU). / OE1[ O]:  /1/C/   2(ILE). / N  [ N]:   2.90 
/1/A/  99(TYR). / OH [ O]:  /1/C/   2(ILE). / CA [ C]:   3.78 
/1/A/ 159(TYR). / OH [ O]:  /1/C/   2(ILE). / CA [ C]:   3.86 
/1/A/  63(GLU). / OE1[ O]:  /1/C/   2(ILE). / CA [ C]:   3.93 
/1/A/  99(TYR). / OH [ O]:  /1/C/   2(ILE). / CB [ C]:   3.40 
/1/A/  63(GLU). / OE1[ O]:  /1/C/   2(ILE). / CB [ C]:   3.93 
/1/A/  66(LYS). / CB [ C]:  /1/C/   2(ILE). / CG1[ C]:   3.82 
/1/A/  66(LYS). / CE [ C]:  /1/C/   2(ILE). / CG1[ C]:   3.79 
/1/A/  63(GLU). / OE1[ O]:  /1/C/   2(ILE). / CG1[ C]:   3.40 
/1/A/  70(HIS). / NE2[ N]:  /1/C/   2(ILE). / CD1[ C]:   3.81 
/1/A/  67(VAL). / CA [ C]:  /1/C/   2(ILE). / CD1[ C]:   3.74 
/1/A/  67(VAL). / CB [ C]:  /1/C/   2(ILE). / CD1[ C]:   3.76 
/1/A/  63(GLU). / O  [ O]:  /1/C/   2(ILE). / CD1[ C]:   3.81 
/1/A/  66(LYS). / CB [ C]:  /1/C/   2(ILE). / CD1[ C]:   3.48 
/1/A/  66(LYS). / C  [ C]:  /1/C/   2(ILE). / CD1[ C]:   3.76 
/1/A/  67(VAL). / N  [ N]:  /1/C/   2(ILE). / CD1[ C]:   3.53 
/1/A/   7(TYR). / CG [ C]:  /1/C/   2(ILE). / CG2[ C]:   3.75 
/1/A/   7(TYR). / CD1[ C]:  /1/C/   2(ILE). / CG2[ C]:   3.36 
/1/A/   7(TYR). / CE1[ C]:  /1/C/   2(ILE). / CG2[ C]:   3.14 
/1/A/   7(TYR). / CZ [ C]:  /1/C/   2(ILE). / CG2[ C]:   3.36 
/1/A/   7(TYR). / OH [ O]:  /1/C/   2(ILE). / CG2[ C]:   3.93 
/1/A/   7(TYR). / CE2[ C]:  /1/C/   2(ILE). / CG2[ C]:   3.72 
/1/A/   7(TYR). / CD2[ C]:  /1/C/   2(ILE). / CG2[ C]:   3.88 
/1/A/  63(GLU). / OE1[ O]:  /1/C/   2(ILE). / CG2[ C]:   3.90 
/1/A/  99(TYR). / OH [ O]:  /1/C/   2(ILE). / C  [ C]:   3.84 
/1/A/  66(LYS). / NZ [ N]:  /1/C/   2(ILE). / C  [ C]:   3.84 
/1/A/ 159(TYR). / CE1[ C]:  /1/C/   2(ILE). / C  [ C]:   3.79 
/1/A/ 159(TYR). / OH [ O]:  /1/C/   2(ILE). / C  [ C]:   3.98 
/1/A/  66(LYS). / CD [ C]:  /1/C/   2(ILE). / O  [ O]:   3.81 
/1/A/  66(LYS). / NZ [ N]:  /1/C/   2(ILE). / O  [ O]:   2.86 
/1/A/ 159(TYR). / CE1[ C]:  /1/C/   2(ILE). / O  [ O]:   3.97 
/1/A/  66(LYS). / CE [ C]:  /1/C/   2(ILE). / O  [ O]:   3.71 
/1/A/  77(ASP). / CG [ C]:  /1/C/   9(VAL). / N  [ N]:   3.79 
/1/A/  77(ASP). / OD1[ O]:  /1/C/   9(VAL). / N  [ N]:   2.96 
/1/A/ 143(THR). / OG1[ O]:  /1/C/   9(VAL). / CA [ C]:   3.89 
/1/A/ 143(THR). / CG2[ C]:  /1/C/   9(VAL). / CA [ C]:   3.80 
/1/A/ 147(TRP). / CZ2[ C]:  /1/C/   9(VAL). / CA [ C]:   3.93 
/1/A/ 143(THR). / OG1[ O]:  /1/C/   9(VAL). / CB [ C]:   3.64 
/1/A/ 143(THR). / CG2[ C]:  /1/C/   9(VAL). / CB [ C]:   3.99 
/1/A/ 147(TRP). / CZ2[ C]:  /1/C/   9(VAL). / CG1[ C]:   3.95 
/1/A/ 116(TYR). / CE1[ C]:  /1/C/   9(VAL). / CG1[ C]:   3.89 
/1/A/ 116(TYR). / CZ [ C]:  /1/C/   9(VAL). / CG1[ C]:   3.76 
/1/A/  77(ASP). / OD2[ O]:  /1/C/   9(VAL). / CG1[ C]:   3.96 
/1/A/  81(LEU). / CD1[ C]:  /1/C/   9(VAL). / CG2[ C]:   3.82 
/1/A/  77(ASP). / CB [ C]:  /1/C/   9(VAL). / CG2[ C]:   3.93 
/1/A/  77(ASP). / CG [ C]:  /1/C/   9(VAL). / CG2[ C]:   3.83 
/1/A/  77(ASP). / OD1[ O]:  /1/C/   9(VAL). / CG2[ C]:   3.66 
/1/A/  84(TYR). / OH [ O]:  /1/C/   9(VAL). / C  [ C]:   3.71 
/1/A/ 143(THR). / OG1[ O]:  /1/C/   9(VAL). / C  [ C]:   3.66 
/1/A/ 146(LYS). / CE [ C]:  /1/C/   9(VAL). / C  [ C]:   3.75 
/1/A/ 146(LYS). / NZ [ N]:  /1/C/   9(VAL). / C  [ C]:   3.62 
/1/A/ 146(LYS). / CE [ C]:  /1/C/   9(VAL). / O  [ O]:   3.55 
/1/A/ 146(LYS). / NZ [ N]:  /1/C/   9(VAL). / O  [ O]:   2.93 
/1/A/  80(THR). / CG2[ C]:  /1/C/   9(VAL). / O  [ O]:   3.65 
/1/A/  84(TYR). / CZ [ C]:  /1/C/   9(VAL). / OXT[ O]:   3.65 
/1/A/  84(TYR). / OH [ O]:  /1/C/   9(VAL). / OXT[ O]:   2.84 
/1/A/  84(TYR). / CE2[ C]:  /1/C/   9(VAL). / OXT[ O]:   3.60 
/1/A/ 143(THR). / CA [ C]:  /1/C/   9(VAL). / OXT[ O]:   3.78 
/1/A/ 143(THR). / CB [ C]:  /1/C/   9(VAL). / OXT[ O]:   3.49 
/1/A/ 143(THR). / OG1[ O]:  /1/C/   9(VAL). / OXT[ O]:   2.70 
/1/A/ 146(LYS). / CE [ C]:  /1/C/   9(VAL). / OXT[ O]:   3.52 
/1/A/ 143(THR). / CG2[ C]:  /1/C/   9(VAL). / OXT[ O]:   3.66 
 
Appendix A3. Total contacts between MIDAHIPQV peptide and HLA-A*0201 
molecule. 
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